Oct 22, 2020
Edgewise Therapeutics Appoints Behrad Derakhshan as Chief Business OfficerOct 22, 2020
BELLUS Health Closes US$40 Million Public Offering of Common Shares in Canada and the United States, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesOct 22, 2020
Phase 1 Clinical Study will Evaluate ADI-001 Safety and Efficacy in Patients with B-cell non-Hodgkin’s lymphomaOct 20, 2020
Mereo BioPharma Appoints Christine Fox as Chief Financial Officer and Heidi Petersen as Senior Vice President, Regulatory AffairsOct 20, 2020
Selecta Biosciences and AskBio Receive FDA Rare Pediatric Disease Designation for their Gene Therapy for Methylmalonic AcidemiaOct 20, 2020
Keros Therapeutics, Inc. Announces Dosing of First Participants in Phase 2 Clinical Trial of KER-050 in Myelodysplastic Syndromes (MDS)Oct 19, 2020
ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor ProgramOct 19, 2020
Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab (Anti-TIGIT)Oct 19, 2020
VelosBio Announces First Patient Dosed in Phase 2 Trial of VLS-101 in Solid TumorsOct 16, 2020
Edgewise Therapeutics Appoints Michael Carruthers as Chief Financial OfficerOct 16, 2020
IMARA ANNOUNCES FIRST PATIENT DOSED IN FORTE PHASE 2B CLINICAL TRIAL OF IMR-687 IN BETA-THALASSEMIAOct 15, 2020
VectivBio Closes $110 Million Crossover Financing to Advance Transformational Medicines for Rare DiseasesOct 15, 2020
Gemini Therapeutics and FS Development Corp. Announce Merger Agreement Creating Publicly Listed Precision Medicine Company Focused on Age-Related Macular DegenerationOct 13, 2020
Nabriva’s XENLETA Demonstrates High Efficacy in Patients of Advanced Age with Community-Acquired Bacterial Pneumonia (CABP)Oct 13, 2020
Passage Bio Announces Publication of Preclinical Data That Show Single Injection of Optimized AAV Vector into Cerebral Spinal Fluid Corrects Neurological Disease, Supporting Advancement of PBGM01 into ClinicOct 13, 2020
SpringWorks Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesOct 13, 2020
PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C MutationOct 13, 2020
CTI BioPharma Initiates Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe ThrombocytopeniaOct 8, 2020
TigerConnect Closes $45M Series D To Meet Soaring DemandOct 8, 2020
Xenon Pharmaceuticals Receives FDA Feedback and is on Track to Initiate XEN496 Phase 3 Clinical Trial for the Treatment of KCNQ2-DEE Before Year-EndOct 8, 2020
Selecta Biosciences and IGAN Biosciences Enter into Research License and Option Agreement to Study Selecta’s ImmTOR™ Immune Tolerance Platform in Combination with IGAN’s IgA Protease for the Treatment of IgA NephropathyOct 8, 2020
Neurocrine Biosciences and Xenon Pharmaceuticals Provide Regulatory Update on Ongoing Collaboration to Develop First-In-Class Treatment for EpilepsyOct 8, 2020
scPharmaceuticals Provides Business UpdateOct 8, 2020
X4 Pharmaceuticals Announces Fast Track Designation Granted by the FDA to Mavorixafor for the Treatment of WHIM SyndromeOct 6, 2020
Augmedix Closes $25 Million Private PlacementOct 6, 2020
Arcutis Biotherapeutics Announces Closing of Public Offering and Concurrent Private Placement of Common StockOct 5, 2020
New Data from Corvus Phase 1 Study of CPI-006 Continues to Support its Potential as a Treatment for COVID-19Oct 5, 2020
Corvus Pharmaceuticals Announces Co-Founding of Angel Pharmaceuticals in ChinaOct 5, 2020
SpringWorks Therapeutics Announces Clinical Collaboration with Pfizer Inc. to Evaluate Nirogacestat in Combination with PF?06863135 in Patients with Relapsed or Refractory Multiple MyelomaOct 1, 2020
X4 Pharmaceuticals Expands Board of Directors Through Appointment of Biopharmaceutical Industry Veteran Alison LawtonSep 30, 2020
Selecta Biosciences and Sobi Announce Topline Data of SEL-212 from the Phase 2 COMPARE Trial Supporting the Potential for Important Clinical Improvement in Patients with Chronic Refractory GoutSep 29, 2020
Fusion Pharmaceuticals Appoints Maria Stahl As Chief Legal OfficerSep 29, 2020
Arcutis Announces Positive Topline Data from Phase 2 Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic DermatitisSep 28, 2020
Mereo BioPharma Announces Changes to Board of DirectorsSep 28, 2020
BIOSHIN, BIOHAVEN'S ASIA-PACIFIC SUBSIDIARY, RAISES $60M IN SERIES A FUNDING TO ADVANCE NEUROSCIENCE PIPELINE IN ASIA-PACIFIC REGIONSep 28, 2020
Ascendis Pharma A/S Announces Preliminary Six-Month Data from Open-Label Extension of Phase 2 PaTH Forward Trial and Files IND Amendment to Initiate Phase 3 PaTHway Trial of TransCon™ PTH in Adult HypoparathyroidismSep 25, 2020
TELA Bio Presents Additional Data from BRAVO Study of OviTex® for Ventral Hernia RepairSep 25, 2020
Graybug Appoints Three New Members to its Board of DirectorsSep 25, 2020
Galecto Raises $64 Million to Accelerate Development of Clinical PipelineSep 24, 2020
PMV Pharma Announces Pricing of Initial Public OfferingSep 24, 2020
Mereo BioPharma Receives FDA Rare Pediatric Disease Designation for Setrusumab for the Treatment of Osteogenesis ImperfectaSep 24, 2020
Graybug Vision Announces Pricing of Upsized Initial Public OfferingSep 23, 2020
Ascendis Pharma A/S Announces Filing of the Clinical Trial Notification for Phase 3 Clinical Trial of TransCon™ hGH for Pediatric Growth Hormone Deficiency in JapanSep 23, 2020
First Patient Randomized in the Phase 3 DISSOLVE Clinical Program of SEL-212 for Chronic Refractory GoutSep 23, 2020
Silverback Therapeutics Raises $85 Million in Series C Financing; Company Announces Executive PromotionsSep 23, 2020
AMA Dermatology Publishes Results from Verrica’s Two Pivotal Phase III CAMP (Cantharidin Application in Molluscum Patients) TrialsSep 23, 2020
Verona Pharma Initiates Phase 3 Clinical Trials with Nebulized Ensifentrine for the Maintenance Treatment of COPDSep 21, 2020
Intended Delisting and Cancellation of Ordinary Shares from Trading on AIMSep 21, 2020
Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple MyelomaSep 21, 2020
CRINETICS PHARMACEUTICALS RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM FDA FOR CRN04777 FOR THE TREATMENT OF CONGENITAL HYPERINSULINISMSep 18, 2020
SpringWorks Therapeutics Enters into Sponsored Research Agreement with Fred Hutchinson Cancer Research Center to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple MyelomaSep 17, 2020
New Data from Ciforadenant Phase 1b/2 Clinical Study Presented at ESMO Virtual Congress 2020Sep 17, 2020
Acutus Medical Reports Second Quarter 2020 Financial ResultsSep 17, 2020
Acutus Medical Announces FDA Clearance of Second-Generation AcQMap 3D Imaging & Mapping CatheterSep 17, 2020
ESSA Pharma Announces the Presentation of Additional Preclinical Data for EPI-7386 at the ESMO Virtual Congress 2020Sep 17, 2020
Passage Bio Announces Publication of Preclinical Gene Therapy Study Data from Frontotemporal Dementia ProgramSep 16, 2020
Arcutis Completes Enrollment in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque PsoriasisSep 16, 2020
SpringWorks Therapeutics Announces Collaboration with Children’s Oncology Group to Conduct a Phase 2 Clinical Trial of Nirogacestat in Pediatric Patients with Desmoid Tumors and Reports Publication of Nirogacestat Case Series in Pediatric/Young Adult Desmoid Tumor PatientsSep 16, 2020
Verona Pharma Announces Publication of Phase 2b COPD Symptom Data in the International Journal of Chronic Obstructive Pulmonary DiseaseSep 16, 2020
Adicet Bio Appoints Nick Harvey as Chief Financial OfficerSep 16, 2020
89bio Announces Pricing of Upsized Public Offering of Common StockSep 15, 2020
Aerpio Announces Enrollment Completed in the 28-Day Phase 2 Razuprotafib Glaucoma TrialSep 15, 2020
Compass Therapeutics, Inc. Provides Corporate UpdateSep 15, 2020
Galecto’s Oral Galectin-3 Inhibitor GB1211 Well Tolerated in Phase I Clinical Data Presented Recently at Several Scientific ConferencesSep 15, 2020
VectivBio Appoints Nader N. Youssef, M.D., as Senior Vice President, Head of Global Clinical Development and Medical AffairsSep 15, 2020
Adicet Announces Completion of Merger with resTORbioSep 14, 2020
SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple MyelomaSep 14, 2020
NextCure Announces Appointment of John G. Houston, Ph.D., to its Board of DirectorsSep 14, 2020
Valneva Announces Major COVID-19 Vaccine Partnership with U.K. GovernmentSep 14, 2020
89bio Announces Positive Topline Results from its Phase 1b/2a Trial of BIO89-100 in NASHSep 14, 2020
ESCAPE BIO CLOSES $73 MILLION IN CROSSOVER FINANCING TO ADVANCE CLINICAL DEVELOPMENT OF PRECISION NEUROLOGY MEDICINES FOR GENETIC NEURODEGENERATION – ESCAPE BIOSep 14, 2020
Synlogic Appoints David Hava, Ph.D., as Chief Scientific OfficerSep 14, 2020
ESSA Pharma Announces Fast Track Designation Granted by the FDA to EPI-7386 for the Treatment of Metastatic Castration-Resistant Prostate CancerSep 11, 2020
Keros Therapeutics Presents Results from Preclinical Studies Investigating KER-012 at the American Society for Bone and Mineral Research 2020 Annual MeetingSep 11, 2020
Corvus Pharmaceuticals Appoints Edith Mitchell, M.D., to Board of DirectorsSep 10, 2020
Corvus Pharmaceuticals Provides Update on Clinical Trial of CPI-006 for Patients with COVID-19Sep 10, 2020
Gemini Therapeutics Enrolls First Patient in Phase 2a Study of GEM103 for Dry Age-related Macular DegenerationSep 10, 2020
Prevail Therapeutics Announces Appointment of William H. Carson, M.D., to Board of DirectorsSep 10, 2020
Nabriva Therapeutics Granted New Technology Add-On Payment for XENLETA® (lefamulin) and CONTEPO™ (fosfomycin) by Centers for Medicare & Medicaid ServicesSep 9, 2020
Cleave Therapeutics Announces Preclinical Research Collaboration with Jazz Pharmaceuticals in Acute Myeloid Leukemia (AML)Sep 9, 2020
Adagio Therapeutics Strengthens Management Team with Appointments of Eric Kimble as Chief Commercial Officer and Ed Campanaro as SVP of Clinical OperationsSep 9, 2020
Kinnate Biopharma Appoints Dean J. Mitchell as Chairman of the BoardSep 9, 2020
Valneva Announces New IXIARO® Supply Contract with the US Government worth up to $166 millionSep 8, 2020
BELLUS Health Announces Design for its Phase 2b Trial with BLU-5937 in Refractory Chronic CoughSep 8, 2020
Arcutis Biotherapeutics to Accelerate ARQ-151 (Topical Roflumilast Cream) into Phase 3 Trials for the Treatment of Atopic Dermatitis Following End-of-Phase 2 Meeting with FDASep 8, 2020
Valneva Initiates Phase 3 Clinical Study for its Chikungunya Vaccine Candidate VLA1553Sep 8, 2020
VelosBio Appoints Paul Bavier as General CounselSep 8, 2020
Ascendis Pharma A/S Submits Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TransCon™ hGH for Treatment of Pediatric Growth Hormone DeficiencySep 8, 2020
Acutus Medical Announces Pulsed Field Ablation Program and Initial Pre-Clinical ResultsSep 8, 2020
Verona Pharma Initiates Pilot Study with pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19Sep 8, 2020
PMV Pharma Appoints Laurie Stelzer to the Board of Directors and Robert Ticktin as General CounselSep 4, 2020
Graybug Vision Appoints Robert Breuil as Chief Financial OfficerSep 4, 2020
CRINETICS PHARMACEUTICALS PROVIDES NEW DATA FROM PALTUSOTINE AND ACTH ANTAGONIST DEVELOPMENT PROGRAMS AT EUROPEAN CONGRESS OF ENDOCRINOLOGYSep 4, 2020
Ascendis Pharma A/S Announces U.S. Food and Drug Administration (FDA) Accepts Biologics License Application (BLA) for TransCon™ hGH for Pediatric Growth Hormone Deficiency (GHD)Sep 3, 2020
89bio Initiates Phase 2 Trial of BIO89-100 in Patients with Severe HypertriglyceridemiaSep 3, 2020
CRINETICS PHARMACEUTICALS APPOINTS RARE DISEASE EXECUTIVE, CAMILLE L. BEDROSIAN, M.D., TO BOARD OF DIRECTORSSep 3, 2020
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement Priced At-The-Market of Common Shares and 15-Month Purchase Warrants for Potential Additional Gross Proceeds of $23.9 MillionSep 2, 2020
X4 Pharmaceuticals Announces Publication of Mavorixafor Phase 2 Clinical Data for Treatment of WHIM Syndrome in ‘Blood’ - the Official Journal of the American Society of HematologySep 1, 2020
Aerpio and Quantum Leap Announce First Patients Dosed with Razuprotafib in the I-SPY COVID Trial to Treat ARDS in Critically-ill COVID-19 PatientsSep 1, 2020
Selecta Biosciences Secures Up To $35 Million Debt Financing with Oxford Finance LLC and Silicon Valley BankSep 1, 2020
TigerConnect Acquires Call Scheduler, Launches Fully-Integrated TigerSchedule™ to Simplify Physician On-Call SchedulingAug 31, 2020
Pandion Reports Second Quarter 2020 Financial Results and Provides Business UpdateAug 31, 2020
VelosBio Announces FDA Fast Track and Orphan Drug Designations for VLS-101 in Patients with Mantle Cell LymphomaAug 31, 2020
Turning Point Therapeutics Announces Scientific Advisory BoardAug 31, 2020
NeuroPace Raises $67 Million Financing to Support Commercial Expansion of the RNS® System for Refractory EpilepsyAug 27, 2020
Gemini Therapeutics Appoints Dr. Tuyen Ong as Independent DirectorAug 27, 2020
Galecto, Inc. Receives U.S. and EU Orphan Drug Designations for GB0139 in Idiopathic Pulmonary FibrosisAug 26, 2020
Silverback Therapeutics Initiates Phase 1 Clinical Study of SBT6050Aug 26, 2020
Kinnate Biopharma Closes $98 Million Series C FinancingAug 26, 2020
Harpoon Therapeutics Names Karin Ann Thacker, M.Sc., VP Regulatory Affairs and Quality AssuranceAug 25, 2020
Mereo BioPharma Announces Initiation of Placebo-Controlled Phase 1b/2 Clinical Trial with Alvelestat in COVID-19 Respiratory DiseaseAug 25, 2020
Imara Receives Orphan Drug Designation from the European Commission for IMR-687 for the Treatment of Sickle Cell DiseaseAug 25, 2020
ReViral Raises $44 Million in Series C FinancingAug 24, 2020
Xtant Medical Announces U.S. Commercial Launch of the Matriform� Si for Spinal Fusion ProceduresAug 24, 2020
Compass Therapeutics Announces Publication in the Journal Science of Preclinical Data Supporting the Potential of CTX-2026, a Novel Antibody to the Butyrophilin BTN3A1, in Ovarian Cancer Tumor ModelsAug 24, 2020
Prelude Therapeutics Announces Closing of $50M Series C FinancingAug 24, 2020
Turning Point Therapeutics Granted Fast-Track Designation for Repotrectinib in NTRK-Positive TKI-Pretreated Advanced Solid TumorsAug 24, 2020
Tricida Receives Complete Response Letter from the FDA for its New Drug Application for Veverimer for the Treatment of Metabolic Acidosis and Slowing of Kidney Disease Progression in Patients with Metabolic Acidosis Associated with CKDAug 21, 2020
Harmony Biosciences Announces Closing of its Upsized Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional SharesAug 20, 2020
AbCellera Acquires OrthoMab Bispecific Platform to Propel the Development of Antibody Therapies for Pharma and Biotech PartnersAug 19, 2020
Verona Pharma Initiates Multiple Dose Part of Phase 2 Clinical Trial with pMDI Formulation of Ensifentrine in COPDAug 19, 2020
Turning Point Therapeutics Reports Early Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib, Provides Regulatory UpdateAug 18, 2020
Ikena Oncology Appoints Dr. Sergio Santillana, MD, MSc, MBA as Chief Medical OfficerAug 17, 2020
Xenon Pharmaceuticals Appoints Dr. Chris Von Seggern as Chief Commercial OfficerAug 17, 2020
Aerin Medical Announces Appointment of Matt Brokaw as President and CEO and Closing of $48MM Equity FinancingAug 14, 2020
Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2020Aug 14, 2020
Imara Reports Second Quarter 2020 Financial Results and Business HighlightsAug 13, 2020
scPharmaceuticals Inc. Reports Second Quarter 2020 Financial Results and Provides Business UpdateAug 13, 2020
Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial ResultsAug 13, 2020
89bio Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateAug 13, 2020
Imara Announces First Patient Dosed in Ardent Phase 2b Clinical Trial of IMR-687 in Sickle Cell DiseaseAug 13, 2020
BELLUS Health Reports Second Quarter 2020 Financial Results and Business HighlightsAug 13, 2020
Passage Bio Reports Second Quarter 2020 Financial Results and Recent Business HighlightsAug 12, 2020
SpringWorks Therapeutics Reports Second Quarter 2020 Financial Results and Recent Business HighlightsAug 12, 2020
Aerpio Reports Second Quarter 2020 Financial Results and Provides Business UpdateAug 12, 2020
TELA Bio Announces Second Quarter 2020 Financial ResultsAug 12, 2020
Ikena Oncology Announces Publication in Nature Communications of Preclinical Data Supporting the Therapeutic Potential of AHR BlockadeAug 12, 2020
Ascendis Pharma A/S Receives Orphan Designation for TransCon™ CNP for the Treatment of Achondroplasia in EuropeAug 11, 2020
Prevail Therapeutics Reports Second Quarter 2020 Financial Results and Business HighlightsAug 11, 2020
Arcutis Announces Second Quarter 2020 Financial Results and Provides Business UpdateAug 11, 2020
Press Release: Bayer to Acquire UK-Based KaNDy TherapeuticsAug 11, 2020
KaNDY Therapeutics to be acquired by Bayer AG for up to $1.5 billionAug 11, 2020
Fusion Pharmaceuticals Announces Second Quarter 2020 Financial Results And Business UpdateAug 11, 2020
Alector Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateAug 11, 2020
Alpine Immune Sciences Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateAug 11, 2020
Verrica Pharmaceuticals Licenses LTX-315, A First-in-Class Oncolytic Peptide Based Immunotherapy, from Lytix Biopharma AS, for the Treatment of Dermatologic Oncology IndicationsAug 10, 2020
Turning Point Therapeutics Reports Second-Quarter Financial Results, Provides Operational UpdatesAug 10, 2020
Keros Therapeutics to be Featured on The Balancing Act's """"Behind the Mystery"""" Rare Disease SeriesAug 10, 2020
Acutus Medical Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesAug 10, 2020
Aeglea BioTherapeutics Reports Second Quarter 2020 Financial Results and Corporate HighlightsAug 10, 2020
Terns Appoints Senthil Sundaram as Chief Executive Officer, Mark Vignola, PhD, as Chief Financial Officer, and Erink Quirk, M.D. as PresidentAug 7, 2020
Crinetics Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateAug 6, 2020
Selecta Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate UpdatesAug 6, 2020
Xenon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateAug 6, 2020
Sierra Oncology Strengthens Management Team to Implement North American Pre-Commercialization Strategy for MomelotinibAug 6, 2020
NextCure Reports Second Quarter 2020 Financial ResultsAug 6, 2020
Kala Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateAug 6, 2020
ObsEva Announces Second Quarter 2020 Financial Results and Business UpdateAug 6, 2020
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2020Aug 6, 2020
CTI BioPharma Reports Second Quarter 2020 Financial ResultsAug 6, 2020
Sierra Oncology Reports Second Quarter 2020 ResultsAug 6, 2020
Nabriva Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate UpdatesAug 6, 2020
Glaukos Corporation Announces Second Quarter 2020 Financial ResultsAug 6, 2020
Synlogic Reports Second Quarter 2020 Financial Results and Provides Business UpdateAug 5, 2020
Tricida Announces Second Quarter 2020 Financial ResultsAug 5, 2020
Harpoon Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateAug 5, 2020
Acutus Medical Announces Pricing of Initial Public OfferingAug 5, 2020
Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & Commercialize VP-102 in JapanAug 5, 2020
ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati TherapeuticsAug 5, 2020
Adicet Bio Receives $10 Million Product Development Milestone From RegeneronAug 5, 2020
ORIC Pharmaceuticals Reports Second Quarter 2020 Financial and Operational UpdateAug 5, 2020
GentiBio Launches with $20M Seed Funding from OrbiMed, Novartis Venture Fund and RA Capital Management, L.P. to Develop Engineered Regulatory T cells to Deliver Immune Tolerizing Therapies for Autoimmune and Inflammatory DiseasesAug 5, 2020
Verrica Pharmaceuticals Reports Second Quarter 2020 Financial ResultsAug 4, 2020
Bethany Dudek Joins Arcutis as Vice President of QualityAug 4, 2020
ReViral Announces FDA Fast Track Designation Granted to Sisunatovir For The Treatment of Serious Respiratory Syncytial Virus InfectionAug 4, 2020
Keros Therapeutics, Inc. Announces Completion of Dosing of Planned Cohorts in KER-047 Phase 1 Trial and Provides Program UpdateAug 4, 2020
Aerpio Pharmaceuticals, Inc. Announces a Second Clinical Trial with Funding from MTEC to Evaluate Razuprotafib for the Prevention and Treatment of ARDS in Patients with Moderate to Severe COVID-19Aug 3, 2020
The Journal of Drugs in Dermatology Publishes Results from Positive Phase 1/2a Trial of Arcutis’ ARQ-151 (Topical Roflumilast Cream) for the Treatment of Chronic Plaque PsoriasisAug 3, 2020
Aspen Neuroscience Announces Management TransitionAug 3, 2020
AbCellera Provides COVID-19 Program Update with the Start of Phase 3 Clinical Trials and the Expansion of its COVID-19 Antibody DatabaseAug 3, 2020
VelosBio Appoints Dr. Enoch Kariuki as Chief Financial OfficerAug 3, 2020
PMV Pharma Closes $70 Million in Series D FinancingAug 3, 2020
Dr. Rich Heyman appointed as Chair of the Board of Directors of PMV PharmaAug 3, 2020
Selecta Biosciences Appoints Peter G. Traber, MD as Chief Medical OfficerAug 3, 2020
Graybug Vision Appoints Leading Ophthalmologists and Retinal Experts to Join Its Scientific Advisory BoardJul 31, 2020
Preliminary Data from Long-Term Safety Study Support Chronic Use of ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque PsoriasisJul 31, 2020
Stereotaxis and Acutus Medical Announce First Integrated Cardiac Ablation Procedure with TeleRobotic SupportJul 30, 2020
resTORbio Provides Corporate Update and Reports Second Quarter 2020 Financial ResultsJul 30, 2020
Terns Announces Completion and Positive Results From Phase 1 Clinical Trial of TERN-201, A SSAO Inhibitor in Development for NASHJul 30, 2020
Imara Announces IMR-687 Granted Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Beta-ThalassemiaJul 30, 2020
Synlogic Announces Promotion of Antoine 'Tony' Awad to Chief Operating Officer and Additions to Leadership TeamJul 30, 2020
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial ResultsJul 30, 2020
X4 Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateJul 29, 2020
Imara Added to Membership of U.S. Small-Cap Russell 2000® IndexJul 28, 2020
resTORbio Announces an Award from the National Institute on Aging to Fund a Pilot Study of RTB101 as COVID-19 Prophylaxis in Older AdultsJul 28, 2020
Sobi and Selecta announce closing of previously announced strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory GoutJul 28, 2020
ESSA Pharma Announces Proposed Public Offering of Common SharesJul 28, 2020
Sierra Oncology Appoints Christina Thomson as General CounselJul 28, 2020
Terns and Hanson Pharma Announce Collaboration and License Agreement for TNR-000632 in Greater ChinaJul 28, 2020
Cleave Therapeutics Announces Commencement of Phase 1 Clinical Study of CB-5339, A Valosin-Containing Protein (VCP)/p97 Inhibitor, in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)Jul 28, 2020
NABRIVA Receives European Approval for XENLETA® (lefamulin) for Treatment of Community-Acquired Pneumonia (CAP)Jul 28, 2020
Alector Announces Promising Preliminary Data from AL001 Phase 1b and Phase 2 Open-Label Long-Term Dosing Study of People with Frontotemporal DementiaJul 28, 2020
ESSA Pharma Completes Public Offering for Aggregate Gross Proceeds of US$48,990,000Jul 27, 2020
MBX Biosciences Closes $34.6 Million Series A Financing in Rare Endocrine DiseasesJul 27, 2020
New Published Data Show NeuroPace’s RNS® System Provides Patients with Unprecedented Seizure Reduction and Improved Quality of LifeJul 22, 2020
Scientific Summary: Cyrus NextGen Antibody structure prediction beats Schrodinger and others in a large independent benchmarkJul 22, 2020
Valneva Announces Positive Initial Results for Phase 2 Study of Lyme Disease Vaccine CandidateJul 22, 2020
Closing of Financing, Issued Share Capital and Total Voting RightsJul 22, 2020
SpringWorks Therapeutics Announces Full Enrollment of Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Desmoid TumorsJul 21, 2020
New Cyrus “NextGen” antibody software outperforms the competition in third party test with BIOCAD biotechnologyJul 21, 2020
AbCellera Announces Agreement with Alloy Therapeutics to Integrate Access to ATX-Gx™ Humanized Mice Platform for Antibody Discovery ProgramsJul 20, 2020
Arcutis Enrolls Last Patient in Phase 2b Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Scalp PsoriasisJul 20, 2020
Valneva Confirms Participation in UK Government COVID-19 Vaccine Response ProgramJul 20, 2020
HLS Therapeutics welcomes both CADTH's recommendation to reimburse Vascepa® (icosapent ethyl) for patients with established cardiovascular disease and PMPRB's notification on its introductory priceJul 16, 2020
XENLETA® (lefamulin) Receives Health Canada Approval for Treatment of Community Acquired PneumoniaJul 16, 2020
Adimab Spins Out Adagio Therapeutics to Develop Broadly Protective Coronavirus AntibodiesJul 15, 2020
Nabriva Therapeutics Enters into Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S.Jul 15, 2020
ESSA Pharma Announces First Patient Dosed in a Phase 1 Clinical Trial of EPI-7386 for Metastatic Castration-Resistant Prostrate CancerJul 15, 2020
The New England Journal of Medicine Publishes Results from Positive Phase 2b Trial of Arcutis’ ARQ-151 (Topical Roflumilast Cream) for the Treatment of Chronic Plaque PsoriasisJul 15, 2020
ObsEva SA Awarded Clinical Science Award for Oral Presentation at ESHRE Virtual 36th Annual Meeting, July 2020Jul 15, 2020
Tricida Provides Regulatory Update on VeverimerJul 14, 2020
Verrica Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for VP-102 for the Treatment of Molluscum ContagiosumJul 13, 2020
Use of Cyrus Bench cited in review article of human diseases caused by formin INF2 mutationsJul 13, 2020
Turning Point Therapeutics Names Andrew Partridge As Executive Vice President and Chief Commercial OfficerJul 13, 2020
NextCure Provides an Interim Update of the Phase 2 Portion of the NC318 Monotherapy Phase 1/2 Trial and Announces Departure of Chief Medical OfficerJul 13, 2020
Arcutis Initiates Patient Enrollment in the Phase 2b Portion of the Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand EczemaJul 13, 2020
89bio Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional SharesJul 10, 2020
scPharmaceuticals Appoints Sara Bonstein to Board of DirectorsJul 9, 2020
TELA Bio Announces Interim Analysis from BRAVO Study of OviTex® for Ventral Hernia RepairJul 9, 2020
Inspire Medical Systems, Inc. Announces Appointment of Veteran Consumer Marketing Executive Georgia Garinois-Melenikiotou to its Board of DirectorsJul 8, 2020
Edgewise Therapeutics Appoints Abby H. Bronson, M.B.A., as Vice President, Patient Advocacy and External InnovationJul 8, 2020
Kinnate Biopharma Appoints Dr. Richard Williams as Chief Medical OfficerJul 8, 2020
VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in OncologyJul 8, 2020
CRINETICS PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FOR PALTUSOTINE FOR THE TREATMENT OF ACROMEGALYJul 8, 2020
KLAS Rates TigerConnect Among Top Advanced Clinical Communication PlatformsJul 7, 2020
Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement For Repotrectinib in Greater ChinaJul 7, 2020
NextCure Initiates Phase 1/2 Clinical Study of NC410, a Novel Immunomedicine, for Solid TumorsJul 7, 2020
Corvus Pharmaceuticals Initiates Clinical Trial of Novel Immunotherapy for Patients with COVID-19Jul 6, 2020
ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine FibroidsJul 6, 2020
Ascendis Pharma A/S Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation PlanJul 6, 2020
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSsJul 6, 2020
BELLUS Health Announces Topline Results from its Phase 2 RELIEF Trial of BLU-5937 for the Treatment of Refractory Chronic CoughJul 2, 2020
HARPOON THERAPEUTICS ANNOUNCES CHANGES TO BOARD OF DIRECTORSJul 1, 2020
scPharmaceuticals Announces FUROSCIX® NDA ResubmissionJul 1, 2020
ObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPAJun 30, 2020
Mereo BioPharma Strengthens Management Team; Appoints John Lewicki, PhD, as Chief Scientific Officer and Ann Kapoun, PhD, as SVP of Translational Research and DevelopmentJun 30, 2020
TELA Bio Announces Closing of Public Offering of Common StockJun 30, 2020
WEP Clinical Partners With Nabriva Therapeutics For The Named Patient Supply Of Xenleta® (Lefamulin)Jun 29, 2020
Verrica Pharmaceuticals Provides Regulatory Update on VP-102Jun 29, 2020
IMARA ADDED TO MEMBERSHIP OF U.S. SMALL-CAP RUSSELL 2000® INDEXJun 26, 2020
Passage Bio Added to Russell 2000 IndexJun 26, 2020
Ascendis Pharma A/S Announces Submission of Biologics License Application (BLA) to FDA for TransCon™ hGH in Pediatric Growth Hormone DeficiencyJun 25, 2020
Fusion Pharmaceuticals Announces Pricing Of Initial Public OfferingJun 25, 2020
Alector Announces Publication of Preclinical and Phase 1 Data Validating Potential of AL002, a TREM2 Activating Antibody for the Treatment of Alzheimer’s Disease, in The Journal of Experimental MedicineJun 25, 2020
IMARA ANNOUNCES RECIPIENTS OF REAL IMPACT GRANTS PROGRAM TO SUPPORT PEOPLE AFFECTED BY RARE GENETIC BLOOD DISORDERSJun 24, 2020
IMARA RECEIVES ORPHAN DRUG DESIGNATION FOR IMR-687 FOR TREATMENT OF BETA-THALASSEMIAJun 24, 2020
Alpine Immune Sciences Announces First Patient Dosed in NEON-1 Phase 1 Trial of ALPN-202 in Patients with Advanced MalignanciesJun 23, 2020
TELA Bio Announces Proposed Public Offering of Common StockJun 23, 2020
Gilead Sciences Secures Exclusive Option to Acquire Pionyr ImmunotherapeuticsJun 23, 2020
Repare Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional SharesJun 23, 2020
Gilead Sciences Secures Exclusive Option to Acquire Pionyr ImmunotherapeuticsJun 23, 2020
Compass Therapeutics Completes Reverse Merger and Closes $60 Million Private PlacementJun 22, 2020
Arcutis Enrolls Last Patient in Phase 2 Proof of Concept Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic DermatitisJun 22, 2020
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at the 2020 American Association for Cancer Research Virtual Annual Meeting IIJun 22, 2020
Ascendis Pharma A/S Announces Presentation of Preclinical Data for TransCon IL-2 ?/? at AACR Virtual Annual Meeting 2020Jun 22, 2020
TELA Bio, Inc. to Join the Russell 2000® IndexJun 22, 2020
ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist and CD73 Inhibitor Programs at the 2020 American Association for Cancer Research Virtual Annual Meeting IIJun 22, 2020
Ikena Oncology Presents New Preclinical Data Highlighting the Anti-Cancer Effects of TEAD Inhibition on the Hippo Signaling PathwayJun 22, 2020
Turning Point Therapeutics’ Lead Drug Candidate Repotrectinib Increases Effectiveness of KRAS-G12C and MEK Inhibitors in Preclincal KRAS Cancer ModelsJun 22, 2020
BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical TrialJun 22, 2020
SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and GlaxoSmithKline’s Belantamab Mafodotin for the Treatment of Relapsed or Refractory Multiple MyelomaJun 19, 2020
Nabriva Therapeutics Receives Complete Response Letter from FDA on NDA for CONTEPO™ (fosfomycin) for injectionJun 18, 2020
Sarepta Therapeutics and Selecta Biosciences Enter Into Research License and Option Agreement for Selecta’s ImmTOR Immune Tolerance Platform in Neuromuscular DiseasesJun 18, 2020
Valneva and Bavarian Nordic Announce Marketing and Distribution PartnershipJun 18, 2020
Alpine Immune Sciences and AbbVie Announce Option and License Agreement for the Development and Commercialization of ALPN-101Jun 17, 2020
Edgewise Therapeutics Appoints Kirsten L. Gruis, M.D., M.S. as Chief Medical OfficerJun 16, 2020
Precision Oncology News: Kinnate Exiting Stealth Mode With Plans to Move Lead RAF Inhibitor Into Clinical Trials Next YearJun 16, 2020
Inspire Medical Systems, Inc. Announces Cigna Coverage for Inspire Therapy for the Treatment of Obstructive Sleep ApneaJun 15, 2020
Batavia Biosciences and Valneva Collaborate to Accelerate Development of Low-cost Inactivated Polio VaccineJun 15, 2020
Augmedix Announces New Board Member, Jennifer M. CarterJun 15, 2020
Anthony Bihl Joins Sonendo® Board of DirectorsJun 12, 2020
Verrica Pharmaceuticals Announces Positive Results from Two New Pooled Analyses of the Phase 3 CAMP Trials of VP-102 in Molluscum ContagiosumJun 12, 2020
Keros Therapeutics Presents Results from Clinical and Preclinical Studies Investigating KER-050, along with Preclinical Data from its ALK2 Inhibitor Program, at the European Hematology Association 2020 Annual MeetingJun 12, 2020
IMARA PRESENTS POSITIVE INTERIM RESULTS FROM PHASE 2A STUDY OF IMR-687 IN SICKLE CELL DISEASE AT THE VIRTUAL EUROPEAN HEMATOLOGY ASSOCIATION ANNUAL CONGRESSJun 12, 2020
Sierra Oncology Reports Favorable Long-Term Safety and Dose Intensity Data for MomelotinibJun 12, 2020
X4 Pharmaceuticals Presents Positive Clinical Data from Phase 2 Study of Mavorixafor in WHIM Syndrome at EHA 2020Jun 11, 2020
CRINETICS PHARMACEUTICALS CONFIRMS COMPLETION FOR HALF OF THE ENROLLED PATIENTS IN THE ONGOING PHASE 2 ACROBAT EDGE CLINICAL TRIAL FOR PALTUSOTINEJun 11, 2020
Sobi and Selecta announce strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory GoutJun 11, 2020
X4 Pharmaceuticals Promotes Renato Skerlj, Ph.D., to Chief Scientific OfficerJun 10, 2020
Verrica Pharmaceuticals Appoints Diem Nguyen, Ph.D., M.B.A., to its Board of DirectorsJun 9, 2020
Pandion Therapeutics Announces Issuance of U.S. Patent for Bifunctional Molecules Derived from TALON™ PlatformJun 9, 2020
ORIC Pharmaceuticals Appoints Lori Kunkel, M.D., to its Board of DirectorsJun 8, 2020
Ascendis Pharma A/S Announces Participation in ENDO Online 2020Jun 8, 2020
Alpine Immune Sciences Provides Clinical Update of its Phase 1 Trial of ALPN-101 in Healthy Volunteers at the European League Against Rheumatism (EULAR) E-Congress 2020Jun 8, 2020
Glaukos Corporation Announces Pricing of Private Offering of $250 Million of 2.75% Convertible Senior NotesJun 8, 2020
Inspire Medical Systems, Inc. Announces Appointment of Medical Technology Industry Veteran Phil Ebeling as Chief Operating OfficerJun 5, 2020
Intellia Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional SharesJun 5, 2020
Menlo Therapeutics Announces Pricing of Offering of Common StockJun 4, 2020
89bio Appoints Veteran Finance Executive Lota Zoth to Board of DirectorsJun 4, 2020
Alpine Immune Sciences Presents Preclinical Data on Novel Dual BAFF/APRIL Inhibitory Domains for B cell Mediated Autoimmune Diseases at the European Congress of Rheumatology E-Congress 2020Jun 4, 2020
Prevail Therapeutics Appoints Kira Schwartz, J.D., as General CounselJun 4, 2020
Silverback Therapeutics Appoints Vickie L. Capps to Board of Directors and Audit Committee ChairJun 2, 2020
Menlo Therapeutics Announces Positive Results from Phase 2 Trial of FCD105 for the Treatment of Moderate-to-Severe Acne VulgarisJun 2, 2020
WAKIX® (pitolisant) Data from Harmony Bioscienes Included on American Academy of Neurology Science Highlights Virtual PlatformJun 2, 2020
Valneva Announces Publication in The Lancet of Complete Phase 1 Data for its Single-Shot Chikungunya Vaccine CandidateJun 1, 2020
AbCellera’s Rapid Pandemic Response Platform Contributes to the World’s First COVID-19 Clinical Trial for a Potential Monoclonal Antibody TreatmentJun 1, 2020
Ayisha Jeter Joins Arcutis as Vice President of Market AccessJun 1, 2020
Publication in Nature Communications Highlights the Preclinical Development of SYNB1891 and its Potential as a Dual Innate Immune Activator to Stimulate an Immune Response in Difficult to Treat TumorsJun 1, 2020
CTI BioPharma Announces Enrollment of First Patient in COVID-19 PRE-VENT Phase 3 Clinical TrialJun 1, 2020
Regeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based TreatmentsJun 1, 2020
HLS Therapeutics to Become Distributor of the Saladax MyCare� Psychiatry Line including the Insite Point-of-Care Device and Antipsychotic ReagentsMay 29, 2020
Menlo Therapeutics Receives FDA Approval of ZILXI™ (minocycline) topical foam, 1.5%, the First Topical Minocycline Treatment for RosaceaMay 29, 2020
NextCure Presents Biomarker Data and Updated Clinical Results from Phase 1 Portion of its NC318 Clinical Trial at the 2020 Virtual American Society of Clinical Oncology Annual MeetingMay 29, 2020
ObsEva SA to present at the Jefferies Virtual Healthcare Conference June 3rd, 2020May 29, 2020
HARPOON THERAPEUTICS PRESENTS INTERIM PHASE 1 DATA FROM AN ONGOING DOSE ESCALATION TRIAL FOR THE PSMA-TARGETING TRITAC® HPN424 AT THE ASCO20 VIRTUAL SCIENTIFIC PROGRAMMay 29, 2020
Turning Point Therapeutics Presents Preclinical Data For Novel RET Inhibitor Candidate, TPX-0046May 29, 2020
Corvus Pharmaceuticals Presents Updated Clinical Data Supporting and Refining the Adenosine Gene Signature’s Ability to Identify Patients Likely to Respond to Treatment with CiforadenantMay 28, 2020
resTORbio Announces Initiation of Study to Evaluate if Antiviral Prophylaxis with RTB101 Reduces the Severity of COVID-19 in Nursing Home ResidentsMay 27, 2020
AbCellera Closes $105 Million Series B Financing to Further Advance World-Leading Antibody Drug Discovery PlatformMay 27, 2020
Aerpio Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative Announce the Selection of Razuprotafib for Evaluation in the I-SPY COVID Trial for the Treatment of Acute Respiratory Distress Syndrome in COVID-19 PatientsMay 27, 2020
Jay Ramsinghani Joins Arcutis as Vice President of Commercial Strategy and OperationsMay 27, 2020
Turning Point Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common StockMay 27, 2020
Kinnate Biopharma Appoints Nima Farzan as Chief Executive OfficerMay 27, 2020
resTORbio Provides Corporate Update and Reports First Quarter 2020 Financial ResultsMay 27, 2020
CRINETICS PHARMACEUTICALS APPOINTS ADRIANA CABRÉ, MBA, AS VICE PRESIDENT OF HUMAN RESOURCESMay 27, 2020
Q32 Bio Launches to Develop Novel Therapeutics Targeting Regulators of Innate and Adaptive ImmunityMay 26, 2020
Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of NeurologyMay 26, 2020
Sierra Oncology Appoints Dr. Stephen Dilly as President and Chief Executive OfficerMay 26, 2020
SpringWorks Therapeutics Appoints Julie Hambleton, M.D. to its Board of DirectorsMay 26, 2020
Repare Therapeutics Announces Multi-Target Discovery Collaboration with Bristol Myers SquibbMay 26, 2020
KALA PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR EYSUVIS™ FOR DRY EYE DISEASEMay 26, 2020
TransMedics Announces Positive Top-line Results from U.S. Pivotal OCS� Liver PROTECT TrialMay 26, 2020
TransMedics Announces Pricing of Public Offering of Common StockMay 22, 2020
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial ResultsMay 22, 2020
AbCellera Announces Multi-Year Antibody Discovery Collaboration with LillyMay 22, 2020
Tricida Announces Closing of Offering of $200 Million of 3.50% Convertible Senior Notes Due 2027, Including Full Exercise of Option to Purchase Additional NotesMay 21, 2020
Xenon Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate UpdateMay 21, 2020
Synlogic Announces Termination of AbbVie Collaboration AgreementMay 21, 2020
Passage Bio Receives Rare Pediatric Disease Designation for PBGM01 for Patients with GM1 GangliosidosisMay 20, 2020
ORIC Pharmaceuticals Reports First Quarter 2020 Financial and Operational ResultsMay 20, 2020
New Alliance Maps the Way in ElectrophysiologyMay 20, 2020
scPharmaceuticals Announces Pricing of Public Offering of Common StockMay 19, 2020
Ascendis Pharma A/S Reports First Quarter 2020 Financial ResultsMay 19, 2020
Galecto Appoints New Chair and Strengthens Board of DirectorsMay 19, 2020
Pandion Therapeutics Appoints John S. Sundy, M.D., Ph.D., as Chief Medical OfficerMay 18, 2020
Graybug Vision Appoints Parisa Zamiri, Physician-Scientist with Deep Expertise in Ophthalmology, as Chief Medical OfficerMay 18, 2020
National Burden of Macrolide-Resistant Streptococcus Pneumoniae in the United States From Blood and Respiratory Tract Cultures Approaches 40 PercentMay 15, 2020
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 2020 Virtual American Urological Association (AUA) Annual MeetingMay 14, 2020
X4 Pharmaceuticals Announces Data from Phase 2 Open-Label Extension Trial of Mavorixafor in WHIM Syndrome as Published in EHA AbstractMay 14, 2020
Prevail Therapeutics Reports First Quarter 2020 Financial Results and Business HighlightsMay 14, 2020
Verona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical ProgramMay 14, 2020
Alpine Immune Sciences Reports First Quarter 2020 Financial Results and Provides Company UpdateMay 14, 2020
BELLUS Health Reports First Quarter 2020 Financial Results and Business Highlights, and Provides Updates on BLU-5937May 13, 2020
89bio Reports First Quarter 2020 Financial Results and Provides Corporate UpdateMay 13, 2020
Alector Reports 2020 First Quarter Financial Results and Business HighlightsMay 12, 2020
scPharmaceuticals Inc. Reports First Quarter 2020 Financial Results and Provides Business UpdateMay 12, 2020
Intellia Therapeutics Reports Progress on CRISPR/Cas9 AML Cancer Therapy Using Proprietary Cell Engineering Process at the 23rd Annual Meeting of the American Society of Gene and Cell TherapyMay 12, 2020
TELA Bio Announces First Quarter 2020 Financial ResultsMay 12, 2020
SpringWorks Therapeutics Reports First Quarter 2020 Financial Results and Recent Business HighlightsMay 12, 2020
Arcutis Announces First Quarter 2020 Financial Results and Provides Business UpdateMay 12, 2020
Turning Point Therapeutics Reports First-Quarter Financial Results, Provides Update on Operations and COVID-19 ResponseMay 12, 2020
Aerpio Announces Amended Licensing Deal with Gossamer Bio on its Inflammatory Bowel Disease (IBD) Product Candidate GB004 (formerly AKB-4924)May 11, 2020
Nabriva Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate UpdatesMay 11, 2020
Ascendis Pharma A/S Will Appoint Jesper Høiland as Global Chief Commercial OfficerMay 11, 2020
Augmedix Introduces New Services that Increase Clinician Productivity and Enhance the Clinician-Patient RelationshipMay 11, 2020
Passage Bio Reports First Quarter 2020 Financial Results and Recent Business HighlightsMay 8, 2020
CRINETICS PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATEMay 8, 2020
Synlogic Reports First Quarter 2020 Financial Results and Provides Business UpdateMay 7, 2020
Sierra Oncology Reports First Quarter 2020 ResultsMay 7, 2020
Passage Bio Announces Expansion of Gene Therapy Collaboration with University of PennsylvaniaMay 7, 2020
Verrica Pharmaceuticals Reports First Quarter 2020 Financial ResultsMay 7, 2020
X4 Pharmaceuticals Provides Corporate Update, Including Expected Impact of COVID-19, and Reports First Quarter 2020 Financial ResultsMay 7, 2020
KALA PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATEMay 7, 2020
Selecta Biosciences Reports First Quarter 2020 Financial ResultsMay 7, 2020
Aeglea BioTherapeutics Reports First Quarter 2020 Financial Results and Corporate HighlightsMay 7, 2020
Tricida Announces First Quarter 2020 Financial ResultsMay 7, 2020
Intellia Therapeutics Announces First Quarter 2020 Financial ResultsMay 7, 2020
CTI BioPharma Reports First Quarter 2020 Financial ResultsMay 7, 2020
Gemini Therapeutics Appoints Marc E. Uknis, MD, FACS as Chief Medical OfficerMay 7, 2020
Aerpio Reports First Quarter 2020 Financial Results and Provides Business UpdateMay 7, 2020
NextCure Reports First Quarter 2020 Financial ResultsMay 7, 2020
IMARA REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTSMay 7, 2020
Glaukos Corporation Announces First Quarter 2020 Financial ResultsMay 7, 2020
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2020May 6, 2020
HARPOON THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATEMay 6, 2020
Galecto Advances Phase 2b Study of GB0139 in Idiopathic Pulmonary Fibrosis; Recruitment Remains on Track Despite COVID-19 CrisisMay 6, 2020
IMARA LAUNCHES ‘REAL IMPACT’ COMMUNITY SUPPORT PROGRAM TO ADDRESS UNMET NEEDS AFFECTING PEOPLE WITH RARE GENETIC BLOOD DISORDERSMay 5, 2020
ObsEva Announces First Quarter 2020 Financial Results and Business UpdateMay 5, 2020
Inspire Medical Systems, Inc. Announces First Quarter 2020 Financial ResultsMay 5, 2020
XENLETA® (Lefamulin) Treatment Results in a Rapid Time-to-Clinical Response in Hospitalized Patients with Community-Acquired Bacterial Pneumonia (CABP)May 4, 2020
IMARA ANNOUNCES APPOINTMENT OF STEPHEN M. MIGAUSKY AS GENERAL COUNSELMay 4, 2020
Galecto presents GB0139 preclinical and clinical data on anti-fibrotic activity as online Experimental Biology 2020 posterMay 3, 2020
AbCellera Receives $175.6 million from the Government of Canada to Discover Solutions for COVID-19 and Build a Manufacturing Facility for Antibody DrugsApr 30, 2020
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2020 Financial ResultsApr 30, 2020
Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15Apr 30, 2020
Intellia Therapeutics Names David Lebwohl, M.D., Chief Medical OfficerApr 30, 2020
Aeglea BioTherapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesApr 30, 2020
Verona Pharma plc: Operational Update and Financial Results for the Three Months Ended March 31, 2020Apr 29, 2020
Aspen Neuroscience Announces Addition to Board of DirectorsApr 29, 2020
resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy TechnologyApr 29, 2020
resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy TechnologyApr 28, 2020
Selecta Biosciences Appoints Dr. Goran Ando to its Board of DirectorsApr 28, 2020
Gemini Therapeutics Appoints David Lubner as Independent DirectorApr 28, 2020
ORIC Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesApr 27, 2020
HARPOON THERAPEUTICS DOSES FIRST PATIENT WITH HPN217, A BCMA TARGETING TRITAC, FOR MULTIPLE MYELOMAApr 27, 2020
Galecto Appoints Jonathan Freve as Chief Financial OfficerApr 27, 2020
CTI Biopharma Announces Initiation of Phase 3 PRE-VENT Study Evaluating Pacritinib in Hospitalized Patients with Severe COVID-19Apr 27, 2020
Halley E. Gilbert Appointed to Arcutis Board of DirectorsApr 23, 2020
Menlo Therapeutics and Cutia Therapeutics Enter into Exclusive License Agreement for AMZEEQ™ and Approved Topical Minocycline Products in Greater ChinaApr 23, 2020
TELA Bio Announces Changes to its Board of DirectorsApr 23, 2020
Imara Strengthens Board of Directors With Appointment of Edward R. Conner, M.D.Apr 22, 2020
Silverback Therapeutics Announces Appointment of Veteran Executive Laura Shawver, Ph.D. as President and CEOApr 22, 2020
Valneva and Dynavax Announce Collaboration to Advance Vaccine Development for COVID-19Apr 21, 2020
Inspire Medical Systems Announces FDA Approval of Expanded Age Range for Inspire TherapyApr 21, 2020
Nature Communications Highlights Research by Scientists at Graybug Vision and Johns Hopkins University on Sustained Treatment of Retinal DiseasesApr 21, 2020
Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand EczemaApr 19, 2020
Ascendis Pharma A/S Announces Top-line Data from Fixed Dose Portion of Phase 2 Trial Demonstrating Potential of TransCon™ PTH as a Replacement Therapy for HypoparathyroidismApr 17, 2020
Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesApr 16, 2020
TigerConnect Launches TigerTouch Video and Voice Telehealth Features to Help Hospitals Combat COVID-19Apr 16, 2020
Inspire Medical Systems, Inc. Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesApr 16, 2020
Clinical Cancer Research Highlights Potent Antitumor Activity of Repotrectinib in Treatment-Naïve and Solvent-Front Mutation Ros1-Positive Non-Small Cell Lung CancerApr 15, 2020
Ascendis Pharma A/S Receives Orphan Drug Designation for TransCon™ hGH as Treatment for Growth Hormone Deficiency in the United StatesApr 15, 2020
Carl Gordon named to 2020 Forbes Midas List of top venture capitalistsApr 14, 2020
ObsEva to Increase Issued Share Capital by Creating Additional Treasury SharesApr 13, 2020
89bio Announces Closing of Enrollment in its Phase 1b/2a NASH Trial and Reports New Preclinical Data Confirming BIO89-100’s Mechanism of Action Via Potent FGF Receptor AgonismApr 13, 2020
Arvinas Provides Update on Business Continuity Related to the Impact of the COVID-19 PandemicApr 13, 2020
Inspire Medical Systems, Inc. Provides First Quarter and Full Year 2020 UpdateApr 13, 2020
NextCure Provides Update on Clinical Trial Activities Due to Impact of COVID-19 PandemicApr 9, 2020
Centers for Medicare & Medicaid Services Issues Product-Specific J-Code for XENLETAApr 9, 2020
Glaukos Provides Update on COVID-19 Impact and Preliminary Net Sales Range for the First Quarter of 2020Apr 8, 2020
Aeglea BioTherapeutics Announces Approval of Clinical Trial Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)Apr 7, 2020
X4 Pharmaceuticals Showcases Strategic Focus on WHIM Syndrome During 2020 Analyst Day WebinarApr 7, 2020
Keros Therapeutics Announces Pricing of Initial Public Offering of Common StockApr 6, 2020
BELLUS Health Announces Completion of Dosing in Phase 2 RELIEF Trial with BLU-5937 for the Treatment of Refractory Chronic CoughApr 6, 2020
CRINETICS PHARMACEUTICALS REPORTS POSITIVE INTERIM RESULTS FOR THE ACROBAT EDGE PHASE 2 TRIAL OF PALTUSOTINE (CRN00808) IN ACROMEGALY PATIENTS AND PROVIDES CORPORATE UPDATEApr 6, 2020
ObsEva SA Announces New Interim Chief Financial OfficerApr 6, 2020
Aspen Neuroscience Announces Reconstitution of the Board of Directors with the Addition of Seasoned Industry ExecutivesApr 3, 2020
resTORbio Announces Delay of its Ongoing Phase 1b/2a trial of RTB101 in Patients with Parkinson’s Disease Due to COVID-19 Level 4 Alert in New ZealandApr 2, 2020
ORIC PHARMACEUTICALS APPOINTS CHRISTIAN V. KUHLEN, M.D., AS GENERAL COUNSELApr 1, 2020
HARPOON THERAPEUTICS APPOINTS TWO NEW MEMBERS TO ITS BOARD OF DIRECTORSApr 1, 2020
Ascendis Pharma A/S Reports Full-Year 2019 Financial ResultsApr 1, 2020
Aspen Neuroscience Announces $70 Million Series A Financing Led by OrbiMed to Advance Development of the First Autologous Neuron Replacement Therapy to Treat Parkinson DiseaseApr 1, 2020
Pandion Therapeutics Announces Close of $80 Million Series B FinancingMar 31, 2020
Health Catalyst Launches Four Additional COVID-19 Solutions and a Modular BundleMar 31, 2020
Xenon Pharmaceuticals Provides Corporate Update in the Context of COVID-19Mar 31, 2020
FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia TherapeuticsMar 31, 2020
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL AND SPECIALMar 31, 2020
Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPDMar 30, 2020
NextCure Announces Appointment of Veteran Oncology Executive Garry Nicholson to its Board of DirectorsMar 30, 2020
Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial ResultsMar 30, 2020
Harmony Biosciences Highlights Publication of Narcolepsy Treatment Scientific Review in Sleep MedicineMar 30, 2020
Synlogic Provides Summary of Impact of COVID-19 on Clinical Program Progress and Operational ActivitiesMar 30, 2020
Compass Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy and Safety of CTX-471, a Unique Fully Human Agonist of CD137Mar 27, 2020
TELA Bio Announces Fourth Quarter and Full Year 2019 Financial ResultsMar 26, 2020
Prevail Therapeutics Reports Full Year 2019 Financial Results and Business HighlightsMar 25, 2020
BELLUS Health Announces Closing of Transaction to Acquire Remaining Intellectual Property Rights to BLU-5937 from adMare BioInnovationsMar 25, 2020
89bio Appoints Healthcare Industry Veteran Steven Altschuler, M.D., as Chairman of the Board of DirectorsMar 25, 2020
Alector Enters into a Licensing Agreement with Innovent Biologics to Develop and Commercialize AL008 in Oncology Indications in ChinaMar 24, 2020
Alector Reports 2019 Fourth Quarter and Full Year Financial Results and Business HighlightsMar 24, 2020
Health Catalyst Expands COVID-19 Response Support and Provides Infrastructure to Enable Readiness for Future DemandsMar 24, 2020
Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR006 to Slow the Progression of Frontotemporal Dementia with a GRN MutationMar 24, 2020
Glaukos Provides COVID-19 Pandemic UpdateMar 24, 2020
scPharmaceuticals Inc. Reports Fourth Quarter and Year Ended 2019 Financial Results and Provides Business UpdateMar 23, 2020
Kimberly Lathroum Joins Arcutis as Vice President of MarketingMar 23, 2020
ObsEva Provides Update Related to COVID-19 PandemicMar 23, 2020
Fusion Pharmaceuticals Appoints James J. O’Leary, M.D. As Chief Medical OfficerMar 23, 2020
Alector Announces the Appointment of Paula Hammond, Ph.D., to the Board of DirectorsMar 20, 2020
Verona Pharma plc: Issue of Equity and Total Voting RightsMar 19, 2020
BELLUS Health Announces Completion of Enrollment in Phase 2 RELIEF Trial of BLU-5937 for the Treatment of Refractory Chronic CoughMar 18, 2020
SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039Mar 18, 2020
89bio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate UpdateMar 18, 2020
Alpine Immune Sciences’ ALPN-101 Receives FDA Orphan Drug Designations for the Prevention and Treatment of Acute Graft Versus Host DiseaseMar 17, 2020
Health Catalyst Plans to Support Health System Clients� COVID-19 Response with Three Initial Solutions Focused on Patient Tracking, Public Health Surveillance and Staff Augmentation SupportMar 16, 2020
Arcutis Announces Inclusion of Children in On-going Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast (ARQ-151) as a Potential Once Daily Topical Treatment for Plaque PsoriasisMar 16, 2020
Arvinas Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate UpdateMar 16, 2020
Aerpio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business UpdateMar 16, 2020
TURNING POINT THERAPEUTICS REPORTS FOURTH-QUARTER, FULL- YEAR 2019 FINANCIAL AND OPERATIONAL RESULTSMar 13, 2020
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial ResultsMar 12, 2020
X4 Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial ResultsMar 12, 2020
CTI BioPharma Reports Fourth Quarter and Full Year 2019 Financial ResultsMar 12, 2020
Nabriva Therapeutics Reports Fourth Quarter and Year End 2019 Financial Results and Recent Corporate HighlightsMar 12, 2020
AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-19Mar 12, 2020
Sonendo® Appoints Amit Agarwal as Vice President of MarketingMar 12, 2020
HARPOON THERAPEUTICS REPORTS FOURTH QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATEMar 12, 2020
resTORbio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate UpdateMar 12, 2020
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business HighlightsMar 12, 2020
Synlogic Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business UpdateMar 12, 2020
Selecta Biosciences Reports Fourth Quarter 2019 and Year-End Financial ResultsMar 11, 2020
Verrica Pharmaceuticals Secures $55 Million in Loan Facilities Led by Silicon Valley BankMar 11, 2020
Silverback Therapeutics Raises $78.5 Million in Oversubscribed Series B FinancingMar 10, 2020
KALA PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF 16,000,000 SHARES OF COMMON STOCKMar 9, 2020
NeuroPace RNS System Receives FDA Approval for MRI Labeling, Allowing Thousands More Patients to Benefit from Personalized, Data-Driven Epilepsy TreatmentMar 9, 2020
Tricida Hires Robert McKague as Executive Vice President, General Counsel & Chief Compliance OfficerMar 9, 2020
KALA PHARMACEUTICALS ANNOUNCES STATISTICALLY SIGNIFICANT RESULTS FOR PRIMARY AND KEY SECONDARY ENDPOINTS IN STRIDE 3 CLINICAL TRIAL EVALUATING EYSUVIS™ FOR SIGNS AND SYMPTOMS OF DRY EYE DISEASEMar 9, 2020
Xenon Pharmaceuticals Reports 2019 Financial Results and Provides Corporate UpdateMar 9, 2020
CRINETICS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATEMar 6, 2020
Keros Therapeutics Closes $56 Million Series C Financing to Advance its Programs in Hematologic and Musculoskeletal DisordersMar 6, 2020
CTI BioPharma Announces Closing of Rights OfferingMar 5, 2020
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial ResultsMar 5, 2020
ObsEva Announces Year End 2019 Financial Results and Business UpdateMar 5, 2020
Heather Rowe Armstrong Joins Arcutis as Vice President of Investor Relations and Corporate CommunicationsMar 5, 2020
Passage Bio Appoints Athena Countouriotis to Board of DirectorsMar 4, 2020
Fusion Pharmaceuticals Announces Appointment Of Steven Gannon To Board Of DirectorsMar 3, 2020
Prevail Therapeutics Provides Clinical Advancement Update on PR001 for the Treatment of Parkinson’s Disease with GBA1 mutationsMar 3, 2020
Sierra Oncology Reports 2019 Year End ResultsMar 2, 2020
ORIC PHARMACEUTICALS APPOINTS MARDI C. DIER TO ITS BOARD OF DIRECTORSMar 2, 2020
Prevail Therapeutics Announces Investigational New Drug Application Active for PR006 for the Treatment of Frontotemporal Dementia with GRN MutationFeb 28, 2020
Graybug Vision presents preclinical results for GB-401, a potential sustained-delivery treatment of up to six months for primary open angle glaucoma, at the American Glaucoma Society Annual MeetingFeb 27, 2020
MapKure, BeiGene and SpringWorks Announce Initiation of Phase 1 Clinical Trial of BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid TumorsFeb 27, 2020
Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business UpdateFeb 27, 2020
Glaukos Corporation Announces Fourth Quarter and Full Year 2019 Financial ResultsFeb 27, 2020
BELLUS Health Reports Full Year 2019 Financial Results and Business Highlights on BLU-5937Feb 27, 2020
Tricida Announces Fourth Quarter and Full-Year 2019 Financial ResultsFeb 27, 2020
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial ResultsFeb 27, 2020
Verona Pharma Reports Financial Results for the Full Year Ended December 31, 2019 and Provides Corporate UpdateFeb 27, 2020
Passage Bio Announces Pricing of Initial Public OfferingFeb 27, 2020
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL AND SPECIALFeb 26, 2020
Numerous Presentations to Showcase Long-Term Efficacy & Safety of Glaukos Technologies at 2020 American Glaucoma Society MeetingFeb 26, 2020
Gemini Therapeutics and Singapore Eye Research Institute Enter Into Research Collaboration to Explore New Targets for Age-related Macular DegenerationFeb 25, 2020
Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2019 Financial Results and Provides 2020 GuidanceFeb 24, 2020
Aeglea BioTherapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results, Highlights Recent MilestonesFeb 20, 2020
Turning Point Therapeutics Names Siegfried Reich as Executive Vice President and Chief Scientific OfficerFeb 19, 2020
resTORbio Announces Interim Results for Phase 1b/2a Trial of RTB101 in Patients with Parkinson’s Disease and Provides Corporate UpdateFeb 18, 2020
Adaptimmune Announces Appointment of Gavin Wood as Chief Financial OfficerFeb 14, 2020
Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory ResearchFeb 14, 2020
CTI BioPharma Announces Commencement of Rights OfferingFeb 14, 2020
Xenon Pharmaceuticals Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional SharesFeb 13, 2020
Corvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1b/2 Clinical Trial of Ciforadenant at the 2020 American Society of Clinical Oncology’s Genitourinary Cancers SymposiumFeb 13, 2020
Arcutis Announces Enrollment of First Patient in Topical Roflumilast Cream Phase 3 Open Label Extension Study in Plaque PsoriasisFeb 12, 2020
Prevail Therapeutics’ PR001 Receives Orphan Drug Designation and Rare Pediatric Disease Designation from FDAFeb 12, 2020
X4 Pharmaceuticals Granted New Composition of Matter Patent for Late-Stage Clinical Candidate MavorixaforFeb 12, 2020
Kala Pharmaceuticals Reports Fourth Quarter And Full Year 2019 Financial ResultsFeb 10, 2020
Intellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposia’s Engineering the Genome ConferenceFeb 10, 2020
Essa Pharma Announces Multiple Abstracts Accepted For Presentation At Upcoming Medical And Scientific SymposiaFeb 7, 2020
Adaptimmune Therapeutics plc Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional American Depositary SharesFeb 7, 2020
Aerpio Pharmaceuticals Presents Data from Fifth Patient Cohort Showing Potential of Topical Ocular Formulation of AKB-9778 Product Candidate When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular HypertensionFeb 6, 2020
Fusion Pharmaceuticals Announces Appointment Of Pablo J. Cagnoni, M.D., To Board Of DirectorsFeb 6, 2020
VectivBio Adds Commercial Expertise with the Appointment of Kevin Harris as Chief Commercial OfficerFeb 6, 2020
Sonendo® Appoints Andrew Kirkpatrick as Chief Operating OfficerFeb 6, 2020
Imara Appoints Joelle Lufkin, M.P.H., as Senior Vice President of DevelopmentFeb 6, 2020
Sierra Oncology Completes Conversion of Preferred to Common Stock and Issues Stock to GileadFeb 5, 2020
Alector Announces FDA Fast Track Designation Granted to AL101 for the Treatment of Patients with Frontotemporal DementiaFeb 4, 2020
TELA Bio Announces Publication of Results from In-Vivo Study Demonstrating Favorable Response to Reinforced Biologics in Hernia RepairFeb 4, 2020
Arcutis Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesFeb 3, 2020
Alector Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesFeb 3, 2020
Valneva Announces New $85 Million Financing Arrangement with Leading US Healthcare Funds Deerfield and OrbiMedFeb 3, 2020
CTI BioPharma Establishes Accelerated Approval Pathway for Pacritinib in Treating Myelofibrosis Patients With Severe ThrombocytopeniaFeb 3, 2020
OrbiMed Announces New General PartnerFeb 3, 2020
Verona Pharma Announces Senior Management ChangesFeb 3, 2020
Galecto Appoints Industry Leader Bertil Lindmark, MD, PhD, as Chief Medical OfficerFeb 3, 2020
Inspire Medical Systems, Inc. Announces Medicare Policy Release Dates and New Draft Local Coverage Determination for Remaining RegionFeb 1, 2020
Corvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1/1b Clinical Trial of CPI-818 at the 12th Annual T-Cell Lymphoma ForumJan 30, 2020
Synlogic Appoints Dr. Michael Burgess to its Board of DirectorsJan 29, 2020
Verrica Pharmaceuticals Announces the Hiring of Two Vice Presidents to Further Grow its Commercial CapabilitiesJan 29, 2020
TELA Bio Announces Appointment of New Chief Commercial OfficerJan 28, 2020
Alector Announces Initiation of Phase 1b Study of AL003 in Alzheimer’s Disease PatientsJan 28, 2020
Passage Bio Appoints Bruce Goldsmith, Ph.D. as Chief Executive OfficerJan 28, 2020
Ikena Oncology Announces Dosing of First Patient in Phase 1 Study Evaluating IK-175 in Patients with Advanced Solid TumorsJan 27, 2020
ORIC Pharmaceuticals Announces First Patient Dosed in Phase 1b Clinical Trial of ORIC-101 in Combination with XTANDI® for the Treatment of Prostate Cancer in Collaboration with AstellasJan 27, 2020
ReViral’s Phase 2a RSV Study publication selected as Editor’s Pick in February 2020 issue of ASM’s Antimicrobial Agents and ChemotherapyJan 27, 2020
Harmony Biosciences Secures $200 Million Debt FacilityJan 27, 2020
Alector Announces Proposed Public Offering of Common StockJan 24, 2020
Alpine Immune Sciences Presents New Preclinical Data at 2020 Crohn's & Colitis Congress ALPN-101 demonstrates efficacy in treatment of chronic inflammatory bowel disease in both in vivo and in vitro modelsJan 23, 2020
Turning Point Therapeutics Names Garry Nicholson to Its Board of DirectorsJan 22, 2020
Sierra Oncology Announces Reverse Stock SplitJan 22, 2020
TigerConnect Names New Chief Technology Officer as it Accelerates Product InnovationJan 22, 2020
Xenon Pharmaceuticals Announces Pricing of $60.0 Million Public Offering of Common SharesJan 22, 2020
Adaptimmune Therapeutics plc Prices Public Offering of American Depositary SharesJan 21, 2020
Arcutis Announces ARQ-154 Program for Scalp Psoriasis and Enrollment of First Patient in Phase 2b Clinical TrialJan 18, 2020
Verrica Pharmaceuticals Announces Presentation of Positive Data from New Pooled Analysis of Phase 3 CAMP Trials of VP-102Jan 15, 2020
Kala Pharmaceuticals Announces Completion of Enrollment of STRIDE 3 Trial for EYSUVIS™ (KPI-121 0.25%) for Dry Eye DiseaseJan 15, 2020
Patricia Turney Joins Arcutis as Senior Vice President, ManufacturingJan 14, 2020
Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell TherapiesJan 14, 2020
Adimab Extends Platform Partnership with Novo NordiskJan 13, 2020
Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D LeadershipJan 13, 2020
Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)Jan 13, 2020
KaNDy Therapeutics Announces Positive Phase 2b Data in Post-Menopausal Women with its Lead Non-Hormonal Product NT-814Jan 13, 2020
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2020 and Provides Corporate UpdateJan 13, 2020
Arcutis Announces Exercise of Option for Exclusive License to Highly Selective JAK1 Inhibitor for All Topical Dermatological Uses in U.S., Canada, Europe and JapanJan 13, 2020
Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor IndicationsJan 13, 2020
Adimab Provides 2019 Update on Clinical PipelineJan 13, 2020
Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium TherapyJan 13, 2020
Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple MyelomaJan 13, 2020
Fusion Pharmaceuticals Announces Investment from Canada Pension Plan Investment Board (CPPIB)Jan 13, 2020
ObsEva and Yuyuan BioScience Technology Announce Sublicense Agreement to Develop and Commercialize Nolasiban in the People’s Republic of ChinaJan 13, 2020
Turning Point Therapeutics Announces Program Updates and Milestones for 2020Jan 12, 2020
Ascendis Pharma A/S Provides Pipeline Update and Reviews Progress Towards Vision 3x3 at 38th Annual J.P. Morgan Healthcare ConferenceJan 10, 2020
Adimab Provides Year-End Update on 2019 Partnership ActivitiesJan 10, 2020
TELA Bio Announces Preliminary Revenue for Fourth Quarter and Full Year 2019Jan 10, 2020
Passage Bio Appoints Sandip Kapadia to Board of DirectorsJan 10, 2020
TERNS PHARMACEUTICALS PRESENTS RESULTS FROM AN ONGOING PHASE 1 CLINICAL TRIAL OF TERN-201, A SSAO INHIBITOR IN DEVELOPMENT FOR NASHJan 9, 2020
Aspen Neuroscience Announces Board of Directors and Scientific Advisory BoardJan 9, 2020
Prevail Therapeutics Provides PR001 Program UpdateJan 9, 2020
Turning Point Therapeutics Announces Management TransitionJan 9, 2020
Intellia Therapeutics Highlights Recent Progress and Anticipated 2020 MilestonesJan 9, 2020
Synlogic Outlines Upcoming Milestones for Clinical Programs and Unveils New Preclinical Pipeline ProgramsJan 9, 2020
Gemini Therapeutics Enrolls First Patient in Phase 1 Study of GEM103 for Dry Age-related Macular DegenerationJan 8, 2020
Arcutis Announces Enrollment of First Patients in Two Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 as a Potential Once Daily Topical Treatment for Plaque PsoriasisJan 8, 2020
Nabriva Therapeutics Receives FDA Acknowledgement of New Drug Application Resubmission for Intravenous CONTEPO™ (fosfomycin) for InjectionJan 8, 2020
Topical Ocular Formulation of Aerpio Pharmaceutical's AKB-9778 Product Candidate Produced IOP Lowering with Minimal Hyperemia When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension in Phase 1b TrialJan 7, 2020
Galecto and PharmAkea merge to create strong clinical-stage company developing first-in-class therapeutics in fibrosis and cancerJan 7, 2020
VectivBio Launches with $35M Financing to Bring Best-in-Disease Medicines to Patients with Serious Rare DiseasesJan 7, 2020
Verona Pharma Appoints David Moskowitz as Vice President, Capital Markets Strategy & Investor RelationsJan 6, 2020
Sonendo® Announces Growth Investment from EW Healthcare PartnersJan 6, 2020
Arcutis Biotherapeutics Announces Filing of Registration Statement for Proposed Initial Public OfferingJan 6, 2020
Turning Point Therapeutics Names Homa Yeganegi Senior Vice President, Project Team Leader and Head of Medical AffairsJan 6, 2020
Alector Initiates First-in-Human Dosing in Phase 1 Study of AL101 for the Treatment of Neurodegenerative DiseasesDec 31, 2019
HLS Therapeutics Announces Health Canada Approval for Vascepa® to Reduce the Risk of Cardiovascular EventsDec 30, 2019
X4 Pharmaceuticals Initiates Phase 1b Clinical Trial of Mavorixafor in Combination with Ibrutinib for the Treatment of Waldenström’s Macroglobulinemia (WM)Dec 30, 2019
Principia Updates PRN1008 Pemphigus Clinical ProgramDec 20, 2019
Nabriva Therapeutics Resubmits New Drug Application for Intravenous CONTEPO™ (fosfomycin) for InjectionDec 20, 2019
Nabriva Therapeutics Announces $20 Million Registered Direct OfferingDec 20, 2019
Alector Added to the NASDAQ Biotechnology IndexDec 13, 2019
Alector Showcases Progress in Immuno-Neurology Clinical Programs and Research Portfolio at R&D DayDec 13, 2019
Alector Appoints Dr. Richard Scheller, Lasker Prize Awarded Scientist, and Dr. Thomas Südhof, Nobel Laureate as Co-Chairs of its Strategic Portfolio Advice and Review CommitteeDec 12, 2019
AskBio Licenses Rights to Selecta Biosciences’ ImmTOR™ Immune Tolerance Platform for the Treatment of Pompe DiseaseDec 12, 2019
Selecta Biosciences Announces $70 Million Private PlacementDec 12, 2019
Selecta Biosciences Announces Completion of Enrollment in Head-to-Head COMPARE Trial of SEL-212Dec 11, 2019
Alector Announces Appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as President and Chief Operating OfficerDec 11, 2019
PMV Pharma Appoints Leila Alland, M.D., as Chief Medical OfficerDec 9, 2019
ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of LinzagolixDec 9, 2019
CTI BioPharma Announces Presentation of Data Supporting Pacritinib's Benefit in Myelofibrosis Patients with Severe Thrombocytopenia at the 61st American Society of Hematology MeetingDec 9, 2019
Alpine Immune Sciences Presents ALPN-101 Phase 1 Healthy Volunteer Study Data and Details of Upcoming Phase I/II BALANCE GVHD Study at the 61st American Society of Hematology Annual MeetingDec 8, 2019
Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 BillionDec 7, 2019
Corvus Pharmaceuticals Presents Preclinical and Initial Clinical Data from the Phase 1/1b Trial of CPI-818 at the American Society of Hematology (ASH) Annual MeetingDec 7, 2019
Principia Presents Consistent Positive Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 TrialDec 6, 2019
Alector Announces Phase 1 Data on AL002 at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) MeetingDec 5, 2019
Alector Announces FDA Fast Track Designation Granted to AL001 for the Treatment of Patients with Frontotemporal DementiaDec 4, 2019
TransMedics’ Organ Care System (OCS™) Technology Used in First U.S. Adult Human Heart Transplants From DCD DonorsDec 3, 2019
Regenerative Medicine Advanced Therapy Designation Granted by FDA to ADP?A2M4 for the Treatment of Synovial SarcomaDec 3, 2019
Tricida Announces Hiring of Elizabeth Faust, Ph.D., as Senior Vice President of Medical AffairsNov 27, 2019
ReViral Appoints Lawrence Blatt and Richard N. Kender to its Board of DirectorsNov 26, 2019
X4 Pharmaceuticals Prices $65 Million Public Offering of Common Stock and Class B WarrantsNov 25, 2019
X4 Pharmaceuticals Announces Proposed Public OfferingNov 21, 2019
Arvinas Appoints Laurie Smaldone Alsup, M.D., to Board of DirectorsNov 21, 2019
Glaukos Completes Acquisition of Avedro, Inc.Nov 21, 2019
Selecta Biosciences Appoints Carrie S. Cox as Chairman of its Board of DirectorsNov 21, 2019
Harpoon Therapeutics And Abbvie Announce Licensing And Option Collaboration To Advance Hpn217, Harpoon’s Bcma-Targeting Tritac®, And Expand Existing Discovery CollaborationNov 19, 2019
NextCure Announces Closing of Public OfferingNov 19, 2019
Verrica Pharmaceuticals Announces Passing of Board of Directors Member Glenn OclassenNov 18, 2019
Nabriva Therapeutics Commends the CDC on the 2019 Antibiotic Resistance Threats Report, Highlighting the Need for New Antibiotics Aligned with Antibiotic StewardshipNov 18, 2019
Ascendis Pharma A/S Reports Third Quarter 2019 Financial ResultsNov 18, 2019
Phase 2a Study Published in Antimicrobial Agents and Chemotherapy Shows Potential of Sisunatovir (RV521) to Combat Respiratory Syncytial Virus InfectionNov 18, 2019
Prevail Therapeutics Announces Appointment of Morgan Sheng, Ph.D., to Board of DirectorsNov 16, 2019
Updated Data from Phase 1 ADP-A2M4 Trial Demonstrating Continued Clinical Benefit for People with Synovial SarcomaNov 15, 2019
resTORbio Announces That the Phase 3 PROTECTOR 1 Trial of RTB101 in Clinically Symptomatic Respiratory Illness Did Not Meet the Primary EndpointNov 14, 2019
Arcutis Appoints Keith Klein as General CounselNov 14, 2019
Ascendis Pharma Expands TransCon™ PTH Phase 2 PaTH Forward Clinical Trial to Expedite Enrollment of Subjects Previously Treated with NATPARA® in the United StatesNov 14, 2019
Tricida Announces Third Quarter 2019 Financial ResultsNov 14, 2019
Verona Pharma plc: PDMR Dealing – Purchase by ChairmanNov 14, 2019
BELLUS Health Reports Financial and Operating Results for the Third Quarter Ended September 30, 2019Nov 14, 2019
NextCure Announces Pricing of Public Offering of Common StockNov 14, 2019
Tricida Announces FDA Acceptance of New Drug Application for VeverimerNov 13, 2019
PMV Pharma Secures $62 Million in Series C Financing To Develop Cancer Drugs Targeting p53Nov 12, 2019
scPharmaceuticals Inc. Reports Third Quarter 2019 Financial Results and Provides Business UpdateNov 12, 2019
Alector Reports Recent Business Highlights and Third Quarter 2019 Financial ResultsNov 12, 2019
X4 Pharmaceuticals Receives Breakthrough Therapy Designation from the FDA for Mavorixafor for the Treatment of WHIM SyndromeNov 12, 2019
Nabriva Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate HighlightsNov 12, 2019
Prevail Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business HighlightsNov 12, 2019
Synlogic Provides Program and Business Update and Reports Third Quarter 2019 Financial ResultsNov 12, 2019
NextCure Reports Third Quarter 2019 Financial ResultsNov 12, 2019
Crinetics Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate UpdateNov 12, 2019
Alpine Immune Sciences Presents New ALPN-101 Preclinical Data at the 2019 American College of Rheumatology (ACR) Annual MeetingNov 12, 2019
Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of Repotrectinib in Pediatric PatientsNov 12, 2019
SpringWorks Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business HighlightsNov 11, 2019
SI-BONE, Inc. Reports Third Quarter 2019 Financial Results and Updates Full-Year 2019 Revenue GuidanceNov 11, 2019
89bio Announces Pricing of Upsized Initial Public OfferingNov 11, 2019
Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic IndicationsNov 11, 2019
Selecta Biosciences Presents New Data at 2019 American College of Rheumatology Annual Meeting from Phase 2 Study of SEL-212 for the Treatment of Patients with Chronic Refractory GoutNov 11, 2019
Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of TPX-0046, a Novel RET/SRC InhibitorNov 9, 2019
NextCure Presents Updated Clinical Data from NC318 Phase 1/2 Clinical Trial at the 34th Annual Meeting of Society for Immunotherapy of Cancer (SITC) and Announces Initiation of Phase 2 Portion of the TrialNov 8, 2019
Selecta Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate UpdateNov 8, 2019
Alpine Immune Sciences Presents New Preclinical Data at The Society for Immunotherapy of Cancer's (SITC) 34th Annual MeetingNov 8, 2019
Corvus Pharmaceuticals Presents Updated Data from CPI-006 Phase 1/1b Clinical Trial at 2019 Society for Immunotherapy of Cancer (SITC) Annual MeetingNov 7, 2019
ObsEva Announces Third Quarter 2019 Financial ResultsNov 7, 2019
Audentes Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate UpdateNov 7, 2019
Obseva Announces That Nolasiban Implant 4 Study Did Not Meet Primary EndpointNov 7, 2019
TELA Bio Announces Pricing of Initial Public Offering of Common StockNov 7, 2019
X4 Pharmaceuticals Reports Third Quarter 2019 Financial Results and Recent Business HighlightsNov 7, 2019
Aerpio Reports Third Quarter 2019 Financial Results and Provides Business UpdateNov 7, 2019
Kala Reports Third Quarter 2019 Financial ResultsNov 6, 2019
Alpine Immune Sciences Announces Oral Presentation of ALPN-101 at the 61st American Society of Hematology Annual Meeting and ExpositionNov 6, 2019
Aeglea BioTherapeutics Reports Third Quarter 2019 Financial Results and Corporate HighlightsNov 6, 2019
Ascendis Pharma A/S Announces First Presentation of Preclinical Data Utilizing TransCon™ Technology in Oncology at SITC 2019Nov 6, 2019
Constellation Pharmaceuticals Announces Third-Quarter and Nine-Month 2019 Financial ResultsNov 6, 2019
Arvinas Announces Pricing of Public Offering of Common StockNov 6, 2019
Adaptimmune Reports Third Quarter 2019 Financial Results and Business UpdateNov 6, 2019
Harpoon Therapeutics Reports Third Quarter 2019 Financial Results And Provides Corporate UpdateNov 6, 2019
Arvinas Announces Proposed Offering of Common StockNov 6, 2019
Verrica Pharmaceuticals Reports Third Quarter 2019 Financial ResultsNov 5, 2019
Principia Biopharma reports third quarter financial resultsNov 5, 2019
resTORbio Reports Third Quarter 2019 Financial Results and Corporate UpdateNov 5, 2019
Silverback Therapeutics to Present Preclinical Data at SITC 34th Annual Meeting Demonstrating SBT6050’s Potential for Robust Single Agent Activity in Tumors Refractory to Checkpoint InhibitionNov 5, 2019
Inspire Medical Systems, Inc. Announces Third Quarter 2019 Financial Results and Increases 2019 OutlookNov 5, 2019
X4 Pharmaceuticals Initiates Phase 1b Clinical Trial of Mavorixafor for the Treatment of Severe Congenital NeutropeniaNov 5, 2019
Xenon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate UpdateNov 5, 2019
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2019Nov 5, 2019
Synthorx Reports Third Quarter Financial ResultsNov 4, 2019
SI-BONE Announces Medicare Physician Payment Increase of 27% for Minimally Invasive SI Joint FusionNov 4, 2019
X4 Pharmaceuticals Appoints Derek Meisner, J.D., as General CounselNov 4, 2019
Aeglea BioTherapeutics Strengthens Leadership Team with Appointment of Ravi M. Rao as Chief Medical Officer and Michael C. Hanley as Chief Commercial OfficerNov 4, 2019
Turning Point Therapeutics Reports Third Quarter 2019 Financial and Operational ResultsNov 4, 2019
CTI BioPharma Reports Third Quarter 2019 Financial ResultsNov 4, 2019
Arvinas Reports Third Quarter 2019 Financial Results and Provides Corporate UpdateNov 1, 2019
ObsEva Announces Clearance to Initiate Pivotal US Phase 3 Clinical Trial (IMPLANT 3) of Nolasiban in Women Undergoing Embryo Transfer Following IVFOct 31, 2019
Intellia Therapeutics Announces Third Quarter 2019 Financial ResultsOct 31, 2019
Promentis Pharmaceuticals Announces Positive Results for Phase 2A Study of SXC-2023 Targeting Novel Glutamatergic Mechanism and Completion of Enrollment for Phase 2 Trichotillomania StudyOct 30, 2019
Arcutis Announces Addition of Three Senior Biopharmaceutical Executives to Management TeamOct 30, 2019
Alpine Immune Sciences Completes Enrollment of Phase I Study of ALPN-101 and Announces Third Quarter Conference CallOct 29, 2019
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial ResultsOct 29, 2019
Selecta Biosciences Presents New Preclinical Data from its Gene Therapy Program at 2019 ESGCT Annual CongressOct 29, 2019
Harpoon Therapeutics Presents Preclinical Data For Hpn328, A Dll3-Targeting T Cell Engager, At Aacr-Nci-Eortc International Conference On Molecular Targets And Cancer TherapeuticsOct 29, 2019
Passage Bio Appoints Richard Morris as Chief Financial OfficerOct 28, 2019
ESSA Pharma Presents Data on EPI-7386 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsOct 28, 2019
ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist and CD73 Inhibitor Programs at AACR-NCI-EORTC Annual ConferenceOct 24, 2019
Intellia Therapeutics Presents In Vivo and Ex Vivo Data at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)Oct 24, 2019
Arcutis Biotherapeutics Announces Positive End-of-Phase 2 Meeting with FDA and Planned Initiation of Phase 3 Program for ARQ-151 for Plaque PsoriasisOct 24, 2019
Compass Therapeutics to Present Preclinical Data on a Novel PD-1/PD-L1 Bispecific Antibody and from its Proprietary Innate Cell Engager Platform at the 2019 SITC MeetingOct 24, 2019
SpringWorks Therapeutics Announces Initiation of Phase 2b ReNeu Clinical Trial of Mirdametinib in Children and Adults with Neurofibromatosis Type 1 (NF1)-Associated Plexiform Neurofibromas (NF1-PN)Oct 23, 2019
Arvinas presents a platform update, including initial data from the first two clinical trials of protac targeted protein degradersOct 23, 2019
Avera eCARE® Selects Tyto Care as an Enterprise Solution for Virtual CareOct 22, 2019
Harpoon therapeutics announces presentation on HPN328 at AACR-NCI-EORTC international conference on molecular targets and cancer therapeuticsOct 22, 2019
Compass Therapeutics Appoints Leading Immuno-Oncology Researchers to Its Immuno-Oncology Scientific Advisory BoardOct 21, 2019
Ascendis Pharma A/S Receives Orphan Designation for TransCon™ hGH for the Treatment of Pediatric Growth Hormone Deficiency in EuropeOct 21, 2019
Aerpio Pharmaceuticals Announces Review of Strategic AlternativesOct 21, 2019
Arcutis Announces the Completion of $94.5 million Series C FinancingOct 21, 2019
ReViral Announces Appointment of Alan Musso as Chief Financial OfficerOct 18, 2019
ESSA Announces Changes to its Board of DirectorsOct 18, 2019
Verrica Pharmaceuticals Announces Presentation of Positive Data from Clinical Trials of VP-102 at the 2019 39th Annual Fall Clinical Dermatology ConferenceOct 18, 2019
Foamix Receives FDA Approval of AMZEEQ™ Topical Minocycline Treatment for Millions of Moderate to Severe Acne SufferersOct 17, 2019
Verona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPDOct 17, 2019
Enyo pharma announces multiple EYP001 data presentations at AASLD conferenceOct 16, 2019
Natera Announces Pricing of Follow-On OfferingOct 16, 2019
Novant Health and Tyto Care Partner to Provide Unique Digital Health OfferingsOct 15, 2019
Terns pharmaceuticals to present postive preclinical data on fxr agonist TERN-101 at the liver meeting 2019Oct 15, 2019
Principia Announces Proposed Public Offering of Common StockOct 15, 2019
Principia Announces Pricing of Public Offering of Common StockOct 15, 2019
Principia Announces Positive Preliminary Data of PRN1008 For Immune Thrombocytopenia in Ongoing Phase 1/2 TrialOct 10, 2019
Principia Announces Positive Preliminary Data of PRN1008 From Its Ongoing Phase 2 Part B Trial in PemphigusOct 10, 2019
Aerpio Pharmaceuticals Announces Interim Results from its Phase 1b Clinical Trial of Topical Ocular Formulation of AKB-9778 for Primary Open Angle GlaucomaOct 9, 2019
TigerConnect Recognized as One of the Best Places to Work in Healthcare for the Fifth Consecutive YearOct 9, 2019
Arcutis Announces Enrollment of Last Patient in Phase 2a Clinical Trial of ARQ-151 Cream as a Potential Topical Treatment for Atopic DermatitisOct 9, 2019
Adaptimmune and Cryoport Announce Agreement to Ensure Safe and Fully Monitored Transport of Adaptimmune’s Cell TherapiesOct 9, 2019
Verrica Pharmaceuticals Appoints Eugene Scavola to the Position of Executive Vice President, Technical OperationsOct 8, 2019
Prevail Therapeutics and Lonza Establish Strategic Collaboration to Develop and Manufacture Prevail's Novel AAV9 Gene Therapy Programs for Patients with Neurodegenerative DiseasesOct 7, 2019
Verrica Pharmaceuticals Announces Leadership Team UpdateOct 5, 2019
Audentes Therapeutics Presents New Positive Data from ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy (XLMTM), at the 24th International Annual Congress of the World Muscle SocietyOct 3, 2019
Enyo pharma announces move to new corporate headquartersOct 2, 2019
Adicet Bio Raises $80M in Series B FinancingOct 2, 2019
resTORbio Presents New Findings on RTB101 During Late-Breaking Session at IDWeek 2019Oct 2, 2019
Arvinas strengthens scientific advisory board with leaders in oncology and neurological disordersOct 2, 2019
NextCure Announces Promotion of Timothy Mayer, Ph.D., to Chief Operating OfficerOct 2, 2019
Graybug Vision Initiates Phase 2b (ALTISSIMO) Clinical Trial of GB-102 in Patients with Wet Age-Related Macular DegenerationOct 1, 2019
CTI BioPharma Begins Patient Enrollment in PACIFICA Pivotal Phase 3 Trial of Pacritinib in Myelofibrosis Patients With Severe ThrombocytopeniaOct 1, 2019
Constellation Pharmaceuticals Announces $65 Million Private Placement with New and Existing InvestorsOct 1, 2019
Bayer and Arvinas unveil targeted protein degradataion joint venture, Oerth BioOct 1, 2019
Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial OfficerSep 30, 2019
X4 Pharmaceuticals Reports Positive Data from Phase 2a Trial of Mavorixafor in Combination with Axitinib in Advanced Clear Cell Renal Cell Carcinoma PatientsSep 30, 2019
Audentes Announces Upcoming Presentations at the 24th International Annual Congress of the World Muscle Society, Including New Data From ASPIRO, the Clinical Trial Evaluating AT132 in Patients With X-Linked Myotubular Myopathy (XLMTM)Sep 30, 2019
Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0046, a Novel RET/SRC InhibitorSep 30, 2019
Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMOSep 30, 2019
European Respiratory Society International Congress, Madrid 29 September 2019Sep 28, 2019
ESSA Pharma Presents New Data on EPI-7386 at the European Society of Medical Oncology (ESMO) 2019 CongressSep 27, 2019
Lefamulin Evaluation Against Pneumonia 2 (LEAP 2) Study Results Published in the Journal of the American Medical AssociationSep 26, 2019
Inspire Medical Systems, Inc. Announces Additional Draft Local Coverage Determinations Proposing Coverage of Inspire TherapySep 26, 2019
Arbitration Decision Affirms Intellia Therapeutics’ Interpretation of Licensing Agreement with Caribou Biosciences on the CRISPR/Cas9 TechnologySep 25, 2019
89bio Announces Dosing of First Patients in NASH Study and Issuance of Composition of Matter PatentSep 25, 2019
SI-BONE, Inc. Announces Publication of Five-Year Prospective Study Results on 103 Patients Treated with Triangular Titanium iFuse Implant SystemSep 24, 2019
Constellation Pharmaceuticals Advances CPI-0209 into Clinical Trials, Expanding its EZH2 FranchiseSep 24, 2019
European Commission Grants Orphan Drug Designation for Nirogacestat for the Treatment of Soft Tissue SarcomaSep 24, 2019
Foundation Medicine and Natera Partner to Advance Personalized Cancer MonitoringSep 23, 2019
Adicet Bio Appoints Francesco Galimi, M.D., Ph.D., SVP and Chief Medical OfficerSep 23, 2019
X4 Pharmaceuticals Appoints William E. Aliski to Board of DirectorsSep 23, 2019
Passage Bio Grows Management Team with Chief Medical Officer and General Counsel AppointmentsSep 19, 2019
Prevail Therapeutics Announces Addition to Russell 2000®, 3000® and Microcap® IndexesSep 18, 2019
Graybug Vision Initiates Clinical Trial in Macular Edema Secondary to Diabetic Macular Edema or Retinal Vein OcclusionSep 18, 2019
scPharmaceuticals Inc. Provides FUROSCIX® Update and Announces Completion of $20.0 Million Term Loan AgreementSep 18, 2019
X4 Pharmaceuticals Appoints Renato Skerlj, Ph.D. as Senior Vice President of Research and DevelopmentSep 18, 2019
Arcutis, Inc.’s Development Program for EczemaSep 17, 2019
Xenon Announces Appointment of Shelley McCloskey as Senior Vice President, Human ResourcesSep 17, 2019
BELLUS Health Announces Exercise of Over-Allotment Option in Connection With Underwritten Public Offering of Common SharesSep 17, 2019
SpringWorks Therapeutics Announces Closing Of Initial Public Offering and Exercise in Full of the Underwriter’s Option to Purchase Additional SharesSep 17, 2019
Edgewise Therapeutics Closes $50 Million Series B FinancingSep 16, 2019
Verrica Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for VP-102 for the Treatment of Molluscum ContagiosumSep 13, 2019
Gemini Therapeutics Announces Leadership AppointmentSep 13, 2019
Imara Submits Confidential Draft Registration Statement for Proposed Initial Public OfferingSep 12, 2019
Ascendis Pharma A/S Announces Presentations on Achondroplasia and TransCon™ CNP at International Skeletal Dysplasia Society MeetingSep 12, 2019
Tricida Launches Metabolic Acidosis Insights, an Online Educational Resource for the Healthcare CommunitySep 12, 2019
SpringWorks Therapeutics Announces Pricing Of Initial Public OfferingSep 11, 2019
ObsEva announces new composition of its Executive CommitteeSep 11, 2019
Boost Epi-On™ Corneal Cross-Linking Data to Be Presented at the 37th Congress of the ESCRSSep 10, 2019
Prevail Therapeutics Provides Program Update on PR001 in Parkinson’s Disease with GBA1 Mutations and Neuronopathic Gaucher DiseaseSep 10, 2019
ORIC Pharmaceuticals Appoints Dominic Piscitelli as Chief Financial OfficerSep 9, 2019
United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4Sep 9, 2019
Nabriva’s XENLETA™ (lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) Now Available in the U.S.Sep 9, 2019
Natera Publishes Largest NIPT Outcomes Study Demonstrating Robust Clinical Performance Over a 4-year PeriodSep 9, 2019
Enyo Pharma Announces New CFO and Provides Clinical Pipelien UpdateSep 9, 2019
Passage Bio Announces New Gene Therapy Development Program for Patients with Charcot-Marie-Tooth Neuropathy Type 2ASep 9, 2019
Flexion Therapeutics and Xenon Pharmaceuticals Announce Flexion’s Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative PainSep 9, 2019
BELLUS Health Closes US$70 Million Public Offering of Common Shares in Canada and the United StatesSep 9, 2019
Alector Initiates Phase 2 Trial of AL001 in Patients with Frontotemporal DementiaSep 6, 2019
Nabriva Therapeutics Earns $5 Million Milestone Payment under its License Agreement with Sinovant SciencesSep 5, 2019
BELLUS Health Announces Pricing of US$70 Million Public Offering in Canada and the United StatesSep 5, 2019
Turning Point Therapeutics Announces Pricing of Public Offering of Common StockSep 4, 2019
Synlogic Announces Appointments of New CMO, Head of Regulatory Affairs, and CFO DepartureSep 4, 2019
Tricida Announces Submission of New Drug Application for Veverimer for the Treatment of Metabolic Acidosis in Patients with Chronic Kidney DiseaseSep 4, 2019
Selecta Biosciences Appoints Brad Dahms as Chief Financial OfficerSep 4, 2019
Passage Bio Closes $110 Million Series B FinancingSep 4, 2019
Synlogic Presents Data from Phase 1/2a Study of SYNB1618 at the Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM)Sep 3, 2019
ObsEva Reports New Clinical Evidence of Nolasiban Mechanism of Action, Supporting Its Potential to Increase Live Birth Rate Following Embryo Transfer in IVFSep 3, 2019
Aeglea BioTherapeutics Announces Positive 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 2019 SSIEM SymposiumSep 3, 2019
BELLUS Health Announces the Launch of a US$60 Million Public Offering of Common Shares in Canada and the United States and the Filing of an Application to List Its Common Shares on NasdaqSep 3, 2019
Turning Point Therapeutics Announces Proposed Public Offering of Common StockSep 3, 2019
SI-BONE, Inc. Announces Wellmark Blue Cross Blue Shield Establishes Positive Coverage for MIS SI Joint Fusion Using iFuseSep 3, 2019
Turning Point Therapeutics Announces Updated Interim Clinical Data of Repotrectinib and Preclinical Data for TPX-0046, a Novel RET/SRC InhibitorAug 30, 2019
SpringWorks Therapeutics Appoints Alan Fuhrman to its Board of DirectorsAug 30, 2019
Principia Biopharma Appoints Shawn Tomasello to its Board of DirectorsAug 29, 2019
Inspire Medical Systems, Inc. Announces Additional Draft Local Coverage Determinations Proposing Coverage of Inspire TherapyAug 29, 2019
SpringWorks Therapeutics Receives Breakthrough Therapy Designation for Nirogacestat for the Treatment of Adult Patients with Progressive, Unresectable, Recurrent or Refractory Desmoid TumorsAug 28, 2019
Ascendis Pharma A/S Reports Second Quarter 2019 Financial ResultsAug 27, 2019
Arvinas announces the initiation of patient dosing in a first-in-human phase 1 study of ARV-471, an estrogen receptor-targeting protac protein degraderAug 27, 2019
Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation treatment for cancer patientsAug 27, 2019
ESSA Pharma Completes Public Offering and Concurrent Private Placement for Aggregate Gross Process of US$36 MillionAug 27, 2019
NeRRe Therapeutics Announces Publication of Positive Results in a Phase 2 Pilot Study of Orvepitant in Chronic Refractory CoughAug 27, 2019
Pionyr Immunotherapeutics Announces Key Leadership Team Addition and Clinical Candidates Targeting Tumor-Associated MacrophagesAug 27, 2019
Cyrus Biotechnology Offers CryoEM Services based on First-in-class, Peer-reviewed Rosetta Software MethodsAug 26, 2019
Inspire Medical Systems, Inc. Announces Draft Local Coverage Determinations Proposing Coverage of Inspire Therapy from Two Regional Medicare AdministratorsAug 26, 2019
BELLUS Health Strengthens Leadership Team with Appointment of Dr. Catherine Bonuccelli, MD as Chief Medical OfficerAug 23, 2019
ESSA Pharma Announces $36 Million Public Offering of Common Stock and Concurrent Private PlacementAug 22, 2019
Medicare Issues Positive Draft Local Coverage Determination for Natera's Signatera� MRD Test in Colorectal CancerAug 20, 2019
Graybug Vision Secures $80 million of Additional Funding to Advance its Potentially Transformative Retina and Glaucoma Clinical ProgramsAug 20, 2019
Synlogic Discontinues Development of SYNB1020 to Treat HyperammonemiaAug 19, 2019
Nabriva Therapeutics Receives U.S. FDA Approval of Xenleta™ (lefamulin) to Treat Community-Acquired Bacterial Pneumonia (CABP)Aug 16, 2019
Nabriva Therapeutics Provides Update on the Planned Resubmission of the New Drug Application for Intravenous CONTEPO™ (fosfomycin) for InjectionAug 15, 2019
Inspire Medical Systems, Inc. Announces Additional 17.7 Million Covered Lives with Seven New Coverage PoliciesAug 15, 2019
BELLUS Health Announces Share ConsolidationAug 14, 2019
resTORbio Reports Second Quarter 2019 Financial Results and Corporate UpdateAug 14, 2019
Prevail Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business HighlightsAug 13, 2019
Crinetics Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate UpdateAug 13, 2019
Passage Bio Announces Launch of Natural History Study to Evaluate Patients with GM1 GangliosidosisAug 13, 2019
Alpine Immune Sciences Provides Pipeline Update and Reports Second Quarter 2019 Financial ResultsAug 13, 2019
Imara Expands Management Team and Strengthens Expertise Across Strategic Functions as it Advances IMR-687 for Sickle Cell Disease and Beta ThalassemiaAug 13, 2019
Inspire Medical Systems, Inc. Announces New Brand Identity and Website to Better Reach Prospective Patients Struggling with Sleep ApneaAug 12, 2019
Alector Reports Recent Business Highlights and Second Quarter 2019 Financial ResultsAug 12, 2019
Alector Announces the Addition of Kristine Yaffe, M.D., to the Board of DirectorsAug 8, 2019
Principia biopharma reports second quarter financial resultsAug 8, 2019
Synlogic Reports Second Quarter 2019 Financial Results and Provides Program UpdatesAug 8, 2019
Selecta Biosciences Reports Second Quarter 2019 Financial Results and Provides Corporate UpdateAug 8, 2019
BELLUS Health Reports Financial and Operating Results for the Second Quarter Ended June 30, 2019Aug 8, 2019
Nabriva Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate HighlightsAug 8, 2019
ORIC Pharmaceuticals Announces Completion of $55 Million Mezzanine Financing to Advance Pipeline of Novel Therapies Targeting Cancer ResistanceAug 8, 2019
89bio Initiates Phase 1b/2a Proof of Concept Clinical Trial of Investigational Therapy BIO89-100 for the Treatment of NASHAug 8, 2019
Kala Pharmaceuticals Receives FDA Complete Response Letter for KPI-121 0.25% NDA and Plans To Repond with Data from Stride 3 TrialAug 8, 2019
Aerpio Reports Second Quarter 2019 Financial Results and Provides Business UpdateAug 8, 2019
Tricida Announces Second Quarter 2019 Financial ResultsAug 8, 2019
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter Financial ResultsAug 7, 2019
Constellation Pharmaceuticals Announces Second-Quarter and Six-Month 2019 Financial ResultsAug 7, 2019
Selecta Biosciences Combines ImmTOR™ Platform with AskBio’s Industry-Leading Gene Therapy Platform in Strategic PartnershipAug 7, 2019
Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency ObesitiesAug 7, 2019
Glaukos and Avedro Announce Definitive Acquisition AgreementAug 7, 2019
ObsEva Reports Second Quarter 2019 Financial ResultsAug 7, 2019
scPharmaceuticals Inc. Reports Second Quarter 2019 Financial Results and Provides Business UpdateAug 7, 2019
Verrica Pharmaceuticals Reports Second Quarter 2019 Financial ResultsAug 7, 2019
ObsEva SA Announces $75 Million Credit Facility with Oxford Finance LLCAug 7, 2019
Avedro, Inc. Announces Second Quarter 2019 Financial ResultsAug 6, 2019
Turning Point Therapeutics Reports Second Quarter 2019 Financial and Operational ResultsAug 6, 2019
SI-BONE, Inc. Reports Second Quarter 2019 Financial ResultsAug 6, 2019
Inspire Medical Systems, Inc. Announces Second Quarter 2019 Financial Results and Increases 2019 OutlookAug 6, 2019
Verona Pharma plc: Operational Update and Financial Results for the Three and Six Months Ended June 30, 2019Aug 6, 2019
Aeglea BioTherapeutics Reports Second Quarter 2019 Financial Results and Corporate HighlightsAug 6, 2019
Xenon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate UpdateAug 6, 2019
Kala Pharmaceuticals Reports Second Quarter 2019 Financial ResultsAug 6, 2019
Audentes Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate UpdateAug 5, 2019
Arvinas Reports Second Quarter 2019 Financial Results and Provides Corporate UpdateAug 5, 2019
Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPDAug 5, 2019
Harpoon Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate UpdateAug 1, 2019
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2019 Financial ResultsAug 1, 2019
Adaptimmune Reports Second Quarter 2019 Financial Results and Business UpdateAug 1, 2019
Synthorx Reports Second Quarter Financial ResultsAug 1, 2019
CTI BioPharma Reports Second Quarter 2019 Financial ResultsAug 1, 2019
Intellia Therapeutics Announces Second Quarter 2019 Financial Results and Company UpdateAug 1, 2019
New Executive Team Announced at AdaptimmuneAug 1, 2019
Compass Therapeutics Appoints Julie Sunderland to Board of DirectorsJul 31, 2019
Turning Point Therapeutics Initiates Phase 1 Clinical Study of Tpx-0022, a Novel Met Inhibitor Targeting Advanced Solid TumorsJul 30, 2019
Foamix Announces $64 Million Capital Financing Investment by Perceptive Advisors and OrbiMedJul 30, 2019
NeuroPace Appoints Mark Saxton as Vice President of SalesJul 30, 2019
X4 Pharmaceuticals Receives Orphan Drug Designation from European Commission for Mavorixafor for Treatment of WHIM SyndromeJul 30, 2019
Principia announces update to ongoing Phase 2 clinical trial in patients with ITPJul 30, 2019
TransMedics Announces Successful Long Distance Retrieval and Transplantation of Donor Lungs from Hawaii Using Organ Care System (OCS�)Jul 30, 2019
BELLUS Health Announces First Patient Enrolled in Phase 2 Study of BLU-5937 for the Treatment of Refractory Chronic Cough & Pursuit of Second Indication in Chronic PruritusJul 29, 2019
Turning Point Therapeutics Appoints Biotechnology Investment Banker Yi Larson as Executive Vice President and Chief Financial OfficerJul 29, 2019
Arvinas appoints Ronald Peck, M.D as Chief Medical OfficerJul 29, 2019
Rhythm Pharmaceuticals Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for Setmelanotide for the Treatment of Bardet-Biedl SyndromeJul 29, 2019
Rhythm Pharmaceuticals Reports Second Quarter 2019 Financial ResultsJul 29, 2019
Crinetics Pharmaceuticals to Receive Final Award of SBIR Grant from NIH Congenital HyperinsulismJul 26, 2019
ObsEva SA Reports Positive Feedback from Independent Data Monitoring Committee for PROLONG Part B with OBE022Jul 25, 2019
Passage Bio Expands Executive Management TeamJul 25, 2019
Turning Point Therapeutics Names Carol Gallagher, Pharm.D. to its Board of DirectorsJul 25, 2019
Inspire Medical Systems, Inc. Announces Changes to its Board of DirectorsJul 25, 2019
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2019 Earnings and Company UpdateJul 25, 2019
Adaptimmune Starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLSJul 25, 2019
Arvinas strengthens board of directors with addition of Leslie NorwalkJul 24, 2019
Synthorx Initiates Patient Dosing in Australia and Announces Clearance of IND in the U.S. for Lead Immuno-oncology Product Candidate, THOR-707Jul 24, 2019
Health Catalyst Announces Pricing of Initial Public OfferingJul 24, 2019
NeuroPace Announces Michael Favet as CEOJul 24, 2019
Aeglea BioTherapeutics Receives FDA Breakthrough Therapy Designation for Pegzilarginase for Treatment of Arginase 1 DeficiencyJul 24, 2019
Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2019 Financial Results on August 1, 2019Jul 24, 2019
Rhythm Pharmaceuticals Announces Appointment of Stuart Arbuckle to its Board of DirectorsJul 23, 2019
Marinus Pharmaceuticals Announces Data from Magnolia and Amaryllis Phase 2 Studies in Women with Postpartum DepressionJul 23, 2019
resTORbio Announces Early Completion of Enrollment of Phase 3 PROTECTOR 1 Trial with RTB101 in Clinically Symptomatic Respiratory IllnessJul 22, 2019
Arcutis, Inc. Announces Positive Top Line Results for Phase 2b Clinical Trial Evaluating ARQ-151 as a Potential Topical Treatment for Plaque PsoriasisJul 22, 2019
Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer CenterJul 19, 2019
Realm Therapeutics plc Update on Company’s Nasdaq ListingJul 18, 2019
Ascendis Pharma Announces Filing of Investigational New Drug (IND) Application for Initiation of a Global Phase 2 Trial for TransCon™ CNP in Children with AchondroplasiaJul 18, 2019
Augmedix, powered by Glass, accelerates scaling efforts with the nation’s leading healthcare systemsJul 18, 2019
CTI BioPharma Announces Outcome From End-of-Phase-2a Meeting With U.S. Food and Drug Administration (FDA) Regarding Pacritinib for Treatment of MyelofibrosisJul 18, 2019
Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE?A4 to Enhance Antitumor ResponsesJul 18, 2019
ViewRay Announces Conference Call and Webcast of Second Quarter 2019 Financial Results to be Held After Market on August 8, 2019Jul 17, 2019
Rhythm Pharmaceuticals Launches Free Genetic Testing Program for Rare Genetic Disorders of ObesityJul 17, 2019
ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 1 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine FibroidsJul 17, 2019
ObsEva Hosts KOL Meeting on IVF Trends, Unmet Need and Market Potential of NolasibanJul 17, 2019
ObsEva appoints industry expert as Chief Medical Officer to further advance its Phase 3 clinical programsJul 17, 2019
X4 Pharmaceuticals and Abbisko Therapeutics Enter into Oncology Development and Commercialization Agreement for Mavorixafor in Greater ChinaJul 17, 2019
Alector Announces Data from On-going Phase 1b Trial Demonstrating that AL001 Reverses Progranulin Deficiency in Frontotemporal Dementia PatientsJul 17, 2019
SI-BONE To Report Second Quarter 2019 Financial Results on August 6, 2019Jul 16, 2019
ViewRay Announces Appointment of Dr. Gail Wilensky to its Board of DirectorsJul 16, 2019
Crinetics Pharmaceuticals appoints Stephanie Okey to Board of DirectorsJul 16, 2019
SCPHARMACEUTICALS INC. PROVIDES REGULATORY UPDATE ON FUROSCIX®Jul 15, 2019
Selecta Biosciences Appoints Alison Schecter, M.D., as Chief Medical OfficerJul 15, 2019
Synlogic Reports Positive Top-line Data from Phase 1/2a Study of SYNB1618 in Patients with Phenylketonuria and Guides to Next Phase of DevelopmentJul 10, 2019
Acutus Medical Announces Addition of Scott Huennekens as Executive Chairman of the BoardJul 10, 2019
Pionyr Immunotherapeutics and ProBioGen Initiate a Second Immuno-Oncology Contract Development and Manufacturing ProjectJul 10, 2019
Passage Bio Announces New Dedicated Gene Therapy Manufacturing SuiteJul 10, 2019
NIH Study to Utilize NeuroPace RNS® System for Research on the Brain’s Reward SystemJul 9, 2019
Inspire Medical Systems, Inc. Announces UnitedHealthcare Coverage for Inspire Therapy for the Treatment of Obstructive Sleep ApneaJul 9, 2019
Inspire Medical Systems, Inc. to Report Second Quarter 2019 Financial Results on August 6, 2019Jul 9, 2019
ORIC Pharmaceuticals Appoints Lori Friedman, PhD, as Chief Scientific OfficerJul 8, 2019
Compass Therapeutics Announces First Patient Dosed in Phase 1 Trial of CTX-471Jun 27, 2019
Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive OfficerJun 27, 2019
SpringWorks Therapeutics Announces Global Clinical Collaboration with GlaxoSmithKline to Evaluate Nirogacestat in Combination with Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple MyelomaJun 27, 2019
SI-BONE’s iFuse Implant System Surpasses 40,000 ProceduresJun 26, 2019
X4 Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of Mavorixafor for the Treatment of WHIM SyndromeJun 26, 2019
Verrica Pharmaceuticals Achieves Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with Common WartsJun 26, 2019
Intellia Therapeutics' Statement on Recent U.S. Patent and Trademark Office Actions Relating to Key CRISPR/Cas9 Genome Editing TechnologyJun 25, 2019
Verona Pharma Strengthens its Clinical Team Ahead of Phase 3 Development of EnsifentrineJun 25, 2019
Tricida Announces Publication of Positive Long-Term Phase 3 Clinical Trial Results of Veverimer (TRC101) in The LancetJun 24, 2019
Nabriva Therapeutics Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application for LefamulinJun 24, 2019
Realm Shareholders Approve Scheme of Arrangement for Acquisition by ESSA Pharma Inc. at Court MeetingJun 20, 2019
Selecta Biosciences Announces Appointment of Scott D. Myers to Board of DirectorsJun 20, 2019
Acutus Medical Announces $170 Million FinancingJun 20, 2019
Turning Point Therapeutics Initiates Phase 2 Registrational Portion of TRIDENT-1 Clinical StudyJun 19, 2019
Nabriva Therapeutics Submits Type A Meeting Request to FDA for Intravenous CONTEPO™ (fosfomycin) for injectionJun 19, 2019
ObsEva Progressing Toward U.S. Phase 3 Trial for Nolasiban in IVF Following Recent FDA MeetingJun 19, 2019
Rhythm Pharmaceuticals Announces Election of Jennifer Good to its Board of DirectorsJun 19, 2019
Prevail Therapeutics Announces Pricing of Initial Public OfferingJun 18, 2019
Imara Presented Positive, Interim Phase 2a Data on IMR-687 for the Treatment of Sickle Cell Disease at the 24th Congress of the European Hematology AssociationJun 18, 2019
BeiGene and SpringWorks Therapeutics Announce the Formation of MapKure to Develop BGB-3245, an Investigational, Selective Next-Generation RAF Kinase InhibitorJun 17, 2019
SI-BONE Announces the Addition of Mark Foley and Heyward Donigan to the Board of DirectorsJun 17, 2019
Invitae to Acquire Singular Bio to Help Increase Access to Genetic Screening in Early PregnancyJun 13, 2019
PMV Pharma Appoints Deepika Jalota, Pharm.D. as Senior Vice President and Head of Regulatory AffairsJun 13, 2019
Terns Pharmaceuticals Initiates a Phase 1 Clinical Trial of Tern-101Jun 12, 2019
Selecta Biosciences Presents Full Data from Phase 2 Trial of SEL-212 for Chronic Refractory Gout at EULAR 2019Jun 12, 2019
Invitae Announces ID YOUR IRD Program to Expand Access to Genetic Testing for Inherited Retinal DisordersJun 12, 2019
Synlogic and Ginkgo Bioworks Establish Transformational Platform Collaboration for the Accelerated Development of Novel Synthetic Biotic™ MedicinesJun 12, 2019
X4 Pharmaceuticals and Invitae Announce Partnership to Provide No-Cost Genetic Testing to Patients Suspected of Primary Immunodeficiency DiseaseJun 12, 2019
Constellation Pharmaceuticals Presentation Highlights Enhanced EZH2 Target Engagement, Leading to Second-Generation EZH2 Inhibitor CPI-0209Jun 11, 2019
Principia Biopharma Appoints Patrick Machado To Board of DirectorsJun 11, 2019
ReViral Appoints Alex C. Sapir as Chief Executive OfficerJun 10, 2019
Aerpio Initiates Phase 1b Clinical Trial of Topical Ocular Formulation of AKB-9778 for Primary Open Angle GlaucomaJun 7, 2019
Nerre Therapeutics Announces Positive Findings From Phase 2B Study With Orvepitant In Chronic CoughJun 5, 2019
HLS Therapeutics Announces Closing of $50 Million Bought Deal OfferingJun 4, 2019
Verona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPDJun 4, 2019
Prevail Therapeutics Announces IND Active for Phase 1/2 Trial of its Gene Therapy PR001 to Treat Parkinson’s Disease Patients with GBA1 MutationsJun 4, 2019
ObsEva SA Announces Completion of Patient Recruitment in IMPLANT 4 Phase 3 Clinical Trial of Nolasiban for Improving IVF OutcomesJun 3, 2019
TransMedics Announces the Second FDA PMA Approval for its OCS Lung System, Allowing Access to a Larger Pool of Donor Lungs that are Currently Seldomly Utilized for Transplantation Due to Limitations of Cold StorageJun 3, 2019
Alpine Immune Sciences Appoints Biopharma Veteran Wayne Gombotz as Chief Technology OfficerJun 3, 2019
SpringWorks Therapeutics Announces FDA Fast Track Designation for PD-0325901 for the Treatment of a Severe Form of Neurofibromatosis Type 1Jun 3, 2019
ARQ-151 Atopic Dermatitis P2a Trial InitiatedJun 3, 2019
Invitae introduces new service to make it easier for consumers to receive the medical genetic testing that experts trustJun 3, 2019
Interim Data for CPI-0610 in MANIFEST Clinical Trial Showed Signals of Clinical Activity in Myelofibrosis PatientsJun 3, 2019
Aeglea BioTherapeutics Doses First Patient in Pivotal Phase 3 PEACE Trial of Pegzilarginase in Arginase 1 DeficiencyJun 2, 2019
Corvus Pharmaceuticals Presents Initial CPI-006 Phase 1/1b Clinical Data at 2019 ASCO Annual MeetingMay 31, 2019
Turning Point Therapeutics Announces Updated Interim Clinical Data of Repotrectinib in Advanced ROS1+ Non-Small Cell Lung CancerMay 31, 2019
Research from Invitae Demonstrates the Importance of Germline Multigene Panel Testing in Guiding Therapy for Expanding Groups of Cancer PatientsMay 30, 2019
Ascendis Pharma A/S Reports First Quarter 2019 Financial ResultsMay 30, 2019
Passage Bio Announces Third Gene Therapy Development Program in Krabbe Disease and Supports Million Dreams Fundraising GalaMay 29, 2019
Cyrus Biotechnology Integrates DNA/RNA support into its Rosetta-based Protein Design PlatformMay 29, 2019
Audentes Therapeutics Announces Changes to Senior Management TeamMay 29, 2019
Imara Announces FDA Fast Track Designation for IMR-687 for the Treatment of Sickle Cell DiseaseMay 22, 2019
Tyto Care Joins Epic App Orchard to Offer One-of-a-kind Integrated Telehealth Service to Patients and Health ProvidersMay 22, 2019
Synlogic Announces Clinical Collaboration to Evaluate SYNB1891 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid TumorsMay 22, 2019
89bio Reports Positive Top-line Data from Phase 1 Single-Ascending Dose Clinical Trial of BIO89-100, an Investigational Medicine for NASHMay 22, 2019
World's First MRIdian Center Treats 1,000th Patient with MRI-Guided Radiation TherapyMay 21, 2019
Crinetics Pharmaceuticals Initiates Phase 1 Study Of CRN01941 For The Treatment Of Neuroendocrine TumorsMay 21, 2019
BELLUS Health Presents Phase 1 Data for BLU-5937, its Lead Product Candidate for the Treatment of Refractory Chronic Cough, at the American Thoracic Society International ConferenceMay 21, 2019
Merck to Acquire Peloton Therapeutics, Bolstering Oncology PipelineMay 20, 2019
Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at American Thoracic Society 2019 International ConferenceMay 20, 2019
SpringWorks Therapeutics Announces Initiation of Phase 3 Trial (DeFi) of Nirogacestat in Adult Patients with Desmoid TumorsMay 20, 2019
Ascendis Pharma A/S Announces Preliminary Data from Single Arm Phase 3 fliGHt Trial Demonstrated TransCon™ hGH was Safe and Well-Tolerated in Pediatric Subjects Previously Treated with Daily Growth HormoneMay 20, 2019
resTORbio Presents Additional Phase 2b Data at the American Thoracic Society International Conference for RTB101 as a Potential Immunotherapy to Reduce the Incidence of Respiratory Tract Infections in Patients 65 Years of Age and Older with AsthmaMay 20, 2019
Principia Presents Phase 1 Data Of Prn1371 In Patients With Metastatic Bladder CancerMay 16, 2019
Agreement Reached for ESSA Pharma to Acquire Realm TherapeuticsMay 16, 2019
Constellation Pharmaceuticals Provides Interim Update of Data for CPI-0610 in ASCO and EHA AbstractsMay 16, 2019
Prevail Therapeutics Announces Executive Team Promotion and Appointments to Board of DirectorsMay 15, 2019
TigerConnect Names Sarah Shillington SVP of Client SuccessMay 15, 2019
Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell ProductsMay 15, 2019
resTORbio Reports First Quarter 2019 Financial Results and Corporate UpdateMay 15, 2019
X4 Pharmaceuticals and The Leukemia & Lymphoma Society Announce Collaboration to Advance Development of Mavorixafor in Waldenström’s MacroglobulinemiaMay 15, 2019
Turning Point Therapeutics Announces FDA Clearance Of Investigational New Drug Application For TPX-0022, A Novel MET/CSF1R/SRC InhibitorMay 14, 2019
ReViral to Present Data Showing Absence of Clinical Resistance in Volunteers Infected with RSV then Treated with Sisunatovir (RV521)May 14, 2019
resTORbio Appoints Lloyd Klickstein, M.D., Ph.D., as Chief Scientific OfficerMay 14, 2019
Principia Biopharma Announces First Patient Dosed In Sanofi’s Phase 2b Trial Of SAR442168 In Multiple Sclerosis, Triggering $30 Million MilestoneMay 14, 2019
Turning Point Therapeutics Names Biotech Veteran Patrick Machado, J.D. To Its Board Of Directors.May 13, 2019
ORIC Pharmaceuticals Announces Initiation of Phase 1b Study with ORIC-101 in Patients with CancerMay 13, 2019
Alector Reports Recent Business Highlights and First Quarter 2019 Financial ResultsMay 13, 2019
Crinetics Pharmaceuticals Reports First Quarter 2019 Financial Results And Provides Corporate UpdateMay 10, 2019
Nabriva Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate HighlightsMay 9, 2019
Aerpio Reports First Quarter 2019 Financial Results and Provides Business UpdateMay 9, 2019
NeuroPace Shares Positive Data from Studies of the RNS System at the American Academy of Neurology 2019 Annual MeetingMay 9, 2019
Avedro, Inc. Announces First Quarter 2019 Financial ResultsMay 9, 2019
Synlogic Reports First Quarter 2019 Financial Results and Provides Business UpdateMay 9, 2019
resTORbio Announces Initiation of Phase 3 Clinical Program of RTB101 in Clinically Symptomatic Respiratory IllnessMay 9, 2019
Acutus Medical Expands AFib Offerings; Announces Strategic Acquisition and New Partnerships in Monitoring and TherapyMay 9, 2019
Harpoon Therapeutics Reports First Quarter 2019 Financial Results And Provides Corporate UpdateMay 9, 2019
ObsEva SA Announces Initiation of Phase 3 EDELWEISS 2 and 3 Trials of Linzagolix for Endometriosis Associated Pain in U.S., Canada and EuropeMay 9, 2019
Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2019 Financial ResultsMay 9, 2019
ObsEva Reports First Quarter 2019 Financial ResultsMay 9, 2019
Selecta Biosciences Reports First Quarter 2019 Financial Results and Provides Corporate UpdateMay 9, 2019
Kala Pharmaceuticals Reports First Quarter 2019 Financial ResultsMay 8, 2019
Adimab Expands Research Agreement with RegeneronMay 8, 2019
scPharmaceuticals Inc. Reports First Quarter 2019 Financial Results and Provides Business UpdateMay 8, 2019
Tricida Announces First Quarter 2019 Financial ResultsMay 8, 2019
SI-BONE, Inc. Reports First Quarter 2019 Financial ResultsMay 8, 2019
Nabriva Therapeutics Announces Submission of Marketing Authorization Application for Lefamulin to Treat Community-Acquired Pneumonia in Adults by European Medicines AgencyMay 8, 2019
Adimab Announces Multi-Target Expansion for the Discovery of Antibodies with Another Global Pharma PartnerMay 8, 2019
BELLUS Health Provides Update on Its Chronic Cough Drug Candidate BLU-5937 and Reports Financial and Operating Results for the First Quarter Ended March 31, 2019May 8, 2019
Constellation Pharmaceuticals Announces First-Quarter 2019 Financial ResultsMay 8, 2019
Adimab Announces Antibody Discovery Platform Transfer with TakedaMay 7, 2019
Verona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019May 7, 2019
Peloton Therapeutics Appoints Timothy P. Coughlin and Thilo Schroeder, Ph.D. to its Board of DirectorsMay 7, 2019
Audentes Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate UpdateMay 7, 2019
Xenon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate UpdateMay 7, 2019
Verrica Pharmaceuticals Reports First Quarter 2019 Financial ResultsMay 7, 2019
Invitae Reports 47% Growth in Quarterly Revenue and Volume Year-Over-YearMay 7, 2019
Aeglea BioTherapeutics Reports First Quarter 2019 Financial Results and Corporate HighlightsMay 7, 2019
Verona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 TrialsMay 7, 2019
Principia Biopharma Reports First Quarter Financial ResultsMay 7, 2019
Kyn Therapeutics Strengthens Leadership Team with Key AppointmentsMay 7, 2019
Signatera� Blood Test Detects Bladder Cancer Relapse Up to Eight Months Earlier Than Current Clinical StandardsMay 6, 2019
Alector Announces First Alzheimer’s Disease Patient Dosed in Phase 1b Study of AL002May 6, 2019
TransMedics Announces Closing of its Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesMay 6, 2019
Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid TumorsMay 6, 2019
Turning Point Therapeutics And Almac Diagnostic Services Announce Approval Of An Investigational Device Exemption For The Companion Diagnostic Assay To The Registrational TRIDENT-1 Clinical StudyMay 6, 2019
Inspire Medical Systems, Inc. Announces Additional 11.2 Million Covered Lives with New Blue Cross Blue Shield Coverage PoliciesMay 6, 2019
Adaptimmune Reports First Quarter 2019 Financial ResultsMay 3, 2019
Rhythm Pharmaceuticals Reports First Quarter 2019 Financial ResultsMay 2, 2019
ViewRay Reports First Quarter 2019 ResultsMay 2, 2019
CTI BioPharma Reports First Quarter 2019 Financial ResultsMay 2, 2019
Intellia Therapeutics Announces First Quarter 2019 Financial Results and Company UpdateMay 2, 2019
Aerpio Pharmaceuticals Presents Data Showing Potential of AKB-9778, a VE-PTP Inhibitor/Tie2 Activator, to Lower Intra-ocular Pressure in Human SubjectsMay 1, 2019
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial ResultsMay 1, 2019
Audentes Therapeutics Presents New Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for X-linked Myotubular Myopathy, at 22nd Annual Meeting of the American Society of Gene and Cell TherapyMay 1, 2019
Avedro Completes Enrollment in Pivotal U.S. Phase 3 Epi-On Corneal Cross-Linking Clinical Trial for Progressive KeratoconusApr 30, 2019
Synlogic Presents Data Describing a Solid Oral Formulation Process for Synthetic Biotic™ aMedicine SYNB1618 for the Treatment of PKU at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)Apr 30, 2019
Adicet Bio Appoints Anil Singhal Chief Executive OfficerApr 30, 2019
Synthorx Reports First Quarter Financial ResultsApr 30, 2019
Arcutis, Inc. Announces Board of DirectorsApr 30, 2019
Nabriva Therapeutics Receives Complete Response Letter from FDA on NDA for Intravenous CONTEPO™ (fosfomycin) for injectionApr 29, 2019
ObsEva SA Reports Further Infant Follow-up Data from IMPLANT2 Trial Echoing Favorable Safety Profile of Nolasiban in IVFApr 29, 2019
Intellia Therapeutics Presents New In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell TherapyApr 26, 2019
Acutus Medical’s New Contact Mapping Software Receives CE MarkApr 25, 2019
TELA Bio® Appoints Kurt Azarbarzin Chairman of Board of DirectorsApr 24, 2019
X4 Pharmaceuticals Appoints E. Lynne Kelley, M.D. as Chief Medical OfficerApr 24, 2019
Ascendis Pharma A/S Announces Presentations Related to Rare Disease Endocrinology Pipeline at Upcoming Medical ConferencesApr 23, 2019
Audentes Therapeutics Announces Launch of New State-of-the-Art Internal cGMP Plasmid Manufacturing FacilityApr 22, 2019
Turning Point Therapeutics Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters’ Option To Purchase Additional SharesApr 18, 2019
Alpine Immune Science Appoints Stanford Peng to President and Head of Research and DevelopmentApr 18, 2019
ViewRay Partners with Leading Canadian Distributor to Bring MRI-guided Radiation Therapy to CanadaApr 18, 2019
TELA Bio® Announces 510(k) Clearance for Restella™ Reconstructive BioScaffolds for Reconstructive SurgeryApr 18, 2019
Principia Bipharma Appoints Shao-Lee Lin Md PhD to Board of DirectorsApr 18, 2019
Harpoon Therapeutics Doses First Patient with a Mesothelin-Targeting T Cell Engager (HPN536) in Phase 1/2A Clinical Trial for Ovarian and Other Solid Tumor CancersApr 17, 2019
Alector Announces First Frontotemporal Dementia Patient Dosed in Phase 1b Study of AL001Apr 17, 2019
ViewRay Partners with Largest Independent Distributor in Australia and New Zealand to Bring Benefits of MRI-Guided Radiation Therapy to the RegionApr 16, 2019
Inspire Medical Systems, Inc. Announces the 5,000th Patient to Receive Inspire TherapyApr 16, 2019
Turning Point Therapeutics Announces Pricing Of Initial Public OfferingApr 16, 2019
Selecta Biosciences Presents New Preclinical Data from its Gene Therapy Program at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual MeetingApr 15, 2019
SI-BONE, Inc. Announces FDA Clearance of iFuse Bedrock™ Novel Spinopelvic Fixation TechnologyApr 12, 2019
X4 Pharmaceuticals Prices $85.8 Million Public Offering of Common Stock and Class A WarrantsApr 11, 2019
Clementia Pharmaceuticals Inc. Announces Receipt of Final Court Approval for Plan of Arrangement With Ipsen S.A.Apr 11, 2019
X4 Pharmaceuticals Announces Proposed Public Offering of Common Stock and Class A WarrantsApr 11, 2019
ViewRay Announces Publication of Retrospective Study on MR-guided Radiation Treatment for Locally Advanced Pancreatic CancerApr 10, 2019
Imara Appoints Chief Financial & Chief Operating OfficerApr 10, 2019
Realm Therapeutics Announces 2018 Annual Report Available and Form 20-F FilingApr 9, 2019
Verona Pharma Granted Key EU Patent Related to Late-stage COPD Clinical Candidate EnsifentrineApr 9, 2019
Clementia Pharmaceuticals Inc. Shareholders Approve Plan of Arrangement With Ipsen S.A.Apr 9, 2019
Peloton Therapeutics Announces Completion of Enrollment in Phase 2 Trial of PT2977 for Treatment of von Hippel-Lindau Disease-associated Renal Cell CarcinomaApr 9, 2019
Synlogic Appoints Scott Plevy M.D. as Chief Scientific OfficerApr 8, 2019
Audentes Therapeutics Announces Expansion of AAV Technology Platform and Pipeline with New Development Programs for Duchenne Muscular Dystrophy and Myotonic DystrophyApr 8, 2019
Turning Point Therapeutics Appoints Annette North As Executive Vice President And General CounselApr 8, 2019
https://www.reviral.co.uk/news/45/48/ReViral-Announces-Grant-of-Key-US-Composition-of-Matter-Patent-For-Their-Respiratory-Syncytial-Virus-inhibitor-programme.htmlApr 8, 2019
Inspire Medical Systems, Inc. Announces Three New Positive Coverage Policies Issued by Blue Cross Blue Shield PlansApr 8, 2019
Tricida Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesApr 7, 2019
Aeglea BioTherapeutics Announces New Positive Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 Annual Meeting of the Society for Inherited Metabolic DisordersApr 5, 2019
Avedro Reaches Reimbursement Milestone for Its FDA-Approved Procedure for Progressive KeratoconusApr 5, 2019
Realm Therapeutics Announces Receipt of Nasdaq Listing Determination and Requests HearingApr 4, 2019
Grant of Options and RSUs and PDMR DealingsApr 3, 2019
Sierra Reports Late-Breaking SRA141 Preclinical Data in Poster at AACR 2019Apr 3, 2019
Ascendis Pharma A/S Reports Full Year 2018 Financial ResultsApr 3, 2019
BELLUS Health Announces Clearance of U.S. IND for BLU-5937 Phase 2 Study in Chronic Cough PatientsApr 3, 2019
Sonendo® to Launch the GentleWave® System in Canada at AAE 2019Apr 3, 2019
Tricida Announces Pricing of Public Offering of Common StockApr 2, 2019
X4 Pharmaceuticals Appoints Murray W. Stewart, M.D. to Board of DirectorsApr 2, 2019
resTORbio Announces Initiation of Phase 1b/2a Trial of RTB101 in Parkinson’s DiseaseApr 2, 2019
ORIC Pharmaceuticals Presents Evidence of Glucocorticoid Receptor-Medicated Cancer Treatment Resistance at the AACR Annual MeetingApr 2, 2019
Adaptimmune Presents Safety Data with Evidence of Tumor Necrosis in One Patient from ADP-A2AFP Study at American Association for Cancer Research (AACR) MeetingApr 1, 2019
Fusion Pharmaceuticals Raises $105 Million In Oversubscribed Series B FinancingApr 1, 2019
Constellation Pharmaceuticals Presents Results from Phase 1b Portion of ProSTAR Clinical Trial of CPI-1205 at AACR MeetingApr 1, 2019
Alector Initiates Phase 1 Trial of AL003 for the Treatment of Patients with Alzheimer’s DiseaseApr 1, 2019
Audentes Therapeutics Appoints Legal and Corporate Communications Executives; Promotes Thomas P. Soloway to Executive Vice President and Chief Financial OfficerApr 1, 2019
Sierra Reports Late-Breaking Preclinical Data for SRA737 Presented at AACR 2019Apr 1, 2019
Adaptimmune Presents Preclinical Data for its Next Generation SPEAR T-cell Targeting MAGE-A4 at the American Association for Cancer Research (AACR) Annual MeetingApr 1, 2019
SpringWorks Therapeutics Completes $125 Million Series B FinancingApr 1, 2019
Tricida Announces Proposed Public Offering of Common StockApr 1, 2019
X4 Pharmaceuticals Provides Business and Clinical Development UpdateApr 1, 2019
Happy April 1! Announcing Cyrus ROSVAC-4!Apr 1, 2019
Turning Point Therapeutics’ Kinase Inhibitors Show High Potency Against Targeted Oncogene Drivers And Their MutationsApr 1, 2019
Peloton Therapeutics Announces Clinical Data Update for PT2977 at European International Kidney Cancer SymposiumMar 29, 2019
Selecta Biosciences Initiates Head-to-Head Clinical Trial (COMPARE) of SEL-212 vs. KRYSTEXXA® in Patients with Chronic Refractory Gout and Strengthens Management TeamMar 28, 2019
Tricida Announces $200 Million Debt Facility With Hercules CapitalMar 28, 2019
Tricida Announces Positive Results From Long-Term Clinical Trial of TRC101 in Patients With CKD and Metabolic AcidosisMar 28, 2019
Tricida Announces Fourth Quarter and Full-Year 2018 Financial ResultsMar 28, 2019
Rhythm Pharmaceuticals Announces Promising Clinical Data in MC4R Pathway Heterozygous Obesity and Strategy for Further DevelopmentMar 27, 2019
Imara Appoints Chief Medical OfficerMar 26, 2019
Alector Reports Recent Business Highlights and Fourth Quarter and Full Year 2018 Financial ResultsMar 25, 2019
Turning Point Therapeutics Appoints Jim Mazzola to Lead Corporate Communication and Investor RelationsMar 25, 2019
Ascendis Pharma Announces Results of Study at ENDO 2019 Evaluating Impact of Hypoparathyroidism on Patient Quality-of-LifeMar 24, 2019
Ascendis Pharma Announces Phase 3 heiGHt Trial Demonstrated Superior Efficacy and Comparable Safety and Tolerability of TransCon™ hGH to a Daily Growth HormoneMar 22, 2019
2018 Annual Report and Accounts and Notice of AGMMar 22, 2019
resTORbio, Inc. Announces Closing Public Offering of Common StockMar 21, 2019
Dr. Martin Edwards Joins Verona Pharma as Non-Executive DirectorMar 21, 2019
Sonendo® Announces Three Key HiresMar 21, 2019
Avedro, Inc. Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Full Year 2019 Financial OutlookMar 21, 2019
scPharmaceuticals Inc. Reports Fourth Quarter and Year Ended 2018 Financial Results and Provides Business UpdateMar 21, 2019
Turning Point Therapeutics Files Registration Statement for Proposed Initial Public OfferingMar 19, 2019
Crinetics Pharmaceuticals Doses First Patients in Phase 2 Clinical Trials of CRN00808 for AcromegalyMar 19, 2019
Principia Biopharma Reports Fourth Quarter and Full Year 2018 Financial ResultsMar 18, 2019
Imara Closes a $63MM Series B Cross-Over FinancingMar 18, 2019
Aerpio Pharmaceuticals Announces Results From TIME-2b Study of AKB-9778 in Diabetic RetinopathyMar 18, 2019
resTORbio Reports Fourth Quarter and Full Year 2018 Financial ResultsMar 18, 2019
Alpine Immune Sciences Provides Corporate Update and Reports Full Year 2018 Financial ResultsMar 18, 2019
Crinetics Pharmaceuticals Appoints Gina Ford, RPH, MBA, as Vice President, Corporate Strategy and Commercial PlanningMar 18, 2019
resTORbio Announces Positive End-of-Phase 2 Meeting with FDA and Planned Initiation of Global Phase 3 Program for RTB101Mar 17, 2019
Prevail Therapeutics Secures $50 Million in Series B Financing to Advance Pipeline of Gene Therapies for Neurodegenerative DiseasesMar 15, 2019
Selecta Biosciences Announces Fourth Quarter and Year End 2018 Financial Results and Provides Corporate UpdateMar 15, 2019
Stereotaxis and Acutus Medical Combine Robotic Precision and High-Resolution Imaging to Treat Arrhythmias in First Integrated ProceduresMar 14, 2019
ViewRay Reports Fourth Quarter and Full Year 2018 ResultsMar 14, 2019
Crinetics Pharmaceuticals Announces Upcoming Presentations at ENDO2019Mar 14, 2019
Harpoon Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate UpdateMar 14, 2019
Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2018 Financial ResultsMar 13, 2019
CTI BioPharma Reports Fourth Quarter and Full Year 2018 Financial Results and Recent HighlightsMar 13, 2019
Avedro, Inc. Announces Appointment of Patrick B. Jacques as Vice President of SalesMar 13, 2019
ObsEva SA to Present OBE022 Clinical Data for Treatment of Pre-term labor (PTL) at the SRI 66th Annual Scientific Meeting, March 12 -16, 2019Mar 13, 2019
Crinetics Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial Results And Provides Corporate UpdateMar 13, 2019
X4 Pharmaceuticals Completes Merger with ArsanisMar 12, 2019
Nabriva Therapeutics Reports 2018 Financial Results and Recent Corporate HighlightsMar 12, 2019
Synlogic Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business UpdateMar 11, 2019
Marinus Pharmaceuticals Provides Business Update and 2018 Financial ResultsMar 11, 2019
Tricida Announces Publication of Positive TRC101 Pivotal Trial Results in The LancetMar 11, 2019
Principia Biopharma Reacquires Rights to Oral Immunoproteasome ProgramMar 11, 2019
TELA Bio® Announces Multiple Presentations at American Hernia Society Annual Meeting in Las VegasMar 11, 2019
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial ResultsMar 8, 2019
Sublimity Therapeutics to Present Positive Data for Ulcerative Colitis Drug CandidateMar 8, 2019
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial ResultsMar 7, 2019
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate HighlightsMar 7, 2019
Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business UpdateMar 7, 2019
SI-BONE, Inc. Reports Fourth Quarter and Full Year 2018 Financial ResultsMar 7, 2019
Verrica Reports Fourth Quarter and Full Year 2018 Financial ResultsMar 6, 2019
Synlogic Announces Achievement of Milestone in Collaboration to Develop Synthetic Biotic™ Medicines to Treat Inflammatory Bowel DiseaseMar 6, 2019
Invitae Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common StockMar 6, 2019
Xenon Pharmaceuticals Reports 2018 Financial Results and Provides Corporate UpdateMar 6, 2019
SI-BONE, Inc. Announces Journal of Bone and Joint Surgery (JBJS) Publishes 2-Year Results from iMIA, a European Multicenter Randomized Controlled Trial (RCT) of SI Joint Fusion with iFuse Implant System® vs Conservative CareMar 6, 2019
Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related EpilepsyMar 5, 2019
ObsEva Reports Fourth Quarter and Full Year 2018 Financial Results, Provides Business UpdateMar 5, 2019
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSsMar 5, 2019
Aerpio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business UpdateMar 5, 2019
Cyrus Biotechnology Announces Release of Antibody Structure Prediction Software for Biologics Drug Development and DiscoveryMar 4, 2019
Constellation Pharmaceuticals Appoints Jessica Christo as Chief Product Development OfficerMar 4, 2019
ORIC Pharmaceuticals Appoints Edna Chow Maneval, PhD, as Senior Vice President of Clinical DevelopmentMar 4, 2019
Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone DeficiencyMar 4, 2019
Fusion Pharmaceuticals Announces Appointment Of John J. Crowley As Chief Financial OfficerMar 4, 2019
Verona Pharma Reports Positive Interim Data with Ensifentrine Dry Powder Inhaler Formulation in First of Two-Part Phase 2 Clinical Trial in COPDMar 4, 2019
Inspire Medical Systems, Inc. Announces Five New Positive Coverage Policies Issued by Blue Cross Blue Shield PlansMar 4, 2019
Invitae Announces Proposed Public Offering of Common StockMar 4, 2019
NextCure and Yale Publish Nature Medicine Paper Detailing Novel Immunomedicine Target Siglec-15Mar 2, 2019
Verrica Pharmaceuticals Presents Positive Results from Two Phase 3 Clinical Trials of VP-102 in Late-Breaking Oral Presentation at the 2019 American Academy of Dermatology MeetingMar 2, 2019
Principia Biopharma Announces Positive Data From Phase 2 Pemphigus Vulgaris Trial At 2019 American Academy Of Dermatology Annual Meeting In Late-Breaking PresentationMar 1, 2019
Principia Biopharma Presents Phase 1 Clinical Data From CNS Penetrating BTK Inhibitor Candidate PRN2246/SAR442168 at ACTRIMS 2019Feb 28, 2019
Sierra Oncology Reports 2018 Year End ResultsFeb 28, 2019
Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon CNP as Treatment for AchondroplasiaFeb 28, 2019
Audentes Therapeutics Recognizes Rare Disease Day by Launching """"Be Bold for Courageous Patients"""" Program to Support Patients Living with Rare DiseasesFeb 27, 2019
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial ResultsFeb 27, 2019
CORRECTING and REPLACING -- Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business UpdateFeb 27, 2019
Sierra Oncology Announces Late-Breaking Oral and Poster Presentations at AACR 2019 for SRA737 and SRA141 Preclinical DataFeb 27, 2019
Audentes Therapeutics Reports Fourth Quarter 2018 and Full Year Financial Results and Provides Corporate UpdateFeb 26, 2019
Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2018 Financial ResultsFeb 26, 2019
Verona Pharma Reports Financial Results for Full Year Ended December 31, 2018 and Provides Clinical Development UpdateFeb 26, 2019
ReViral Ltd Appoints Seth Hetherington as Chief Medical Officer as it Prepares its Lead RSV Candidate to Enter Pediatric Phase IIa Clinical TrialsFeb 26, 2019
Marinus Announces Leadership TransitionFeb 25, 2019
Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease PortfolioFeb 22, 2019
Kala Pharmaceuticals Reports Inducement Grand Under NASDAQ Listing Rule 5635©(4)Feb 21, 2019
BELLUS Health Presents 2018 Highlights and 2019 Corporate PlanFeb 21, 2019
ViewRay Announces FDA 510(k) Clearance for Advancements in MRI and Functional Imaging Technologies for MRIdian MRI-Guided Radiation Therapy SystemFeb 20, 2019
Constellation Pharmaceuticals Announces Appointment to Board of DirectorsFeb 20, 2019
Peloton Therapeutics Secures $150 Million in Series E FinancingFeb 19, 2019
Invitae More Than Doubles Annual Volume and Revenue Year-Over-Year, Delivering 117% in Revenue Growth Driven by 102% Growth in Volume in 2018Feb 19, 2019
Modis Therapeutics Announces that MT1621 Receives Breakthrough Therapy Designation from FDA For the Treatment of TK2 DeficiencyFeb 19, 2019
Nabriva Therapeutics Announces Acceptance of New Drug Applications by the FDA for Intravenous and Oral Lefamulin to Treat Community-Acquired Bacterial Pneumonia in AdultsFeb 19, 2019
Alpine Immune Sciences Presents Preclinical ALPN-101 GvHD Data at the 2019 Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR (TCT Meetings)Feb 13, 2019
Avedro Announces Pricing of Initial Public OfferingFeb 12, 2019
Invitae Launches Non-Invasive Prenatal Screening (NIPS), Offering In-Depth Genetic Information in Early PregnancyFeb 12, 2019
NeuroPace Announces New Category I CPT Code from AMA for Electrocorticography from an Implanted Brain NeurostimulatorFeb 12, 2019
Synlogic Appoints Patricia N. Hurter, Ph.D. to Board of DirectorsFeb 11, 2019
CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®Feb 11, 2019
Alpine Immune Sciences Announces First Subjects Dosed in Phase I Clinical Trial for Lead Autoimmune/Inflammatory Disease Program ALPN-101Feb 11, 2019
Ascendis Pharma Initiates Global Phase 2 Trial for TransCon PTH in Adult Subjects with HypoparathyroidismFeb 11, 2019
Clementia Granted Rare Pediatric Disease Designation by FDA for Palovarotene for Fibrodysplasia Ossificans ProgressivaFeb 7, 2019
Sublimity Therapeutics Presents Encouraging New Efficacy Data at the 2019 Crohn's & Colitis CongressFeb 7, 2019
Health Catalyst Secures up to $100 Million with Financing Led By OrbiMedFeb 7, 2019
Harpoon Therapeutics Announces Pricing of Initial Public OfferingFeb 7, 2019
Alector Announces Pricing of Initial Public OfferingFeb 6, 2019
resTORbio Appoints Erkan Baloglu, Ph.D., M.B.A., as Vice President of Drug Discovery and Medicinal ChemistryFeb 6, 2019
Corvus Presents Updated Biomarker and Clinical Results from Lead Pipeline Programs�CPI-444 and CPI-006 at Immuno-Oncology 360� ConferenceFeb 6, 2019
HLS Therapeutics Announces Graduation to the Toronto Stock ExchangeFeb 6, 2019
Aeglea BioTherapeutics Announces Pricing of $60.0 Million Public OfferingFeb 5, 2019
Aeglea BioTherapeutics Announces Proposed Public Offering of Common StockFeb 5, 2019
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Feb 5, 2019
Graybug Vision Appoints Frédéric Guerard as Chief Executive Officer Pharmaceutical Industry Veteran and Former Worldwide Business Franchise Head of Ophthalmology at NovartisFeb 4, 2019
SI-BONE, Inc. Announces Additional Exclusive Coverage Policies for iFuseFeb 4, 2019
Avedro Launches Initial Public OfferingFeb 4, 2019
Kyn Therapeutics Appoints Douglas Carlson as Chief Financial OfficerFeb 1, 2019
CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development UpdateJan 31, 2019
Audentes Therapeutics Announces Next Steps in the Development of AT132 to Treat XLMTM Following Collaborative Initial Meeting with FDA Under RMAT DesignationJan 29, 2019
scPharmaceuticals Inc. Announces Development Agreement with West Pharmaceutical Services for Next-Generation FUROSCIX� On-Body InfusorJan 28, 2019
Corvus Pharmaceuticals Announces Appointment of New Member of Board of Directors and Hiring of Chief Medical OfficerJan 28, 2019
Xenon Provides Key Regulatory Updates on XEN007 and XEN1101Jan 24, 2019
Intellia Therapeutics Names Fred Cohen, M.D., to Board of DirectorsJan 24, 2019
TELA Bio Announces First Patient in Europe Treated with OviTex® Reinforced BioScaffoldsJan 23, 2019
Selecta Biosciences Announces Pricing of Public Offering of Common StockJan 23, 2019
ObsEva SA Reports Initial Good Safety of OBE022 in Pregnant Women with Preterm Labour and Announces Start of Part B of the PROLONG TrialJan 22, 2019
World's First MRIdian Center Celebrates Five Years of MRI-Guided Radiation TreatmentsJan 22, 2019
Selecta Biosciences Announces Proposed Public Offering of Common StockJan 21, 2019
Graybug Vision Presents Top Line Results of Phase 1/2a ADAGIO Study at Hawaiian Eye & Retina 2019Jan 18, 2019
Kala Pharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635C(4)Jan 18, 2019
Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene to Develop Immuno-oncology TherapiesJan 17, 2019
Tricida Announces Hiring of Susannah Cantrell, Ph.D., as Chief Commercial OfficerJan 17, 2019
Proteus Digital Health® Launches Digital Oncology Medicines to Improve Patient OutcomesJan 17, 2019
Terns Pharmaceuticals Announces the Appointment of Erin Quirk, M.D., as Chief Medical OfficerJan 17, 2019
Aerpio Pharmaceuticals Announces Completion of Patient Dosing in TIME-2b Study of AKB-9778 in Diabetic RetinopathyJan 17, 2019
Promentis Pharmaceuticals Announces Commencement of Phase 2 Studies for SXC-2023 Targeting Novel Glutamatergic MechanismJan 16, 2019
Inspire Medical Systems, Inc. Announces a Positive Coverage Policy Issued by Horizon Blue Cross Blue Shield of New JerseyJan 16, 2019
Alpine Immune Sciences Announces $25 Million Private PlacementJan 16, 2019
Science Translational Medicine Publishes First-in-Human Clinical Data and Supporting Preclinical Data for SYNB1020, Synlogic’s Synthetic Biotic™ Medicine in Development as a Potential Treatment for HyperammonemiaJan 14, 2019
Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance TreatmentJan 14, 2019
Inspire Medical Systems, Inc. Announces First BCBS Coverage Policy following Evidence Street’s Positive Therapy Indication SummaryJan 14, 2019
Nabriva Therapeutics Provides Update on PDUFA Date for Intravenous CONTEPO™Jan 10, 2019
Corvus Announces Presentation of Preclinical Data on CPI-818, a First-in-class Covalent Inhibitor of ITK Targeting T-Cell LymphomasJan 10, 2019
TELA Bio begins commercialization for Large Size OviTex® Reinforced BioScaffolds for Hernia Repair and Abdominal Wall Reconstruction after Aroa Biosurgery receives 510k clearance.Jan 9, 2019
Verona Pharma Receives WHO Approval for “ensifentrine” as Recommended INN for RPL554Jan 9, 2019
Venus Medtech Announces Agreement to Acquire Keystone Heart, LTDJan 9, 2019
Adimab Provides 2018 Update on Clinical PipelineJan 8, 2019
Corvus Announces Enrollment in Second Arm of Phase 1/1b Dose-Escalation Trial of Anti-CD73 Antibody, CPI-006, Focused on Combination with CPI-444 Adenosine AntagonistJan 8, 2019
Dr. Mary Kerr CEO NeRRe Therapeutics Presents at the Biotech Showcase, San FranciscoJan 8, 2019
Adimab Provides Year-End Update on 2018 Partnership ActivitiesJan 7, 2019
Cyrus Bio announces full release of rapid and accurate protein mutational free energy tool in Cyrus BenchJan 7, 2019
Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety ReviewsJan 7, 2019
Invitae reports 2018 preliminary financial results, delivering more than 100% volume and revenue growth in 2018; projects sustained growth in expanding markets through 2019 and beyondJan 7, 2019
Gemini Therapeutics Announces the Initiation of CLARITY, a Disease Registry and Natural History Study of Subjects with Dry AMD and High-Risk GenotypesJan 7, 2019
Kala Pharmaceuticals Announces the Launch of Inveltys and the Hiring of a Specialty Ophthalmology Sales OrganizationJan 7, 2019
Adimab Partner Innovent Receives Product Approval for PD-1 Antibody for Hodgkin's LymphomaJan 7, 2019
Verrica Appoints Neil D. DeHenes as Vice President of Distribution, Trade and Channel StrategyJan 7, 2019
Sublimity Therapeutics Receives Investigational New Drug (IND) Clearance from U.S. Food and Drug Administration (FDA)Jan 7, 2019
ViewRay Announces Preliminary Fourth Quarter and Fiscal Year 2018 ResultsJan 7, 2019
Audentes Therapeutics Reports on Recent Progress and Outlines 2019 Key PrioritiesJan 7, 2019
Ascendis Pharma A/S Introduces Vision 3x3: A Strategic Roadmap Through 2025 to Achieve Sustainable Growth Using Multiple ApproachesJan 7, 2019
Inspire Medical Systems, Inc. Announces a Positive Coverage Policy Issued by Horizon Blue Cross Blue Shield of New JerseyJan 7, 2019
KaNDy Therapeutics Announces the Appointmetn of Andrew Kay as Independent Chairman of the BoardJan 7, 2019
SI-BONE Reports Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2018Jan 6, 2019
Xenon Pharmaceuticals Outlines 2019 Key MilestonesJan 4, 2019
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Jan 4, 2019
ViewRay Announces First Patient Enrolled in Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) Trial for Locally Advanced Pancreatic CancerJan 4, 2019
Nabriva Therapeutics Provides Update on PDUFA Date for Intravenous CONTEPO™Jan 3, 2019
Constellation Pharmaceuticals Provides Update on MANIFEST Clinical Trial of CPI-0610 in Myelofibrosis, Reviews 2018 Accomplishments, and Announces 2019 Data Disclosure Plans for Lead ProgramsJan 3, 2019
Audentes Therapeutics Appoints Eric B. Mosbrooker as Senior Vice President and Chief Commercial OfficerJan 3, 2019
E-Scape Bio Appoints Dr. Carrolee Barlow as Chief Medical OfficerJan 3, 2019
Synlogic Progresses Clinical and Preclinical Pipeline and Outlines 2019 CatalystsJan 3, 2019
Verona Pharma Appoints Kathleen Rickard, MD, as Chief Medical Officer to Lead Late Stage Clinical Development of RPL554Jan 3, 2019
Verrica Achieves Positive Topline Results from Two Pivotal Phase 3 Clinical Trials of VP-102 in Patients with Molluscum ContagiosumJan 3, 2019
Selecta Biosciences Expands Potential for ImmTOR™ Platform and Streamlined Structure Under Leadership of New CEO, Carsten Brunn, Ph.D.Jan 2, 2019
Nora Brennan Joins TELA Bio® as Chief Financial OfficerJan 2, 2019
Harpoon Therapeutics Announces Preliminary Safety and Pharmacology Data From Its HPN424 Phase 1 Trial in Prostate CancerDec 20, 2018
Nabriva Therapeutics Submits New Drug Applications to U.S. Food and Drug Administration for Intravenous and Oral Lefamulin to Treat Community-Acquired Bacterial Pneumonia in AdultsDec 19, 2018
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635C(4)Dec 19, 2018
resTORbio Appoints William Marshall, M.D., as Vice President of Medical SciencesDec 19, 2018
Kyn Therapeutics Announces Initiation of Phase 1b/2 Clinical Studies of ARY-007 in Collaboration with MerckDec 18, 2018
CTI BioPharma Provides Program Update Following Regulatory Feedback from the U.S. FDA on Pacritinib DevelopmentDec 18, 2018
BELLUS Health Closes $35M Financing to Support Development of its Lead Drug Candidate BLU-5937 for Chronic CoughDec 17, 2018
Inspire Medical Systems, Inc. Announces Full Exercise of Underwriters’ Option to Purchase Additional SharesDec 17, 2018
Principia Biopharma Issues Statement About the Passing of Board Member Lewis J. ShusterDec 17, 2018
Verona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPDDec 17, 2018
Turning Point Therapeutics Mourns the Death of Board Member Lewis ShusterDec 13, 2018
CTI BioPharma Announces Restructuring PlanDec 13, 2018
Rhythm Pharmaceuticals Announces First Patient Enrolled in Pivotal Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström SyndromesDec 12, 2018
Adaptimmune Announces that Gwen Binder will leave in January 2019Dec 12, 2018
Marinus Pharmaceuticals Announces Pricing of Public Offering of Common StockDec 12, 2018
Synlogic Expands Capabilities in Manufacturing with the Appointment of Head of Technical Operations and Establishment of In-house Production of Clinical Trial Material for its Synthetic BioticTM MedicinesDec 12, 2018
Singulex receives new, broad patent for highly sensitive methods for analysis of troponinDec 11, 2018
Aeglea BioTherapeutics Announces Design of Pivotal Phase 3 PEACE Trial Evaluating Pegzilarginase in Arginase 1 DeficiencyDec 11, 2018
BELLUS Health Announces Pricing of $35 Million Public Offering of Common SharesDec 11, 2018
Anthem Blue Cross Blue Shield Joins List of 60 Commercial Plans Covering Avedro's FDA-Approved Corneal Cross-Linking ProcedureDec 11, 2018
Marinus Pharmaceuticals Announces Public Offering of Common StockDec 11, 2018
KaNDy Therapeutics Announces Initiation of Phase 2B Trial of NT-814 For the Treatment of Troublesome Post-Menopausal SymptomsDec 10, 2018
Constellation Pharmaceuticals Initiates Phase 2 Portion of ProSTAR Clinical Trial in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)Dec 10, 2018
BELLUS Health Announces Overnight Marketed Equity OfferingDec 10, 2018
Marinus Pharmaceuticals Announces Positive Ganaxolone Data in Women With Postpartum DepressionDec 7, 2018
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Dec 7, 2018
ObsEva R&D Day Showcases Multiple Women’s Health Programs and Outlines Plans for Transition to Commercial OperationsDec 6, 2018
SI-BONE, Inc. Announces Blue Cross Blue Shield of Arizona (BCBS AZ) Establishes Positive Coverage for MIS SI Joint Fusion Exclusively with the Triangular Titanium iFuse Implant SystemDec 6, 2018
Inspire Medical Systems, Inc. Announces Pricing of Offering of Common StockDec 6, 2018
Intellia Therapeutics and Novartis Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing in Additional Stem Cell PopulationDec 5, 2018
ReViral Board member Raymond Schinazi decorated with French Legion of HonourDec 5, 2018
Prevail Therapeutics Announces Executive Leadership AppointmentsDec 4, 2018
Inspire Medical Systems, Inc. Announces Proposed Offering of Common StockDec 4, 2018
Marinus Pharmaceuticals Phase 2 Clinical Trial Data Show Long-term Effectiveness of Ganaxolone in Reducing Seizure Frequency in CDKL5 Deficiency Disorder PatientsDec 3, 2018
Xenon Announces Final Results of XEN1101 Phase 1 Clinical Trial and Update on XEN901 Phase 1 Clinical Trial at the American Epilepsy Society (AES) Annual MeetingDec 3, 2018
Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with MomelotinibDec 3, 2018
Selecta Biosciences Announces New Employment Inducement GrantsDec 2, 2018
Harpoon Therapeutics Presents Preclinical Data Supporting Development of HPN217, A New BCMA-Targeting TRITAC, at the 2018 American Society of Hematology (ASH) Annual MeetingDec 2, 2018
NeuroPace Announces Final Results from the Largest Prospective Clinical Study in the Field of Neuromodulation with 9-Year Follow-Up at the 2018 American Epilepsy Society Annual MeetingNov 30, 2018
Inspire Medical Systems, Inc. Announces Publication of Data From ADHERE RegistryNov 30, 2018
Clementia Announces the Departure of Chief Commercial OfficerNov 29, 2018
SI-BONE, Inc. Reports Third Quarter 2018 Financial ResultsNov 29, 2018
Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737Nov 29, 2018
Realm Therapeutics Provides Update on Strategic ReviewNov 29, 2018
Constellation Pharmaceuticals Appoints Patrick Trojer, Ph.D., as Chief Scientific OfficerNov 29, 2018
Principia Biopharma Reports Positive PRN1008 Phase 2 Top-Line Results And Initiates Phase 3 Pemphigus ProgramNov 28, 2018
Ascendis Pharma A/S Reports Third Quarter 2018 Financial ResultsNov 28, 2018
Turning Point Therapeutics Appoints Jacob Chacko, M.D., to its Board of DirectorsNov 28, 2018
ObsEva SA Announces Initiation of Phase 3 IMPLANT 4 Trial of Nolasiban in Europe, Canada and Russia for Improving IVF OutcomesNov 28, 2018
Ascendis Pharma A/S Announces Positive Preliminary Phase 1 Data for TransCon CNPNov 27, 2018
Arsanis and X4 Pharmaceuticals Agree to MergerNov 26, 2018
ORIC Pharmaceuticals Appoints Matt Panuwat as Chief Business OfficerNov 26, 2018
FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2)Nov 26, 2018
CTI BioPharma Provides Program Update Following Regulatory Feedback on Pacritinib Development from the European Medicines AgencyNov 23, 2018
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635C(4)Nov 21, 2018
Rob Fuchs joins ViewRay as Chief Human Resources OfficerNov 20, 2018
Permanent J Code Issued for Avedro's Photrexa® Drug FormulationsNov 19, 2018
BELLUS Health Announces Positive Top-Line Phase 1 Results for its Chronic Cough Drug Candidate BLU-5937Nov 16, 2018
Alector Strengthens Board of Directors with Appointments of David Wehner, Richard Scheller and Louis LavigneNov 16, 2018
Promentis Pharmaceuticals Announces Successful Completion of Phase 1 Studies for SXC-2023 Targeting Novel Glutamatergic MechanismNov 15, 2018
Rhythm Pharmaceuticals Announces Presentation of Updated Clinical Data from Phase 2 Basket Studies Evaluating Setmelanotide in Alström Syndrome at ObesityWeek 2018Nov 15, 2018
Alector Initiates Phase 1 Trial of AL002 for the Treatment of Patients with Alzheimer’s DiseaseNov 15, 2018
Sierra Oncology Reports Preclinical Efficacy for Chk1 inhibitor SRA737 in Treatment Refractory Ovarian Cancer Models at the EORTC-NCI-AACR SymposiumNov 15, 2018
Constellation Pharmaceuticals Highlights EZH2 Inhibition Program in Prostate Cancer at Biomedical ConferenceNov 14, 2018
Attenua Announces First Patient Treated in Phase 2 Clinical Trial in Chronic Cough with BradaniclineNov 14, 2018
Ascendis Pharma A/S Announces Third Quarter 2018 Financial Results and Business Update Conference Call on November 28Nov 13, 2018
Sierra Oncology Reports SRA141 Preclinical Efficacy at EORTC-NCI-AACR SymposiumNov 13, 2018
scPharmaceuticals Inc. Reports Third Quarter 2018 Financial Results and Provides Business UpdateNov 13, 2018
Crinetics Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate UpdateNov 13, 2018
NextCure Raises $93 Million in Series B Financing — Proceeds Will Advance Growing Portfolio of Novel Immunomedicine Drug CandidatesNov 13, 2018
Modis Therapeutics Announces PRIME Designation Granted by the European Medicines Agency to MT1621 for the Treatment of TK2 DeficiencyNov 13, 2018
resTORbio Reports Third Quarter 2018 Financial ResultsNov 13, 2018
Synlogic Reports Third Quarter 2018 Financial Results and Provides Program UpdatesNov 12, 2018
Synlogic Presents Data at the 2018 Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD)Nov 11, 2018
Harpoon Therapeutics Announces Closing of $70M Series C FinancingNov 10, 2018
Corvus Pharmaceuticals Announces Updated Results from Ongoing Clinical Studies of Lead Programs, CPI-444 and CPI-006, at SITC 33rd Annual MeetingNov 9, 2018
Synthorx to Present Preclinical Data for THOR-707, a “Not-Alpha” IL-2 Synthorin, for the Treatment of Solid Tumors at SITC 2018Nov 9, 2018
Rhythm Pharmaceuticals Reports Third Quarter 2018 Financial ResultsNov 9, 2018
Harpoon Therapeutics Unveils ProTriTAC Platform: A Novel, Protease-Activated T Cell Engager Platform Designed to Access a Broad Landscape of Solid Tumor TargetsNov 9, 2018
Arsanis Reports Financial Results for Third Quarter 2018Nov 9, 2018
Alpine Immue Sciences Advances Oncology Programs with New ALPN-202 Preclinical Data and Key Additions to Scientific Advisory BoardNov 8, 2018
Constellation Pharmaceuticals Announces Third-Quarter and Nine-Month 2018 Financial ResultsNov 8, 2018
Sierra Oncology Reports Third Quarter ResultsNov 8, 2018
Aeglea BioTherapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate HighlightsNov 8, 2018
resTORbio Co-Founder and Chief Medical Officer Joan Mannick, M.D., to Present on TORC1 Inhibition at The Gerontological Society of America 2018 Annual Scientific MeetingNov 8, 2018
Alpine Immue Sciences Provides Corporate Update and Reports Third Quarter 2018 Financial ResultsNov 8, 2018
Selecta Biosciences Announces Third Quarter 2018 Financial Results and Provides Corporate UpdateNov 8, 2018
ViewRay Reports Third Quarter 2018 ResultsNov 8, 2018
Tricida Announces Third Quarter 2018 Financial ResultsNov 8, 2018
Ascendis Pharma Announces Formation of VISEN Pharmaceuticals to Develop and Commercialize TransCon™ Endocrinology Rare Disease Therapies in ChinaNov 8, 2018
Kala Pharmaceuticals Reports Third Quarter 2018 Financial ResultsNov 8, 2018
Loxo Oncology Reports Third Quarter 2018 Financial ResultsNov 8, 2018
ObsEva Reports Third Quarter 2018 Financial Results and Provides Business UpdateNov 7, 2018
SpringWorks Therapeutics Receives FDA Fast Track Designation for Nirogacestat for the Treatment of Adult Patients with Desmoid TumorsNov 7, 2018
Waljit Dhillo, Professor in Endocrinology & Metabolism, Consultant Endocrinologist and an NIHR Research Professor at Imperial College London has joined KaNDy Therapeutics as a Scientific and Clinical AdvisorNov 7, 2018
Aerpio Reports Third Quarter 2018 Financial Results and Provides Business UpdateNov 7, 2018
Verrica Pharmaceuticals Reports Third Quarter 2018 Financial ResultsNov 7, 2018
Clementia Reports Third Quarter 2018 Operating Results and Pipeline UpdatesNov 7, 2018
Pieris Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate UpdateNov 7, 2018
Invitae Reports 106% Annual Revenue Growth Driven by 95% Annual Growth in Volume in Third Quarter 2018Nov 6, 2018
Synlogic Presents Preclinical Data from First Synthetic BioticTM Clinical Candidate in Immuno-Oncology at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual MeetingNov 6, 2018
Principia Biopharma Reports Third Quarter Financial ResultsNov 6, 2018
Xenon Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate UpdateNov 6, 2018
Nabriva Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate HighlightsNov 6, 2018
Audentes Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate UpdateNov 6, 2018
Adaptimmune Reports Third Quarter 2018 Financial Results and Business UpdateNov 6, 2018
resTORbio Appoints Michael Grissinger to its Board of DirectorsNov 6, 2018
TELA Bio® Appoints Kurt Azarbarzin to Board of DirectorsNov 6, 2018
ENYO Pharma announces the successful completion of phase Ib with its FXR agonist EYP001 and the start of phase II studies in two indications, NASH and HBVNov 6, 2018
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2018Nov 5, 2018
Audentes Therapeutics Board of Directors Appoints Co-Founder and Chief Executive Officer Matthew R. Patterson as ChairmanNov 5, 2018
Lilly and NextCure Announce Collaboration to Discover and Develop Novel Immuno-Oncology MedicinesNov 5, 2018
SpringWorks Therapeutics Receives FDA Orphan Drug Designation for MEK Inhibitor (PD-0325901) for the Treatment of Neurofibromatosis Type 1Nov 1, 2018
Corvus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business UpdateNov 1, 2018
CTI BioPharma Reports Third Quarter 2018 Financial ResultsNov 1, 2018
Nabriva Therapeutics Completes Submission of New Drug Application to U.S. Food and Drug Administration for Intravenous CONTEPO™ to Treat Complicated Urinary Tract InfectionsNov 1, 2018
Constellation Pharmaceuticals Receives FDA Fast Track Designation for CPI-0610 in Treatment of MyelofibrosisOct 31, 2018
Verona Pharma Completes Enrollment in Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance TreatmentOct 31, 2018
BELLUS Health Announces Issuance of New U.S. Patent Claiming P2X3 Selectivity as a Means of Minimizing Taste Effects for its Lead Chronic Cough Drug Candidate BLU-5937Oct 31, 2018
Intellia Therapeutics Announces Third Quarter 2018 Financial Results and Corporate DevelopmentsOct 30, 2018
Cyrus Biotechnology and OpenEye Scientific Software Announce Collaboration and Cheminformatics Integration to Expedite New Drug Design and Development with Cyrus Bench PlatformOct 30, 2018
Terns Pharmaceuticals Completes $80 Million Series B Financing to Advance Pipeline of Drugs to Treat NASH and CancerOct 29, 2018
ViewRay signs agreement with GenesisCare to bring the first MRIdian MRI-guided radiotherapy systems to the UKOct 29, 2018
Clementia Announces Pricing of Public Offering of Common SharesOct 29, 2018
Marinus Pharmaceuticals Provides Business Update and Third Quarter 2018 Financial ResultsOct 29, 2018
Invitae expands work with Alnylam Pharmaceuticals to provide access to genetic testing for primary hyperoxaluriaOct 29, 2018
Intellia Therapeutics Names Glenn Goddard as New Chief Financial OfficerOct 29, 2018
Modis Therapeutics Announces Appointment of Matthew R. Patterson to Board of DirectorsOct 26, 2018
Data from Clinical and Pre-Clinical Trials Evaluating Verona Pharma’s RPL554 in Cystic Fibrosis Presented at North American Cystic Fibrosis ConferenceOct 26, 2018
Aeglea BioTherapeutics to Present Preclinical Data on a New Pipeline Therapeutic for Cystinuria in an Oral Presentation at the 2018 American Society of Nephrology (ASN) Annual MeetingOct 25, 2018
Pieris Pharmaceuticals Appoints Matthew L. Sherman, M.D., to its Board of DirectorsOct 25, 2018
Aerpio Pharmaceuticals Announces Presentation of Renal Function Data from TIME-2 Study of AKB-9778 in Diabetic Retinopathy Patients at American Society of Nephrology Kidney Week 2018Oct 25, 2018
Kala Pharmaceuticals Appoints Steven Zhang as Vice President of Medical AffairsOct 24, 2018
TP Therapeutics and Almac Diagnostic Services Enter into Agreement to Develop Next-Generation Sequencing Pan-Cancer Companion DiagnosticOct 24, 2018
PRINCIPIA BIOPHARMA APPOINTS DOLCA THOMAS, M.D. AS CHIEF MEDICAL OFFICEROct 23, 2018
Clementia Announces Plan to Submit a New Drug Application for Palovarotene for the Treatment of FOP Based on Positive Phase 2 ResultsOct 23, 2018
Selecta Biosciences Presents New Interim Data from Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at ACR 2018Oct 23, 2018
NextCure Initiates Clinical Development for NC318, a Siglec-15 Targeting Antibody, for Solid TumorsOct 22, 2018
Alpine Immune Sciences' Lead Program ALPN-101 Demonstrates Preclinical Activity in Inflammatory Arthritis and Neurological InflammationOct 22, 2018
Corvus Pharmaceuticals Announces New Data on Adenosine Gene Signature Biomarker Associated with Patient Response to CPI-444 at European Society for Medical Oncology (ESMO) 2018 CongressOct 22, 2018
Aeglea BioTherapeutics Announces Positive Interim Clinical Data for Pegzilarginase in Advanced Melanoma Patients at the European Society for Medical Oncology 2018 CongressOct 22, 2018
Real-Time Adaptive Radiotherapy Capabilities of ViewRay's MRIdian Highlighted at Investor & Analyst Meeting at ASTRO 2018Oct 21, 2018
Loxo Oncology Announces Larotrectinib Clinical Update in Patients with TRK Fusion Cancers at the European Society for Medical Oncology 2018 CongressOct 20, 2018
Updated Data from Ongoing MAGE-A10 and MAGE-A4 Studies Presented at the 2018 ESMO CongressOct 19, 2018
TP Therapeutics Completes $80 Million Mezzanine Financing Co-Led by Foresite Capital and venBio PartnersOct 19, 2018
PRINCIPIA BIOPHARMA ANNOUNCES PRN1008 RECEIVES ORPHAN-DRUG DESIGNATION FROM FDA FOR TREATMENT OF IMMUNE THROMBOCYTOPENIC PURPURAOct 19, 2018
SI-BONE Announces Closing of Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional SharesOct 18, 2018
scPharmaceuticals Inc. Provides Regulatory Update on FUROSCIXOct 18, 2018
Sonendo® and TDO® Software Expand Their Strategic PartnershipOct 18, 2018
Intellia Therapeutics Presents New Data in In Vivo and Ex Vivo Programs at the 26th Annual Congress of the European Society of Gene and Cell TherapyOct 17, 2018
Aeglea BioTherapeutics Announces New Positive Interim Clinical Data and Improvements in Disease Manifestations for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 DeficiencyOct 17, 2018
Inspire Medical Systems, Inc. Announces Presentation of Clinical Efficacy Data for Inspire Therapy for Treatment of Obstructive Sleep Apnea at Annual ENT Surgeon ConferenceOct 16, 2018
resTORbio Announces Additional RTB101 Phase 2b Data Demonstrating Decreased Incidence of Laboratory-Confirmed RTIs with Severe Symptoms, Total Infections and UTIsOct 16, 2018
KALA PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR KPI-121 0.25% FOR DRY EYE DISEASEOct 16, 2018
PRINCIPIA ACHIEVES $10 MILLION IN ADDITIONAL MILESTONES RELATED TO DEVELOPMENT OF PRN2246/SAR442168Oct 15, 2018
Loxo Oncology Announces Receipt of Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-292 for the Treatment of RET Fusion-Positive Thyroid CancerOct 15, 2018
Rhythm Pharmaceuticals Appoints Murray W. Stewart, M.D., as Chief Medical OfficerOct 11, 2018
Synthorx Appoints Pratik Shah, Ph.D., to its Board of DirectorsOct 11, 2018
KALA PHARMACEUTICALS ANNOUNCES FULL EXERCISE OF UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL SHARESOct 11, 2018
Otsuka and Proteus extend digital drugs tie-upOct 10, 2018
Audentes Therapeutics Announces Pricing of Public Offering of Common StockOct 10, 2018
Marinus Pharmaceuticals Names Dr. Rolando Gutíerrez-Esteinou as VP of Clinical Development and PharmacovigilanceOct 10, 2018
Constellation Pharmaceuticals Enhances and Expands Phase 2 MANIFEST Study of CPI-0610 in MyelofibrosisOct 9, 2018
ObsEva SA Presents Clinical Data from Phase III IMPLANT 2 Trial of Nolasiban in IVF at the American Society of Reproductive Medicine (ASRM) Annual MeetingOct 8, 2018
Inspire Medical Systems, Inc. Announces First Implant of New Sensing Lead in EuropeOct 6, 2018
Loxo Oncology Announces LOXO-292 Durability Update in Patients with RET-Mutant Medullary Thyroid Cancer and RET Fusion-Positive Thyroid Cancer from LIBRETTO-001 at the 88th Annual Meeting of the American Thyroid AssociationOct 5, 2018
Audentes Therapeutics Presents New Positive Interim Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy, at 23rd International Annual Congress of the World Muscle SocietyOct 4, 2018
KANDY THERAPEUTICS PRESENTS NEW COMPELLING DATA WITH LEAD CANDIDATE NT-814 AT THE NORTH AMERICAN MENOPAUSE SOCIETY 2018 ANNUAL MEETINGOct 3, 2018
Introducing the Singulex Clarity C. diff toxin A/B assay, a high-sensitivity, high-precision, single-test solution for the diagnosis of true C. difficile infectionOct 3, 2018
ObsEva SA reports additional positive Phase 3 results of IMPLANT 2 trial showing significant increase of Live Birth Rate (LBR) following IVF with Single Embryo Transfer (SET)Oct 3, 2018
Audentes Therapeutics Announces Co-Founder and Chief Executive Officer Matthew R. Patterson Appointed Chairman of the Alliance for Regenerative MedicineOct 3, 2018
Corvus Pharmaceuticals Announces Publication of Preclinical Results Highlighting Antitumor Activity of CPI-444 in Multiple Tumor Models both as Monotherapy and in Combination StudiesOct 3, 2018
Guardant Health Announces Pricing of Initial Public OfferingOct 2, 2018
KALA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCKOct 2, 2018
Venus Medtech Announces Agreement to Acquire Keystone Heart, LTDOct 2, 2018
KALA PHARMACEUTICALS ANNOUNCES FINANCING FROM ATHYRIUM CAPITAL MANAGEMENT TOTALING $110 MILLIONOct 2, 2018
Synlogic Appoints Dr. Aoife Brennan as President and Chief Executive OfficerOct 2, 2018
Clementia Initiates Phase 1 Clinical Trial of Palovarotene Eye Drop Formulation in Healthy VolunteersOct 1, 2018
MODIS THERAPEUTICS ANNOUNCES $30M SERIES A FINANCINGOct 1, 2018
CTI BioPharma Announces the Continuation of PAC203 Study Following Interim Data ReviewOct 1, 2018
FDA Grants Rare Pediatric Disease Designation to Pegzilarginase for Arginase 1 DeficiencySep 28, 2018
Final results of ObsEva SA Phase 2b EDELWEISS trial of Linzagolix show sustained efficacy and Bone Mineral Density safety, for the treatment of endometriosis-associated painSep 28, 2018
Rhythm Pharmaceuticals Announces Presentation of Updated Clinical Data from Phase 2 Basket Studies Evaluating Setmelanotide in Bardet-Biedl Syndrome and Alström Syndrome at 57th Annual ESPE MeetingSep 28, 2018
Rhythm Pharmaceuticals Announces Launch of TEMPO Registry for Rare Genetic Disorders of ObesitySep 27, 2018
Selecta Biosciences Appoints Carsten Brunn, Ph.D. as President and Chief Executive OfficerSep 26, 2018
Clementia Announces Updated Phase 2 Part B Data on Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP)Sep 26, 2018
Arvinas Announces Pricing of Initial Public OfferingSep 26, 2018
Genewiz To Be Acquired By Brooks AutomationSep 25, 2018
BELLUS Health Announces Appointment of Clinical Advisory BoardSep 25, 2018
Avedro Names Tim Homer Vice President of Health Policy & Market Access in Continued Effort to Expand Market Access and Reimbursement of Cross-LinkingSep 25, 2018
Cigna Is Newest Payer to Join Growing List of Commercial Plans Covering Avedro’s FDA-Approved Cross-Linking Procedure—133 Million Lives Covered in TotalSep 25, 2018
Marinus Completes Enrollment in its Magnolia Postpartum Depression StudySep 25, 2018
Loxo Oncology Announces LOXO-292 Durability Update in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer from LIBRETTO-001 at the IASLC 19th World Conference on Lung CancerSep 24, 2018
HLS Therapeutics Announces that Amarin's REDUCE-IT™ Cardiovascular Outcomes Study of Vascepa® (icosapent ethyl) Capsules Met Primary EndpointSep 24, 2018
Verrica Pharmaceuticals Inc. Announces Inclusion in Russell 2000® and Russell 3000® IndexesSep 24, 2018
TP Therapeutics Announces Updated Interim Phase 1/2 Clinical Trial Data of Repotrectinib (TPX-0005) in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer Patients at 19th World Conference on Lung CancerSep 24, 2018
OncLive report on Repotrectinib: “Repotrectinib Shows Promising Activity in ROS1+ NSCLC”Sep 20, 2018
SI-BONE Files Registration Statement for Proposed Initial Public OfferingSep 20, 2018
Issue of Shares & PDMR AnnouncementSep 19, 2018
Alector Initiates Phase 1 Trial of AL001 for the Treatment of Frontotemporal DementiaSep 19, 2018
Silverback Therapeutics Extends Series A to $47.5 Million to Advance Pipeline of First-in-Class Systemically Delivered, Locally Active TherapiesSep 18, 2018
Sonendo Ships a Record 100,000 GentleWave Procedure InstrumentsSep 18, 2018
resTORbio Appoints Meredith Manning as Chief Commercial OfficerSep 18, 2018
Principia Biopharma Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters’ Option to Purchase Additional SharesSep 17, 2018
Ascendis Pharma A/S Announces Support for Children’s Growth Awareness Week and Day 2018Sep 17, 2018
Xenon Pharmaceuticals Announces Closing of its $63.0 Million Public Offering of Common SharesSep 17, 2018
Realm Therapeutics Provides Corporate Update and Hires Advisor to Support Strategic Review including Formal Sale ProcessSep 17, 2018
ORIC Pharmaceuticals appoints Pratik Multani, MD, as Chief Medical OfficerSep 13, 2018
Acibadem Maslak Hospital in Turkey Introduces Next Generation Cancer Care with MRIdian MR-Image Guided Radiation TherapySep 13, 2018
Principia Biopharma Announces Pricing Of Initial Public OfferingSep 12, 2018
Verrica Announces Successful Phase 2 Innovate Trial and Complete Enrollment of Phase 3 Trials of VP-102 in Molluscum Contagiosum Ahead of ScheduleSep 12, 2018
Xenon Pharmaceuticals Announces Pricing of $63.0 Million Public Offering of Common SharesSep 12, 2018
Constellation Pharmaceuticals Congratulates Dr. David Allis and Dr. Michael Grunstein, Winners of the 2018 Lasker AwardSep 11, 2018
Invitae Appoints Chitra Nayak to its Board of DirectorsSep 11, 2018
TELA Bio Announces Publication of Case Series Evaluating OviTex Reinforced BioScaffolds in Hiatal and Inguinal Hernia RepairSep 10, 2018
Pieris Pharmaceuticals Appoints Peter Kiener, D.Phil. To Its Board Of DirectorsSep 10, 2018
CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing TechnologySep 10, 2018
Xenon Enters into Agreement to Buy Out Milestones and Royalties Related to its XEN1101 ProgramSep 7, 2018
Adaptimmune Therapeutics plc Announces Closing of Registered Direct Offering of American Depositary SharesSep 6, 2018
Xenon Expands Ion Channel Neurology Pipeline with Addition of XEN496, a “Phase 3 Ready” Potassium Channel Modulator for the Treatment of EpilepsySep 6, 2018
BeiGene and SpringWorks Therapeutics Enter into Global Clinical Collaboration to Evaluate Targeted Combination Therapy in Advanced Solid TumorsSep 6, 2018
Verona Pharma Announces Publication of Key Paper on RPL554 in COPD in the European Respiratory JournalSep 5, 2018
Adaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary SharesSep 5, 2018
SpringWorks Therapeutics Announces Appointment of Saqib Islam as Chief Executive OfficerSep 5, 2018
Marinus Appoints Scott Braunstein, MD to its Board of DirectorsSep 5, 2018
Loxo Oncology Announces Receipt of Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-292Sep 4, 2018
Pieris Pharmaceuticals Announces Dosing Of First Patient In Phase I Combination Trial For Prs-343 Plus Anti-Pd-L1 ImmunotherapySep 4, 2018
Constellation Pharmaceuticals Announces Appointments to Board of DirectorsSep 4, 2018
Aeglea BioTherapeutics Announces Positive Interim Clinical Data and Completion of Enrollment for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 DeficiencySep 4, 2018
Synlogic Reports Positive Interim Phase 1/2a Data Demonstrating Safety, Tolerability and Proof-of-Mechanism in Healthy Volunteers for SYNB1618, in Development for the Management of Phenylketonuria (PKU)Aug 30, 2018
Crinetics Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate UpdateAug 29, 2018
Ascendis Pharma A/S Reports Second Quarter 2018 Financial ResultsAug 29, 2018
Xenon Announces Positive XEN1101 Pharmacodynamic Data from Phase 1b TMS StudyAug 29, 2018
Kandy Therapeutics Successfully Raises £25 million in a Series C Financing Funding to Advance a Breakthrough Non-hormonal Treatment for Symptoms of the Menopause, Into a Phase 2b Study in Q4 2018Aug 27, 2018
Loxo Oncology Announces Submission of European Marketing Authorization Application for LarotrectinibAug 23, 2018
E-Scape Bio Appoints Biopharma Industry Veteran Julie Anne Smith as President and Chief Executive OfficerAug 23, 2018
Intellia Therapeutics Presents Progress in Lead In Vivo Program at Cold Spring Harbor Laboratory’s Fourth Meeting on Genome Engineering: The CRISPR-Cas RevolutionAug 23, 2018
Kala Pharmaceuticals Announces FDA Approval of Inveltys for the Treatment of Post-operative Inflammation and Pain Following Ocular SurgeryAug 22, 2018
Sierra Oncology Obtains Debt Facility from Silicon Valley Bank to Acquire and Advance MomelotinibAug 22, 2018
Sierra Oncology Acquires Momelotinib, an Investigational Janus Kinase (JAK) 1/2 and Activin Receptor Type 1 (ACVR1) Inhibitor for Myelofibrosis, from Gilead SciencesAug 21, 2018
Audentes Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by the FDA to AT132 for the Treatment of X-Linked Myotubular MyopathyAug 20, 2018
Xtant Medical Announces Appointment of Chief Financial OfficerAug 17, 2018
ViewRay Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common StockAug 16, 2018
Clementia Announces Completion of Enrollment in Phase 3 MOVE Trial for FOPAug 16, 2018
Synthorx Appoints Immuno-Oncology Veteran Joseph Leveque, M.D., as Chief Medical OfficerAug 15, 2018
Third Dosing Cohort to be initiated in MAGE-A4 SPEAR T-cell Basket Study After Favorable Review of Safety from One Billion Cell Dose CohortAug 15, 2018
Verrica Appoints Neetu Dhaliwal as Vice President of Business DevelopmentAug 15, 2018
Sonendo® Announces GentleWave® System Integration With TDO® Endodontic SoftwareAug 15, 2018
resTORbio Appoints Jeffrey Chodakewitz, M.D., to its Board of DirectorsAug 14, 2018
Aerpio Reports Second Quarter 2018 Financial Results and Provides Business UpdateAug 14, 2018
Realm Therapeutics Reports Top-line Data from Phase 2 Trial of PR022 in Atopic Dermatitis and First Half 2018 Financial ResultsAug 14, 2018
Constellation Pharmaceuticals Announces Second-Quarter and Six-Month 2018 Financial ResultsAug 14, 2018
scPharmaceuticals Inc. Reports Second Quarter 2018 Financial Results and Provides Business UpdateAug 13, 2018
Arsanis Reports Financial Results for Second Quarter 2018Aug 13, 2018
Synlogic Publishes Preclinical Data Supporting Development of SYNB1618, a Synthetic Biotic™ Medicine as a Potential Treatment for PhenylketonuriaAug 9, 2018
Sierra Oncology Reports Second Quarter ResultsAug 9, 2018
Nabriva Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate HighlightsAug 9, 2018
Clementia Reports Second Quarter 2018 Operating Results and Pipeline UpdatesAug 9, 2018
resTORbio Reports Second Quarter 2018 Financial ResultsAug 9, 2018
Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial ResultsAug 9, 2018
Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2018 Financial ResultsAug 9, 2018
Loxo Oncology Reports Second Quarter 2018 Financial ResultsAug 9, 2018
Kala Pharmaceuticals Reports Second Quarter 2018 Financial ResultsAug 9, 2018
Pieris Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate UpdateAug 8, 2018
Synlogic Reports Second Quarter 2018 Financial Results and Provides Program UpdatesAug 8, 2018
Selecta Biosciences Announces Second Quarter 2018 Financial Results and Provides Corporate UpdateAug 8, 2018
Cyrus Biotechnology Appoints Jake Litwicki as VP of EngineeringAug 8, 2018
ObsEva reports Second Quarter 2018 Financial Results and Provides Business UpdateAug 8, 2018
Rhythm Pharmaceuticals Reports Second Quarter 2018 Financial ResultsAug 8, 2018
Alector Receives Orphan Drug Designation from the U.S. FDA for AL001 for the Treatment of Frontotemporal DementiaAug 8, 2018
Tricida Announces Second Quarter 2018 Financial Results and Provides Update on Key InitiativesAug 7, 2018
Invitae Reports More than 160% Annual Revenue Growth Driven by Nearly 140% Annual Growth in Volume in Second Quarter 2018Aug 7, 2018
Verrica Reports Second Quarter 2018 Financial ResultsAug 7, 2018
Audentes Therapeutics Reports Second Quarter 2018 Financial Results and Provides Update on ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular MyopathyAug 7, 2018
Xenon Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate UpdateAug 7, 2018
Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2018Aug 7, 2018
Inspire Medical Systems, Inc. Announces Second Quarter 2018 Financial ResultsAug 7, 2018
SI-BONE, Inc. Announces 23 Commercial Health Insurance Plans Now “Exclusively” Cover Triangular iFuse Implant System® Based on Published Clinical EvidenceAug 6, 2018
OmniGuide, Inc. to Acquire Lisa Laser, Developer of Surgical Laser ProductsAug 6, 2018
Alpine Immune Sciences Strengthens Leadership Team with Appointment of Mark Litton as President and Chief Operating OfficerAug 3, 2018
ViewRay Reports Second Quarter 2018 Financial ResultsAug 2, 2018
Corvus Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business UpdateAug 2, 2018
CTI BioPharma Reports Second Quarter 2018 Financial ResultsAug 2, 2018
Marinus Pharmaceuticals Provides Business Update and Second Quarter 2018 Financial ResultsAug 2, 2018
Adaptimmune Reports Second Quarter 2018 Financial Results and Business UpdateAug 1, 2018
ReViral announces US$55 million series B fundraising to advance RSV clinical studiesAug 1, 2018
Intellia Therapeutics Announces Second Quarter 2018 Financial ResultsAug 1, 2018
Tricida Announces Hiring of Dawn Parsell as Senior Vice President of Clinical DevelopmentAug 1, 2018
Verona Pharma Initiates Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance TreatmentJul 31, 2018
Thomas W. Burns, CEO of Glaukos, Joins Avedro's Board of DirectorsJul 31, 2018
Kala Pharmaceuticals Announces Dosing of First Patient in Phase 3 STRIDE 3 Trial of KPI-121 0.25% in Patients with Dry Eye DiseaseJul 26, 2018
Nabriva Therapeutics Announces Pricing of Public Offering of Ordinary Shares of Approximately $50 MillionJul 26, 2018
Principia Confirms Human CNS Exposure and Good Tolerability of Oral BTK Inhibitor PRN2246Jul 25, 2018
Alector Announces $133 Million in Series E Financing to Advance Broad Portfolio of Immuno-Neurology and Immuno-Oncology ProgramsJul 25, 2018
ObsEva Expands Executive Team Hiring a Chief Commercial OfficerJul 25, 2018
resTORbio Announces Positive Topline Results in Phase 2b Trial of RTB101Jul 24, 2018
Nabriva Therapeutics Strengthens Antibiotics Leadership Position with Acquisition of Zavante TherapeuticsJul 24, 2018
ViewRay Appoints Scott Drake as President, Chief Executive Officer and a Member of the Board of Directors, Shar Matin as Chief Operating Officer, and D. Keith Grossman as a Member of the Board of DirectorsJul 24, 2018
GSK and Adaptimmune Complete Transition of NY-ESO SPEAR T-cell Therapy Program to GSKJul 24, 2018
scPharmaceuticals Announces Appointment of Two New DirectorJul 23, 2018
Ascendis Pharma A/S Announces First Presentation of Preclinical Data Utilizing TransCon™ Technology in Oncology at SITC 2019Jul 23, 2018
Rhythm Pharmaceuticals Receives European Medicines Agency PRIME Designation for Setmelanotide in Rare Genetic Disorders of ObesityJul 20, 2018
Alpine Immune Sciences Completes Sale of S-Nitrosoglutathione Reductase (GSNOR) Assets to Laurel Venture CapitalJul 20, 2018
Crinetics Pharmaceuticals Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional SharesJul 19, 2018
Aeglea BioTherapeutics Appoints Dr. Anthony G. Quinn as President and Chief Executive OfficerJul 18, 2018
Constellation Pharmaceuticals Announces Pricing of Initial Public OfferingJul 18, 2018
CTI BioPharma Announces Pacritinib Program Update Following Type B Meeting with U.S. FDAJul 18, 2018
Adaptimmune Announces Favorable Review of Safety from One Billion Cell Dose Cohort in MAGE-A10 SPEAR T-cell Study and Initiation of Third Dosing CohortsJul 16, 2018
Aeglea BioTherapeutics Appoints Dr. Bryan Lawlis to Board of DirectorsJul 13, 2018
Clementia Appoints Experienced Financial Executive Steve Forte as Chief Financial OfficerJul 12, 2018
Synthorx Expands Leadership Team with Three Key HiresJul 12, 2018
Xenon Pharmaceuticals Announces At-The-Market Equity OfferingJul 11, 2018
resTORbio Announces Science Translational Medicine Publication of Phase 2a Data Showing Improvement in Immune Function and Decreased Infection Rates in People Aged 65 Years and OlderJul 10, 2018
Realm Therapeutics Announces Publication of Pre-Clinical Study Demonstrating Comparable Activity of PR022 and Topical Tofacitinib in the Treatment of Atopic DermatitisJul 10, 2018
Cyrus Biotechnology Launches Immune Epitope Prediction SoftwareJul 9, 2018
Results of Phase III (PIX306) Trial Evaluating Progression-Free Survival of PIXUVRI® (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-Hodgkin LymphomaJul 5, 2018
Clementia Appoints Industry Executive Shawn Tomasello to its Board of DirectorsJul 4, 2018
Realm Therapeutics Announces U.S. SEC Declares Registration Statement Effective and NASDAQ Approves Listing of ADSs Representing Ordinary SharesJul 2, 2018
Tricida Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesJul 2, 2018
CTI BioPharma Announces the Continuation without Modification of PAC203 Phase 2 Study of Pacritinib in Patients with Myelofibrosis Previously Treated with RuxolitinibJun 28, 2018
scPharmaceuticals Appoints Frederick Hudson to Board of DirectorsJun 28, 2018
Corvus Pharmaceuticals Announces Publication of Preclinical Study Results Demonstrating CPI-444 Antitumor Activity as Monotherapy and in Combination with Anti-PD-1 Therapy in Cancer Immunology, ImmunotherapyJun 28, 2018
Arsanis Provides Update Following Completion of Planned Interim Analysis of Phase 2 Clinical Trial of ASN100Jun 27, 2018
Inspire Medical Systems, Inc. Announces Regulatory Approval of Inspire Therapy for Treatment of Moderate to Severe Obstructive Sleep Apnea in JapanJun 27, 2018
Adicet Bio appoints Stewart Abbot, Ph.D. as Chief Scientific OfficerJun 26, 2018
Aerpio Pharmaceuticals Announces Uplisting to Nasdaq Capital Market and Pricing of $45.0 Million Public Offering of Common StockJun 25, 2018
Aerpio Announces Exclusive License Agreement with Gossamer Bio for AKB-4924, a First in Class Hypoxia-Inducible Factor-1 Alpha Stabilizer in Development for Inflammatory Bowel DiseaseJun 25, 2018
Synlogic Presents New Preclinical Data from Synthetic Biotic™ Immuno-Oncology Program at FOCIS 2018Jun 25, 2018
Rhythm Pharmaceuticals, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesJun 25, 2018
Aerpio Pharmaceuticals Announces Proposed Public Offering of Common Stock and Uplisting to Nasdaq Capital MarketJun 25, 2018
Invitae Expands Reproductive Health Offering with Launch of Comprehensive Genetic Carrier ScreeningJun 22, 2018
Lilly Completes Acquisition of ARMO BioSciencesJun 21, 2018
University of Wisconsin Begins Patient Treatments with ViewRay's MRIdian LinacJun 21, 2018
KaNDy Therapeutics and NeRRe Therapeutics announce the appointment of Jo Craig as Head of Chemistry Manufacturing and ControlsJun 21, 2018
Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Congenital Hyperinsulinism and AcromegalyJun 21, 2018
Kandy Therapeutics and Nerre Therapeutics Announce the Appointment of Jo Craig as Head of Chemistry Manufacturing and ControlsJun 21, 2018
Natera Develops Powerful Kidney Transplant Rejection BiomarkerJun 20, 2018
ObsEva Announces Pricing of Follow-on Public OfferingJun 19, 2018
CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Announce Grant of U.S. Patent for CRISPR/Cas9 Genome EditingJun 19, 2018
Kala Pharmaceuticals Announces Update to KPI-121 0.25% Development PlanJun 19, 2018
Verrica Pharmaceuticals Inc. Announces Closing of Initial Public OfferingJun 19, 2018
Marinus Pharmaceuticals Initiates Pivotal Phase 3 Trial in Children with CDKL5 Deficiency DisorderJun 18, 2018
Crinetics Pharmaceuticals Appoints Alan Krasner, M.D., as Chief Medical OfficerJun 18, 2018
Avedro Announces Enrollment of First Patient in U.S. Pivotal Phase 3 Epi-on Corneal Cross-Linking Trial for Progressive KeratoconusJun 18, 2018
ObsEva SA Achieves Primary and Secondary Endpoints for EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with EndometriosisJun 18, 2018
Rhythm Pharmaceuticals Announces New Topline Clinical Data from Ongoing Phase 2 Basket Studies Evaluating Setmelanotide in Rare Genetic Disorders of ObesityJun 15, 2018
Selecta Biosciences Presents Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at EULAR 2018Jun 14, 2018
Rhythm Pharmaceuticals Completes Pivotal Enrollment in Two Ongoing Phase 3 Clinical Trials Evaluating Setmelanotide in Rare Genetic Disorders of ObesityJun 14, 2018
Arsanis Out-Licenses Preclinical Stage Klebsiella pneumoniae Monoclonal Antibodies from ASN300 ProgramJun 13, 2018
Synlogic Presents New Preclinical Data from Synthetic Biotic™ Medicine, SYNB1020, Highlighting Beneficial Activity in Animal Model of Liver Disease at Digestive Disease WeekJun 13, 2018
Invitae Study of 143,000 Patients Shows Importance of Routinely Including Deletion and Duplication Detection with Sequencing in Genetic TestingJun 13, 2018
Pioneer of MR Image-Guided Radiotherapy, Washington University, Begins First Clinical Treatments with its Second ViewRay MRIdian SystemJun 12, 2018
E-Scape Bio Obtains Worldwide Rights from AbbVie for Selective S1P5 Program Targeting CNS-related Lysosomal Storage DisordersJun 12, 2018
resTORbio Announces Appointment of Kerry Russell, M.D., Ph.D., as Vice President of Clinical DevelopmentJun 11, 2018
Synlogic Presents Preclinical Data from Synthetic BioticTM Medicine, SYNB1618, for the Treatment of PhenylketonuriaJun 11, 2018
Study published in Cancer Discovery Indicates that NY-ESO SPEAR T-cells are Long-lived, Self?renewing, and Capable of Persistent Anti-Tumor EffectsJun 7, 2018
Inspire Medical Systems, Inc. Reports First Quarter 2018 Financial ResultsJun 7, 2018
Kandy Therapeutics Announces Positive Clinical Data with Lead Candidate Nt-814 for the Treatment of Symptoms of the MenopauseJun 6, 2018
Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon PTH as Treatment for HypoparathyroidismJun 5, 2018
Audentes Announces Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to AT132 for the treatment of X-Linked Myotubular MyopathyJun 5, 2018
Tricida Announces Positive Pivotal Phase 3 Clinical Trial Results for TRC101 in CKD Patients with Metabolic AcidosisJun 4, 2018
Adaptimmune Presents Detailed Safety Update from Ongoing MAGE-A10 Pilot Studies at ASCOJun 4, 2018
Tricida Announces Kathryn Falberg Joins Board of DirectorsJun 4, 2018
Adaptimmune Announces First Patient to Receive One Billion Target Cell Dose after Positive Safety Data from Pilot Study with MAGE-A4 SPEAR T-cellsJun 4, 2018
Synlogic Presents New Preclinical Data from Synthetic Biotic™ Medicine, SYNB1020, Highlighting Beneficial Activity in Animal Model of Liver Disease at Digestive Disease WeekJun 4, 2018
TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TPX-0005 at ASCO 2018: Data Presented from the Ongoing TRIDENT-1 StudyJun 2, 2018
Updated Myxoid/Round Cell Liposarcoma Data with NY-ESO, Presented at ASCO Annual Meeting, Further Supports Promising Benefit: Risk ProfileJun 2, 2018
Loxo Oncology Announces Positive Interim Clinical Data from LOXO-292 Dose Escalation Trial in RET-Altered Cancers Presented at the American Society of Clinical Oncology Annual MeetingJun 1, 2018
NeuroPace Launches Next Generation RNS System, the World’s Only Brain-Computer Interface for the Treatment of Refractory EpilepsyJun 1, 2018
ObsEva SA to Seek SIX Share ListingMay 31, 2018
scPharmaceuticals Receives Complete Response Letter from the FDA for FUROSCIX®May 31, 2018
Nabriva Therapeutics to Present Lefamulin Data at ASM MicrobeMay 30, 2018
Ascendis Pharma A/S Reports First Quarter 2018 Financial ResultsMay 29, 2018
FDA Accepts Larotrectinib New Drug Application and Grants Priority ReviewMay 24, 2018
Realm Therapeutics Completes Enrollment in Phase 2 Study of PR022 for Atopic DermatitisMay 23, 2018
Clementia Reports Positive Phase 2 Part B Data Showing Treatment with Palovarotene Significantly Reduces New Bone Growth in Patients with FOPMay 23, 2018
World-Leading Oncologists to Meet in Miami for Adaptive MR Image-Guided Radiotherapy SymposiumMay 23, 2018
Realm Therapeutics Publicly Files Registration Statement with the U.S. SEC to Facilitate Nasdaq Listing of ADSs Representing Ordinary SharesMay 22, 2018
resTORbio to Host Key Opinion Leader Symposium on TORC1 InhibitionMay 22, 2018
OmniGuide Surgical Announces Commercial Launch of C-LAS Line of Sight CO2 Laser SystemMay 21, 2018
Xtant Medical Receives FDA 510(K) Clearance for InTice™-C Porous Titanium Cervical Interbody SystemMay 21, 2018
Nabriva Therapeutics Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of Oral Lefamulin for the Treatment of Community-Acquired Bacterial PneumoniaMay 21, 2018
Cerapedics Announces Results From IVANOS Study of i-FACTOR Peptide Enhanced Bone GraftMay 21, 2018
Verona Pharma Presented Clinical Data at ATS 2018 that Further Highlights RPL554 as a First-in-Class Treatment for COPDMay 17, 2018
Intellia Therapeutics Announces WT1 as Its First Cell Therapy Target, Following Presentation of Early Data at the American Society of Gene and Cell Therapy 21st Annual MeetingMay 17, 2018
Pharming Group Interim Report on Financial Results for the First Quarter 2018May 17, 2018
TP Therapeutics Announces Phase 1 Data of Ropotrectinib (TPX-0005) to be Presented at the Annual American Society of Clinical Oncology MeetingMay 16, 2018
Audentes Announces Continuing Positive Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular MyopathyMay 16, 2018
Loxo Oncology Announces Details of LOXO-292 Clinical Data Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual MeetingMay 16, 2018
ObsEva Reports First Quarter 2018 Financial Results and Provides Business UpdateMay 16, 2018
Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American Association for Clinical Oncology (ASCO) Annual MeetingMay 15, 2018
Synlogic Reports First Quarter 2018 Financial Results and Provides Business UpdateMay 15, 2018
Xenon Presents Positive XEN1101 TMS Pharmacodynamic Phase 1 Data at 14th Eilat ConferenceMay 15, 2018
Xenon Presents XEN901 Phase 1 Clinical Update and Supporting Pre-clinical Data at 14th Eilat ConferenceMay 14, 2018
Rhythm Pharmaceuticals Reports First Quarter 2018 Financial ResultsMay 14, 2018
Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2018 Financial ResultsMay 10, 2018
Synlogic Announces Leadership ChangeMay 10, 2018
Pieris Pharmaceuticals Reports First Quarter 2018 Financial Results And Provides Corporate UpdateMay 10, 2018
Arsanis Reports Business Highlights and Financial Results for First Quarter 2018May 10, 2018
resTORbio Reports First Quarter 2018 Financial ResultsMay 10, 2018
Kala Pharmaceuticals Reports First Quarter 2018 Financial ResultsMay 10, 2018
Sierra Oncology Reports First Quarter ResultsMay 10, 2018
ViewRay Reports First Quarter 2018 Financial ResultsMay 10, 2018
Lilly Announces Agreement To Acquire ARMO BioSciencesMay 9, 2018
resTORbio Completes Dosing of Patients in Phase 2b Study to Reduce the Incidence of Respiratory Tract Infections in the ElderlyMay 9, 2018
Kala Pharmaceuticals Strengthens Commercial Organization In Preparation For First Product LaunchMay 9, 2018
Selecta Biosciences Announces First Quarter 2018 Financial Results and Provides Corporate UpdateMay 9, 2018
Invitae Reports 169% Revenue Growth Driven by 150% Growth in Volume in First Quarter 2018May 9, 2018
Clementia Reports First Quarter 2018 Operating Results and Pipeline UpdatesMay 9, 2018
Audentes Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate UpdateMay 9, 2018
Adaptimmune Reports First Quarter 2018 Financial Results and Business UpdateMay 9, 2018
Rhythm Pharmaceuticals Announces Nature Medicine Publication of Longer-Term Data from Phase 2 Study of Setmelanotide for Treatment of LEPR Deficiency ObesityMay 8, 2018
First Cardiac Procedure Using the AcQMap® System by Acutus Medical® Successfully Performed in the United StatesMay 8, 2018
Ascendis Pharma A/S Announces Dosing of First Subjects in Phase 1 Trial of TransCon CNPMay 8, 2018
Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2018 Financial ResultMay 8, 2018
Nabriva Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate HighlightsMay 8, 2018
Natera Reports First Quarter 2018 Financial ResultsMay 8, 2018
Audentes Therapeutics Announces the Promotion of Natalie Holles to President and Chief Operating OfficerMay 8, 2018
Xenon Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate UpdateMay 8, 2018
Loxo Oncology Reports First Quarter 2018 Financial ResultsMay 7, 2018
ORIC has appointed Jacob Chacko, MD as Chief Executive OfficerMay 7, 2018
Inspire Medical Systems, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesMay 7, 2018
Ascendis Pharma A/S Announces Poster Presentation on TransCon PTH Phase 1 Trial at the European Congress of EndocrinologyMay 7, 2018
scPharmaceuticals Inc. Reports First Quarter 2018 Financial Results and Provides Business UpdateMay 7, 2018
Sarepta and Invitae Expand Partnership to Advance Clinical Research in Duchenne Muscular DystrophyMay 3, 2018
Stereotaxis and Acutus Medical Announce Strategic CollaborationMay 3, 2018
CTI BioPharma Reports First Quarter 2018 Financial ResultsMay 3, 2018
Corvus Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business UpdateMay 2, 2018
Avedro Announces $25 Million in Funding to Fuel Innovation and Commercial GrowthMay 2, 2018
Final Results for the Year Ended December 31, 2017 and Business UpdateMay 2, 2018
Marinus Pharmaceuticals Provides Business Update and First Quarter 2018 Financial ResultsMay 1, 2018
Intellia Therapeutics Announces First Quarter 2018 Financial ResultsApr 30, 2018
Miami Cancer Institute at Baptist Health South Florida Becomes Second Institution in the United States to Treat Patients with ViewRay’s MRIdian® LinacApr 30, 2018
Adicet Bio Appoints Elizabeth “E.J.” Read, M.D. as its Chief Technology OfficerApr 30, 2018
Synthorx Announces $63 Million Series C Financing to Advance a Pipeline of Synthorin™ CytokinesApr 30, 2018
Attenua Raises $35M in Series A Financing to Advance Therapy for Chronic CoughApr 30, 2018
Adicet Bio Appoints Elizabeth “E.J.” Read, M.D. as its Chief Technology OfficerApr 27, 2018
Invitae Announces New Program to Offer Genetic Testing to Aid Diagnosis of Spinal Muscular Atrophy (SMA)Apr 27, 2018
Avedro Announces $25 Million in Funding to Fuel Innovation and Commercial GrowthApr 26, 2018
Corvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006, in Patients with Advanced CancerApr 25, 2018
ARMO BioSciences Announces Poster Presentations of Pegilodecakin (AM0010) at the 2018 American Society of Clinical Oncology (ASCO) Annual MeetingApr 25, 2018
Pieris Pharmaceuticals Appoints Ann Barbier, M.D., Ph.D., To Its Board Of DirectorsApr 24, 2018
Sonendo Ships 50,000 GentleWave Procedure Instruments to EndodontistsApr 24, 2018
Singulex Clarity C. diff toxins A/B assay in development shown to be ultrasensitive and highly specific compared with currently available testing optionsApr 23, 2018
Graybug Vision Announces Presentations on Novel Treatments for Wet AMD and Glaucoma at ARVO 2018 Annual MeetingApr 23, 2018
Inspire Medical Systems, Inc. Announces Commencement of its Initial Public OfferingApr 23, 2018
ObsEva Announces Upcoming Presentations Related to its Endometriosis and Uterine Fibroid Development Programs with its Novel Oral GnRH Receptor Antagonist OBE2109 (KLH-2109)Apr 23, 2018
Intellia Therapeutics Announces In Vivo and Ex Vivo Data Presentations at the American Society of Gene and Cell Therapy 21st Annual MeetingApr 20, 2018
Clementia Initiates Phase 2 MO-Ped Trial for Palovarotene in Patients with Multiple OsteochondromasApr 19, 2018
Cyrus Biotechnology Exhibits at the PEGS Protein Engineering Summit in Boston, April 30th May 3rdApr 19, 2018
VU University Medical Center in Amsterdam Delivers First Ever Linear Accelerator-Based On-Table Adaptive MR Image-Guided Radiotherapy Treatment on ViewRay MRIdian LinacApr 18, 2018
Synlogic Doses First Subject in Phase 1/2a Trial of SYNB1618 for Treatment of PhenylketonuriaApr 18, 2018
ViewRay Unveils New Soft Tissue Visualization Technologies to Further Advance MR Image-Guided RadiotherapyApr 18, 2018
Aeglea BioTherapeutics Prices Public Offering of Common StockApr 17, 2018
Aeglea BioTherapeutics Announces Proposed Public Offering of Common StockApr 17, 2018
Alpine Immune Sciences Announces Preclinical Data Demonstrating ALPN-202 Eliminates Tumors and Creates Persistent Tumor Resistance in a Murine Cancer ModelApr 17, 2018
Sierra Late-Breaking Data Demonstrating SRA737 Preclinical Activity with PARPi to be Presented at the AACR 2018 Annual MeetingApr 16, 2018
Summary ToggleSynlogic Presents Preclinical Data from Synthetic Biotic Immuno-Oncology Program at the American Association for Cancer Research 2018 Annual MeetingApr 16, 2018
Adaptimmune Presents MAGE-A4 and MAGE-A10 pre-clinical data at American Association for Cancer Research (AACR) Annual MeetingApr 16, 2018
TELA Bio Announces Series B Investment by Checkmate CapitalApr 13, 2018
Nabriva Therapeutics to Present Data at ECCMID Demonstrating Potential of Lefamulin for Patients with Community-acquired Bacterial PneumoniaApr 12, 2018
Aeglea BioTherapeutics Presents New Phase 1/2 Trial Data Demonstrating Clinically Relevant Treatment Effects in Arginase 1 Deficiency Patients at the 2018 ACMG Annual Clinical Genetics MeetingApr 10, 2018
Invitae research highlights utility of proactive genetic screening, importance of assessing secondary findings in genetic testingApr 10, 2018
Loxo Oncology and Illumina to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion DiagnosticsApr 10, 2018
Avedro Names James Schuermann Chief Business OfficerApr 9, 2018
Constellation Pharmaceuticals Announces $100 Million FinancingApr 9, 2018
SI-BONE, Inc. Announces Publication of 3-Year Long-term Prospective Outcomes Including Randomized Controlled Trial Data on 103 Patients Post SI Joint Fusion with Triangular iFuse Implant SystemApr 9, 2018
Kala Pharmaceuticals to Present at the 2018 American Society of Cataract and Refractive Surgery Annual Meeting (ASCRS) and at the Ophthalmology Innovation Summit at ASCRSApr 9, 2018
SI-BONE, Inc. Hosts ISASS 2018 Sacroiliac Joint Workshop led by David Polly, MD, Bengt Sturesson, MD, Peter Whang, MD and Brad Duhon, MDApr 6, 2018
Summary ToggleSynlogic Announces Registered Direct Offering of Common StockApr 6, 2018
Inspire Medical Systems, Inc. Announces Filing of Registration Statement for Proposed Initial Public OfferingApr 5, 2018
Aeglea BioTherapeutics to Present Pegzilarginase Phase 1 Dose Escalation Data in Patients with Advanced Solid Tumors at 2018 AACR Annual MeetingApr 4, 2018
Arvinas Completes $55 Million Series C Financing to Advance Protein Degradation PlatformApr 4, 2018
Loxo Oncology Announces Acceptance of LOXO-292 Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual MeetingApr 4, 2018
NextCure Appoints Kevin N. Heller, M.D., as Chief Medical Officer and Steve Cobourn, CPA, as Chief Financial Officer.Apr 4, 2018
University Clinic Heidelberg Completes Installation and Commissioning of ViewRay's MRIdian MR Image-Guided Radiotherapy LinacApr 2, 2018
Ascendis Pharma A/S Appoints Thomas A. Larson as Chief Commercial OfficerApr 2, 2018
Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients with Pegzilarginase in Both Monotherapy and KEYTRUDA (Pembrolizumab) Combination TrialsApr 2, 2018
Synlogic Doses First Patient in Phase 1b/2a Trial of SYNB1020 for Treatment of Hyperammonemia in Patients with CirrhosisApr 2, 2018
Rhythm Pharmaceuticals Announces Licensing Agreement with Takeda for the Development and Commercialization of Preclinical Treatment for Prader-Willi SyndromeMar 29, 2018
HLS Therapeutics Announces Fiscal 2017 Financial ResultsMar 29, 2018
resTORbio Reports Fourth Quarter and Full Year 2017 Financial ResultsMar 28, 2018
Invitae Announces Pricing of Public Offering of Common StockMar 28, 2018
Alpine Immune Sciences Provides Corporate Update and Reports Full Year 2017 Financial ResultsMar 28, 2018
Ascendis Pharma A/S Reports Full Year 2017 Financial ResultsMar 28, 2018
Xenon Pharmaceuticals Confirms Closing of Transaction with Teva and Announces Preferred Share Exchange Agreement with BVF Partners L.P.Mar 27, 2018
Nabriva Therapeutics and Roivant Sciences Enter into License Agreement to Develop and Commercialize Lefamulin in Greater ChinaMar 27, 2018
ViewRay Surpasses 50th Order for MRIdian System for Precision Cancer TreatmentMar 26, 2018
TELA Bio Announces Investment Agreement with ProMedica Innovations Venture FundMar 26, 2018
Invitae Announces Proposed Public Offering of Common StockMar 26, 2018
Loxo Oncology Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion CancerMar 26, 2018
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial ResultsMar 23, 2018
Invitae expands network of patients in rare and ultra-rare diseasesMar 21, 2018
Kyn Therapeutics Appoints Chairman and Scientific Advisory Board MemberMar 21, 2018
Nabriva Therapeutics Appoints Jennifer Schranz, M.D., as Chief Medical OfficerMar 21, 2018
Study shows cardiac troponin measurement using ultra-sensitive Singulex cTnI test can identify the presence and severity of coronary artery disease in stable, symptomatic outpatientsMar 20, 2018
ReViral to present at American Chemical SocietyMar 20, 2018
Synlogic Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business UpdateMar 20, 2018
scPharmaceuticals Inc. Reports Fourth Quarter 2017 Financial ResultsMar 19, 2018
resTORbio Announces Formation of Clinical Advisory BoardMar 19, 2018
Synlogic to Present Data at the American Association for Cancer Research 2018 Annual MeetingMar 19, 2018
Ascendis Pharma Announces Two Posters on Rare Disease Pipeline Programs at ENDO 2018Mar 19, 2018
PMV Pharma Appoints Salim Yazji, M.D. as Chief Medical OfficerMar 19, 2018
Rhythm Pharmaceuticals Announces Presentation of Genetic Epidemiology of LEPR, POMC, And PCSK1 Variants at ENDO 2018Mar 16, 2018
Ascendis Pharma A/S Announces Year-End 2017 Financial Results and Business Update Conference Call on March 28Mar 16, 2018
HLS Therapeutics Inc. Opens the MarketMar 16, 2018
Nearly 200 Oncology Experts Gather to Discuss Advanced Applications of MR Image-Guided RadiotherapyMar 16, 2018
Nabriva Therapeutics Reports 2017 Financial Results and Recent Corporate HighlightsMar 16, 2018
Invitae partners with KEW, Inc. to develop somatic mutation detection capabilities to improve cancer care by providing comprehensive genomic informationMar 15, 2018
Adaptimmune Announces Responses in Second Solid Tumor Indication with NY-ESO SPEAR T-cellsMar 15, 2018
ViewRay's MRIdian MR Image-Guided Radiotherapy Linac Receives Japanese Regulatory Approval (Shonin)Mar 15, 2018
Adaptimmune Reports Fourth Quarter / Full Year 2017 Financial Results and Business UpdateMar 14, 2018
Cerapedics Receives FDA IDE Approval to Initiate Study of P-15L Bone Graft for Transforaminal Lumbar Interbody Fusion SurgeryMar 14, 2018
ViewRay Finalizes Order for MR Image-Guided Radiation Therapy System at University Hospital ZurichMar 14, 2018
Late-Breaking Abstract Reporting SRA737 Preclinical Activity in CCNE1-Driven and PARPi-Resistant Cancers Accepted for AACR 2018 Annual MeetingMar 14, 2018
Alpine Immune Sciences Announces Poster Presentation at the 2018 AACR Annual MeetingMar 14, 2018
Intellia Therapeutics Announces Fourth Quarter and Full Year 2017 Financial ResultsMar 14, 2018
Arsanis Granted Key Patents for ASN100 Covering Cross-Neutralizing S. aureus Toxin AntibodiesMar 14, 2018
HLS Therapeutics Completes Merger with Automodular CorporationMar 13, 2018
Study adds to understanding about utility of ultra-sensitive cardiac troponin measurement in diagnosing and predicting cardiovascular syndromesMar 13, 2018
Natera Reports Fourth Quarter and Fiscal Year 2017 Financial ResultsMar 13, 2018
Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business UpdateMar 13, 2018
Dr. Ernesto Aycardi Joins Xenon Pharmaceuticals as Chief Medical OfficerMar 13, 2018
Crinetics Pharmaceuticals Completes $63.5 Million Series B FinancingMar 13, 2018
Aeglea BioTherapeutics Provides Key Clinical Data Update from Phase 1/2 Trial in Arginase 1 Deficiency and Reports Q4 and Full Year 2017 Financial ResultsMar 12, 2018
ViewRay Reports Fourth Quarter and Full Year 2017 Financial ResultsMar 12, 2018
Synlogic Presents Clinical and Preclinical Data from Synthetic Biotic™ Medicine Programs for Treatment of Inborn Errors of Metabolism at Annual Meeting of The Society for Inherited Metabolic DisordersMar 12, 2018
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial ResultsMar 12, 2018
Corvus Pharmaceuticals Announces Closing of Public Offering of Common StockMar 12, 2018
Realm Therapeutics Provides Clinical Update, including Results from a Phase 2 Study of PR013 in Allergic ConjunctivitisMar 9, 2018
Arsanis Reports Financial Results and Highlights for Fourth Quarter and Full Year 2017Mar 9, 2018
Pieris Pharmaceuticals Reports Full-Year 2017 Financial Results And Corporate UpdateMar 9, 2018
CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA OncologyMar 9, 2018
ObsEva Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Business UpdateMar 8, 2018
Audentes Therapeutics Reports Fourth Quarter 2017 and Full Year Financial Results and Provides Corporate UpdateMar 8, 2018
Aeglea BioTherapeutics Doses First Uveal and Cutaneous Melanoma Patients in Phase 1 Cohort Expansions with PegzilarginaseMar 8, 2018
Prevail Therapeutics Announces $75 Million Series A Financing to Advance Gene Therapies for Patients with Parkinson's and Other Neurodegenerative DiseasesMar 7, 2018
CTI BioPharma Reports Fourth Quarter and Full Year 2017 Financial ResultsMar 7, 2018
Pharming Group Report on Preliminary Financial Results for 2017Mar 7, 2018
Xenon Pharmaceuticals Reports 2017 Financial Results and Provides Corporate UpdateMar 7, 2018
TigerConnect Teams with QGendaMar 6, 2018
Marinus Pharmaceuticals Provides Business Update and 2017 Financial ResultsMar 6, 2018
TigerText Renames As TigerConnect to Welcome a New Era of Clinical CommunicationMar 6, 2018
Aeglea BioTherapeutics to Present Adult Repeat Dose Data at 2018 Annual Meeting of The Society for Inherited Metabolic DisordersMar 5, 2018
Kala Pharmaceuticals Appoints Gregory Perry To Board Of Directors And As Audit Committee ChairMar 2, 2018
Verona Pharma Reports Positive Top-Line Data from Phase 2a Trial with RPL554 in Cystic Fibrosis PatientsMar 2, 2018
Sierra Oncology Announces Pricing of Public Offering of Common StockMar 2, 2018
Tricida Announces $100 Million Venture Debt Financing From Hercules CapitalMar 1, 2018
Loxo Oncology Reports Fourth Quarter and Year-End 2017 Financial ResultsMar 1, 2018
ObsEva Announces Presentations Related to its Pre-term labor (PTL) Development Program at SRI 2018 Annual MeetingMar 1, 2018
Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business UpdateFeb 28, 2018
Aerpio Pharmaceuticals Presents Analysis from TIME-2 Study Regarding Effects of AKB-9778 on Renal Function at 2018 Keystone Symposium on Reducing the Burden of Diabetes Related End-Organ InjuryFeb 28, 2018
Study shows high-sensitivity cardiac troponin I concentrations is an independent predictor of obstructive coronary artery disease in patients with suspected stable anginaFeb 28, 2018
Clementia Reports 2017 Operating Results and Business HighlightsFeb 27, 2018
Invitae expands existing credit facility to provide up to $40.0 million in available growth capitalFeb 27, 2018
Sierra Oncology Reports 2017 Year End ResultsFeb 27, 2018
Verona Pharma Reports Operational Update and Financial Results for Full Year Ended December 31, 2017Feb 26, 2018
ObsEva SA Reports Positive Topline Results from IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVFFeb 21, 2018
Loxo Oncology Announces Publication of Larotrectinib Clinical Data in The New England Journal of MedicineFeb 21, 2018
Sierra to Report Preclinical Data Demonstrating SRA737 Synergy with PARPi at the AACR 2018 Annual MeetingFeb 20, 2018
Xenon Pharmaceuticals Advances Second Proprietary Epilepsy Product into the Clinic with Initiation of XEN901 Phase 1 Clinical TrialFeb 20, 2018
Ascendis Pharma A/S Announces Proposed Public Offering of ADSsFeb 16, 2018
Pieris Pharmaceuticals Announces Closing of Public Offering and Exercise of Underwriters' Option to Purchase Additional SharesFeb 15, 2018
Realm Therapeutics Highlights Strong 2017 Performance and Outlines 2018 MilestonesFeb 14, 2018
Xtant Medical Announces Exchange of Outstanding Convertible Notes and Closing of Private PlacementFeb 14, 2018
Pieris Pharmaceuticals Announces Pricing of its Public OfferingFeb 13, 2018
Pieris Pharmaceuticals Announces Public Offering of Common StockFeb 13, 2018
CTI BioPharma Announces Closing Of Underwritten Public Offering Of Common StockFeb 13, 2018
Verona Pharma Provides Clinical Development UpdateFeb 13, 2018
Synlogic Presents Data from Immuno-Oncology Development Program Demonstrating Potent Anti-Tumor Immunity Following Administration of Novel STING Agonist-producing Synthetic Biotic� MedicineFeb 12, 2018
Audentes Therapeutics Announces Dosing of First Patient in VALENS, a Phase 1/2 Clinical Trial of AT342 for the treatment of Crigler-Najjar SyndromeFeb 12, 2018
Invitae reports over 150% volume and over 170% revenue growth for 2017Feb 10, 2018
Corvus Pharmaceuticals Announces Presentation of New Data from Preclinical Study of Novel T-Cell Signaling Pathway Inhibitor at 10th Annual T-Cell Lymphoma ForumFeb 9, 2018
Arvinas Presents New Preclinical Data on Oral Androgen Receptor PROTAC® ARV-110 at ASCO 2018 Genitourinary Cancers SymposiumFeb 9, 2018
Pieris Pharmaceuticals and Seattle Genetics Announce Multi-Program Immuno-Oncology CollaborationFeb 9, 2018
CTI BioPharma Prices Underwritten Public Offering of $60 Million of Common StockFeb 9, 2018
Aerpio Pharmaceuticals Completes Patient Enrollment in TIME-2b Study, a Phase 2b Clinical Trial of Lead Candidate AKB-9778 in Patients with Diabetic RetinopathyFeb 8, 2018
Glaukos iStent® Trabecular Micro-Bypass Stent Reduced IOP and Lowered Medication Burden in Patients with Severe Glaucoma, According to New StudyFeb 6, 2018
Sierra Oncology to host Program Update in New York on February 27thFeb 6, 2018
Audentes Therapeutics Announces Selection of Optimized Clinical Development Candidate for Pompe Disease ProgramFeb 5, 2018
CTI BioPharma Announces Launch of Follow-On OfferingFeb 5, 2018
Positive results achieved in ReViral’s Phase IIa RSV challenge studyJan 31, 2018
Summary ToggleSynlogic Announces Underwriters’ Option Exercise in FullJan 31, 2018
Clementia Appoints Industry Veteran Pierre Legault to its Board of DirectorsJan 30, 2018
resTORbio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesJan 29, 2018
Audentes Therapeutics Announces the Closing of its Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesJan 29, 2018
Sierra Oncology to Present at the DNA Damage Response Therapeutics SummitJan 25, 2018
CTI BioPharma Provides Corporate and European Regulatory UpdateJan 25, 2018
resTORbio Announces Pricing of Initial Public OfferingJan 25, 2018
ARMO BioSciences Announces Pricing of Initial Public OfferingJan 24, 2018
Synlogic Announces Pricing of Public Offering of Common StockJan 24, 2018
Audentes Therapeutics Announces Pricing of Public Offering of Common StockJan 18, 2018
Aeglea BioTherapeutics to Present Preclinical Data at 2018 Keystone Symposia Tumor Metabolism ConferenceJan 18, 2018
CTI BioPharma to Receive $10 Million Milestone Payment for TRISENOXJan 17, 2018
Pharming Announces FDA Acceptance for Review of Supplemental Biologics License Application for RUCONEST® for Prophylaxis of Hereditary Angioedema AttacksJan 11, 2018
Adimab Initiates Update on Clinical Progression of Partner ProgramsJan 10, 2018
Glaukos Corporation’s iDose™ Travoprost Achieves Sustained IOP Reduction and Favorable Safety Profile in 12-Month Interim CohortJan 10, 2018
Adimab Announces Antibody Discovery Collaboration with Boehringer IngelheimJan 8, 2018
Ascendis Pharma Provides Update on Rare Disease Endocrinology Pipeline and Presents Initial Phase 1 Data for TransCon PTHJan 8, 2018
ViewRay Announces Preliminary Fourth Quarter and Fiscal Year 2017 ResultsJan 8, 2018
Tricida Announces Hiring of Jeroen van Beek, Ph.D., as Chief Commercial Officer and Senior Vice PresidentJan 8, 2018
Invitae more than doubles annual volume, exceeds full-year 2017 guidance, and projects momentum to continue in 2018Jan 8, 2018
Xenon Pharmaceuticals Outlines Key Milestones for 2018Jan 8, 2018
Adaptimmune Announces Two Manufacturing Achievements on Its way to Become the First Fully Integrated TCR T-cell Therapy CompanyJan 8, 2018
Adaptimmune Announces Positive Safety Data from Pilot Studies with MAGE-A10 SPEAR T-cells and First Patient to Receive 1 billion Target Cell DoseJan 8, 2018
Adimab Provides Year-End Update on 2017 Partnership ActivitiesJan 6, 2018
Cleave Biosciences Promotes Kanya Rajangam to Chief Medical OfficerJan 5, 2018
Kala Pharmaceuticals Announces Topline Results For Two Phase 3 Trials (Stride 1 And Stride 2) Of Kpi-121 0.25% In Dry Eye DiseaseJan 5, 2018
Kala Pharmaceuticals Announces New Drug Application For Inveltys™ (Kpi-121 1%) Has Been Accepted For Review By The U.S. Food And Drug AdministrationJan 4, 2018
Audentes Announces Positive Interim Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular MyopathyJan 4, 2018
Paul Stead Joins Adaptimmune as Vice President of Business DevelopmentJan 4, 2018
Arvinas Announces Research Collaboration and License Agreement with Pfizer Inc. for the Discovery and Development of Protein Degradation Drug CandidatesJan 4, 2018
Neurogastrx, Inc. Raises $45M Series A To Bring Lead Gi Candidate Through Proof Of ConceptJan 4, 2018
Rhythm Pharmaceuticals Announces Progress in Clinical Development of Setmelanotide for Treatment of Rare Genetic Disorders of ObesityJan 3, 2018
Glaukos Submits IDE Application to FDA to Study iStent infinite™ Trabecular Micro-Bypass SystemJan 3, 2018
ResTORbio Appoints Lynne Sullivan To Its Board Of DirectorsJan 3, 2018
Ascendis Pharma Announces Completion of Target Enrollment in Phase 3 Trial of TransCon Growth Hormone for Pediatric Growth Hormone DeficiencyJan 2, 2018
SI-BONE, Inc. Announces Blue Cross Blue Shield Association Raises Clinical Evidence Rating for MIS SI Joint Fusion